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Abstract 
Background: Tuberculosis (TB) is an infectious disease caused by Mycobacterium 
tuberculosis (MTB) and is a major global health problem with an annual mortality of 1.8 
million people and being the cause of ill-health among many more millions. Rapid and 
accurate diagnosis of TB is key to managing the disease, its control and transmission. Many 
established diagnostic methods suffer from low sensitivity or delays in getting results and 
are inadequate for rapid detection of MTB in pulmonary and extra-pulmonary clinical 
samples. This study examined whether real-time polymerase chain reaction (RT-PCR) assay, 
with a 2 h turn-a-round time, would prove effective for routine detection of MTB in clinical 
microbiology laboratories. 
Methods: A systematic literature search was performed for publications in any language 
(January 1995–November 2016) on the detection of MTB in pathological samples by RT-PCR 
assay. The following databases were used: MEDLINE via PUBMED, EMBASE, BIOSIS Citation 
Index, Web of Science, SCOPUS, ISI Web of Knowledge and Cochrane Infectious Diseases 
Group Specialised Register, grey literature and the World Health Organization and Centers 
for Disease Control and Prevention websites. Studies were only included if they met set 
inclusion criteria. Generated pooled summary estimates (95% CIs) were calculated for 
sensitivity and specificity by use of random-effects meta-analysis when four or more studies 
were available. For meta-analysis, the bivariate model was used because it takes into 
account potential threshold effects and the correlation between sensitivity and specificity. It 
also allows addition of covariates for investigation of potential sources of heterogeneity. 
RevMan 5.3 and Meta-Disc software packages were used. 
Results: Forty-six studies out of 6,706 citations identified met the inclusion criteria, 
providing information from 21 countries with high, moderate and low prevalence of TB. 
Studies included patients with infections identified in primary, secondary and tertiary 
healthcare settings. There were a total of 35,380 samples: 28,406 from pulmonary TB (PTB) 
and 6974 from extra-pulmonary (EPTB). Summary estimates for PTB (31 studies) were: 
sensitivity 0.82; 95% CI, 0.81–0.83; specificity 0.99; 95% CI, 0.99–0.99; positive likelihood 
ratio 43.00 (28.23–64.81); negative likelihood ratio 0.16 (0.12–0.20), diagnostic odds ratio 
324.26 (95% CI 189.08–556.09) and area under curve (AUC) 0.99. Summary estimates for 
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EPTB (25 studies) were: sensitivity 0.70, 95% CI, 0.67–0.72; specificity 0.99, 95% CI, 0.99–
0.99; positive likelihood ratio 29.82 (17.86–49.78); negative likelihood ratio 0.33 (0.26–
0.42); diagnostic odds ratio 125.20 (95% CI 65.75–238.36) and AUC 0.96. Summary 
estimates for subgroup analyses by RT-PCR assay type were: with CobasTaqMan as the RT-
PCR assay (17 studies): sensitivity 0.78, 95% CI, 0.76–0.80; speciﬁcity 0.99, 95% CI, 0.99–0.99 
and AUC 0.98. With Roche Light cycler as the RT-PCR assay (7 studies): sensitivity 0.85, 95% 
CI, 0.80–0.88; speciﬁcity 0.99, 95% CI, 0.98–0.99 and AUC 0.97. With Cepheid & other types 
of RT-PCR assay (22 studies): sensitivity 0.78, 95% CI, 0.77–0.80; speciﬁcity 0.99, 95% CI, 
0.99–0.99 and AUC 0.99. Summary estimates for subgroup analyses by RT-PCR assay target 
sequence genes were: with IS6110 as the RT-PCR assay target sequence gene (22 studies): 
sensitivity 0.79, 0.77–0.81, speciﬁcity 0.98, 0.98–0.98 and AUC 0.99. With 16SRNA as the RT-
PCR assay target sequence gene (7 studies): sensitivity 0.69, 0.66–0.71; speciﬁcity 0.99, 
0.99–0.99 and AUC 0.97. With other genes (17 studies): sensitivity 0.82, 0.80–0.84; 
speciﬁcity 0.99, 0.99–0.99 and AUC 0.98. Summary estimates for subgroup analyses by 
reference tests were: with solid and liquid media combined (25 studies): sensitivity 0.77, 
95% CI, 0.76–0.79; speciﬁcity 0.99, 95% CI, 0.99–0.99 and AUC 0.99. With solid media alone 
(13 studies): sensitivity 0.80, 95% CI, 0.77–0.82; speciﬁcity 0.96, 95% CI, 0.96–0.97 and AUC 
0.98. With liquid media alone (6 studies): sensitivity 0.81, 95% CI, 0.75–0.86; speciﬁcity 0.99, 
95% CI, 0.99–1.00 and AUC 0.94. 
Conclusions: RT-PCR assay demonstrated a high degree of sensitivity for PTB and good 
sensitivity for EPTB. It indicated a high degree of specificity for ruling in TB infection from 
sampling regimes. This was acceptable, but may suggest it as a rule-out add-on diagnostic 
test. RT-PCR assay’s high degree of sensitivity in pulmonary samples and rapidity of 
detection of TB is an important factor in achieving effective global control and for patient 
management in terms of initiating early and appropriate anti-tubercular therapy. 
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Chapter 1: Introduction 
 
This chapter introduces a brief history of tuberculosis (TB) as a disease since antiquity and 
describes its epidemiology with an attendant global burden that knows no boundary. It 
highlights the signs and symptoms of pulmonary tuberculosis (PTB) and extra-pulmonary 
tuberculosis (EPTB) and outlines the aetiology/cause, risk factors, transmission and 
pathogenesis of TB. It explains the social impacts associated with TB such as stigmatization 
and discrimination, and also discusses the relevance of evidence-based medicine (EBM) and 
how systematic review and meta-analysis contribute to EBM. Particular emphasis will be 
made on the synthesis of available evidence scattered across primary sources. The chapter 
will highlight some of the current clinical laboratory algorithms and guidelines for the 
detection of MTB in clinical specimens. The chapter outlines the principle of real-time 
polymerase chain reaction (RT-PCR) assay its application in a clinical microbiology 
laboratory, commercial types and protocol of the assay for MTB detection in clinical 
specimens. Finally, the chapter discusses an overview role of: 
(I) The NHS via a clinical microbiology laboratory and  
(II) World Health Organization (WHO) in the diagnosis, prevention, control and management 
of TB in a timely manner. 
 
In this way, the usefulness of this research work may be demonstrated within the context of 
the aims of the NHS, and most importantly, the launch of the joint PHE and NHS England 
‘Collaborative TB Strategy for England 2015–2020’ and how it will help inform future 
practice. These are discussed with regards to the significance of rapid and accurate 
detection of MTB; the causative agent of TB from clinical specimens using RT-PCR assay as a 
diagnostic tool and how it relates to future studies towards its adoption as a routine assay. 
It is noteworthy as well as germane, that, to combat the spread of any disease of any public 
health magnitude, such as MTB, rapid and accurate detection or identification of the 
causative agent is required. 
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1.1 History of tuberculosis 
TB is an ancient scourge. It has plagued humankind throughout known history and 
prehistory (Hayman, 1984). TB is clearly noted in the Biblical books of Deuteronomy and 
Leviticus using the ancient Hebrew word ‘schachepheth’: a wasting disease (Daniel & Daniel, 
1999). Evidence of TB in humans’ dates back to Neolithic times 2400–3400 BC, where 
mummies have been shown to have evidence of the disease in their spines (Cave, 1939). It 
has been found in relics from ancient Egypt, India and China. Among Egyptian mummies 
spinal TB, known as Pott's disease, has been detected by archaeologists (Morse et al., 1964). 
 
It was also known in classical Greece as far back as 460 BC Hippocrates, where its first 
clinical description was called phthisis (I am wasting away) (Daniel, 1997; Meachen, 1936). 
TB was common both in ancient Greece and Imperial Rome and by 500–1500 AD, due to 
Roman occupation of Europe, it spread to Britain. Between 1650–1900 AD it was identified 
as the White plague of Europe, causing one in five deaths. However, during the industrial 
revolution in Europe between1800–1900 AD, about 50 million people were infected and 7 
million were dying annually. Indeed, there is archeologic evidence from widespread sites 
throughout Europe for TB during the millennium that followed the fall of Rome in the 5th 
century (Roberts & Buikstra, 2003); St. Francis of Assisi died in 1226 at the age of 44, 
probably of TB (Moorman, 1970). A fascinating aspect of TB during the middle ages is that of 
scrofula, which European monarchs, beginning with Clovis in 496 was treated with the ‘royal 
touch’. Hundreds, and sometimes thousands, of scrofulous individuals were touched by 
monarchs during the following several hundred years, a codified ritual to confirm the 
diagnosis (Daniel, 1997).  
 
In 1844, half of the population of England was infected with TB and death rates in London, 
Stockholm and Hamburg approached 800 to 1,000 per 100,000 persons per year at that 
time (Krause, 1928). Approximately all of Europe’s adult population was infected with TB by 
the 1900s (Grigg, 1958). In the face of such prevalence, society responded by romanticizing 
the disease because the ‘wan and pallid faces of the victim of TB’ were thought to be 
attractive (Dubos & Dubos, 1952). Surrounded by patients with TB, medical practitioners 
and scientists struggled to understand its aetiology. TB was indeed infectious in nature and 
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was probably first suggested in 1790 by Benjamin Marten, who attributed the disease to 
‘some certain species of “animalcula’’’ (Doetsch & Benjamin, 1978).  
TB was well established in East Africa by the time Europeans reached the area in the 19th 
century (Daniel, 1998). Archaeological evidence for any disease is generally lacking in East 
Africa. However, Gutierrez and her colleagues concluded that an early progenitor of MTB 
was present in East Africa as early as 3 million years ago and they suggest that it may have 
infected early hominids at that time (Gutierrez et al., 2005). 
TB has claimed victims throughout much of known human history. It reached epidemic 
proportions in Europe and North America during the 18th and 19th centuries, earning the 
sobriquet ‘Captain Among these Men of Death’ (Daniel, 2006). The history of TB was 
changed dramatically on March 24, 1882, when Hermann Heinrich Robert Koch made his 
justly famous presentation ‘Die Aetiologie der Tuberculose’ to the Berlin Physiological 
Society (Daniel, 1997; Daniel, 2005). In his presentation, Koch not only presented 
demonstrations of the tubercle bacillus that he had identified, but also posited his famous 
Koch-Henle postulates, which to this day set the standard for the demonstration of 
infectious aetiology. Koch’s contributions to bacteriology were legion and he was awarded 
the Noble Prize in Medicine or Physiology in 1905 for his elucidation of the aetiology of TB. 
 
1.2 Epidemiology and global burden of TB    
An understanding of the epidemiology of MTB is critical for effective control. TB continues 
to exact its terrible toll on humankind. More than two billion people (about one-third of the 
world population) are estimated to be infected with MTB, a person is newly infected with TB 
every second (Dheda, 2015; Lönnroth & Raviglione, 2009). TB is a major global health 
problem. It causes ill-health among millions of people each year and ranks alongside the 
human immunodeficiency virus (HIV) as a leading cause of death worldwide (WHO, 2015). In 
2014, there were an estimated 9.6 million new TB cases, 5.4 million among men, 3.2 million 
among women and 1.0 million among children. There were also 1.5 million TB deaths (1.1 
million among HIV-negative people and 0.4 million among HIV-positive people), of which 
approximately 890,000 were men, 480,000 were women and 140,000 were children. The 
number of TB deaths is unacceptably high as with timely diagnosis and correct treatment 
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almost all people with TB may be cured (WHO, 2015). According to a 2013 report, the UK 
has the highest incidence rate of TB (8,751 cases) of any Western European country (see 
Figure 1.1, PHE, 2013). 
 
 
Figure 1.1 Estimated incidence of TB by country in 2014 (adapted from WHO Global 
Tuberculosis Report, 2016). 
 
1.3 Biology of MTB 
MTB is a small sized (2–4 µm x 0.2–0.5 µm), rod-shaped or slightly curved slow-growing 
bacterium. It reproduces itself every 24 to 48 h which is extremely slow for bacteria. It is 
non-motile, non-spore forming and has an unusual waxy coating on its cell surface (primarily 
due to the presence of mycolic acid) making the cells impervious to gram staining. The cell 
wall of Mycobacterium under an electron microscope resembles a gram-positive cell wall 
structure. The lipid-rich cell wall contains mycolic acid, 50% of the cell wall dry weight, acid 
fast (retains acidic stains), conferring resistance to detergents and antibacterial and can 
survive in a dry state for weeks. It is an aerobic bacterium and for this reason, during active 
TB disease, MTB is always found in the upper air sacs of the lungs (Gigg, 1958). 
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Figure 1.2 Mycobacterium tuberculosis bacteria (NIAID, 2016). 
 
1.3.1 Mycobacterium lineage  
Kingdom: Bacteria 
Phylum: Actinobacteria 
Class: Actinobacteria 
Subclass: Actinobacteridae 
Order: Actinomycetales 
Suborder: Corynebacterineae 
Family: Mycobacteriaceae 
Genus: Mycobacterium (unique genus) 
Species: M.tuberculosis 
              M.bovis 
              M.africanum 
              M.microti 
              M.canettii 
              M.caprae 
              M.pinnipedii 
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1.4 Aetiology, transmission and risk factors of tuberculosis  
TB is an infectious disease caused by the bacillus MTB. It typically affects the lungs 
(pulmonary TB), but can affect other sites as well (extra-pulmonary TB). TB is a bacterial 
infection spread through inhaling airborne particles, called droplet nuclei, of 1–5 µm in 
diameter. Infectious droplet nuclei are generated when a person who has pulmonary or 
laryngeal TB disease coughs, sneezes, shouts, or sings. The droplet nuclei traverse the 
mouth or nasal passages, upper respiratory tract and bronchi to reach the alveoli of the 
lungs. The infectiousness of a person with TB disease is directly related to the number of 
tubercle bacilli that he or she expels into the air. People who expel many tubercle bacilli are 
more infectious than patients who expel a few or no bacilli (CDC, 2012).  
Overall, a relatively small proportion (5–15%) of the estimated 2–3 billion people infected 
with MTB will develop TB disease during their lifetime. However, the probability of 
developing TB is much higher among people infected with HIV. Generally, persons at high 
risk for developing TB disease fall into two categories. The first category is those who have 
been recently infected with TB bacteria, this includes close contacts of a person with 
infectious TB disease, those who have immigrated from areas of the world with high rates of 
TB, children less than 5 years of age who have a positive TB test, groups with high rates of 
TB transmission, such as the homeless, injection drug users and those with HIV infection, 
those who work or reside with people who are at high risk for TB in facilities or institutions 
such as hospitals, prisoners, homeless shelters, correctional facilities, nursing homes and 
residential homes for those with HIV; the other category is those with weak immune 
systems such as babies and young children. This category also includes those who are 
immune-compromised, especially those with any of the following conditions: HIV infection 
(the virus that causes AIDS), substance abuse, silicosis, diabetes mellitus, severe kidney 
disease, low body weight, organ transplants, head and neck cancer, medical treatments 
such as corticosteroids or organ transplant and specialized treatment for rheumatoid 
arthritis or Crohn’s disease (Akhtar, 2003; Hill et al., 2006; Wood et al., 2010).  
1.5 Signs and symptoms: Pulmonary and extra-pulmonary tuberculosis 
Early symptoms of active TB can include unexplained weight loss, fever, night sweats and 
loss of appetite. However, symptoms may be vague and go unnoticed by those affected. For 
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some, the disease either goes into remission (halts) or becomes chronic and more 
debilitating with a cough (especially if lasting for 3 weeks or longer) with or without sputum 
production, coughing up blood (haemoptysis), chest pain and bloody sputum (saliva), fever, 
fatigue, TB of the kidney may cause blood in the urine, TB meningitis that may cause 
headache or confusion, TB of the spine that may cause back pain, TB of the larynx that can 
cause hoarseness, dyspnea, lymphadenopathy and even pneumonia or phthisis (Pfyffer, 
2007). 
Symptoms of TB involving areas other than the lungs vary, depending upon the organ or 
area affected; extra-pulmonary sites of infection commonly include lymph nodes, pleura, 
and osteoarticular areas, although any organ can be involved. The diagnosis of EPTB can be 
elusive, necessitating a high index of suspicion (Ekaterina, 2014). Figure 1.3 shows a 
summary of the symptoms of PTB and EPTB. 
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Figure 1.3 Symptoms of tuberculosis. 
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1.6 Pathogenesis of tuberculosis 
Infection occurs when a person inhales nuclei droplets that contain tubercle bacilli, which 
reach the alveoli of the lungs and form pulmonary TB if not destroyed. However, in 90–95% 
of the cases, these tubercle bacilli are ingested by alveolar macrophages and the majority of 
these bacilli are destroyed, or inhibited, leading to a latent infection with no clinical 
symptoms (Delogu & Fadda, 2009). The cells form a barrier shell, called a granuloma, that 
keeps the bacilli contained and under control (latent TB infection). A small number may 
multiply intracellularly and are released when the macrophages die. If alive, the disease may 
become progressive in 5–10% of the cases, if the immune system cannot keep the tubercle 
bacilli under control and the bacilli begin to multiply rapidly (TB disease). Surviving bacilli 
may spread by way of lymphatic channels, or through the bloodstream, to more distant 
tissue and organs (including areas of the body in which EPTB disease is most likely to 
develop, e.g. regional lymph nodes, apex of the lung, kidneys, larynx, spine, brain, cervical 
lymphadenitis, pleuritis, pericarditis, synovitis, meningitis and infections of the skin, joint or 
bone (CDC, 2012). Within 2 to 8 weeks, macrophages ingest and can surround the tubercle 
bacilli. This process of dissemination primes the immune system for a systemic response.  
Miliary TB (disseminated TB) is characterized by high and sustained fever, night sweats, dry 
cough, malaise, splenomegaly and skin lesions. Meningitis (high fever, cranial nerve deficits 
and psychic changes) develops in 50% of cases with a high mortality rate if left 
untreated (Krauss et al., 2003). Further details about pathogenesis of TB disease are 
described in the following (see Figure 1.4).  
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          Miliary     
 Meninges 
 Vertebrae 
 Lymph nodes 
 Lungs 
 Liver 
 Spleen 
 Adrenals 
 Joints and long bones 
  
  
 Reactivation or reinfection 
(Lung) tuberculosis 
                  Primary Tuberculosis 
                     (Ghon complex in lung) 
                                          <10% 
Healing,   
calcification 
Dormant 
organisms 
(Greater 
susceptibility) 
 
                      > 90% 
         Secondary (cavity) tuberculosis 
Progressive primary tuberculosis 
  
Greater in  
 Certain racial groups 
 Children 
 Immunocompromised hosts 
Figure 1.4 Pathogenesis of tuberculosis. 
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 1.7 The impact of stigmatization and discrimination  
Social consequences of TB infection include discrimination or outright rejection against 
those infected with TB and members of their households. Family and friends may reject TB 
patients, they may receive less social support during treatment, or they may lose their jobs. 
The strong association between AIDS and TB increases the likelihood of rejection and social 
isolation of TB patients (Saunderson, 1995). 
In some developing countries, discrimination against TB sufferers has taken particularly 
damaging forms, such as divorce or lowered prospects of marriage. Such discrimination 
represents significant costs because the economic prospects for divorced or unmarriageable 
women in many societies are bleak. Discrimination against those suffering from TB also has 
epidemiological consequences. Stigmatization, therefore, is another major social factor that 
MTB patients contend with in society (Saunderson, 1995). 
1.8 Diagnosis of tuberculosis: Role of the clinical microbiology laboratory 
The aim of this section is to highlight the diagnosis of TB. Diagnosis of active and latent TB 
remains a challenge, simply because TB is a diversified disease, any organs can be involved, 
any age group and either gender. Some of the impediments to control of TB are: lack of 
health infrastructure, control is plagued with lack of accuracy and robust and rapid 
diagnostic methods/technologies.  
(i) Clinical diagnosis: This depends on patient’s presentations/symptoms such as 
prolonged cough, fever, night sweats, etc. This also depends on signs such as 
fibrosis or stony dullness due to pleural effusion when seen by clinician. 
(ii) Clinical microbiology laboratory diagnosis: the role of microbiological 
investigations is essential for definitive diagnosis of TB in a clinical laboratory. 
 
Since Koch's 1882 discovery of the staining technique that identified MTB, substantial 
progress has been made in TB diagnosis and control, and subsequently, this marked the 
beginning of a revolution in the clinical laboratory diagnosis of MTB. Nevertheless, in the 
latter part of the 20th century, a long period of neglect of both quality programme 
implementation and research led to persistently high TB incidence rates and failure to 
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develop new tools to adequately address the increasing problem. Today, most of the world 
continues to rely on the same diagnostic test invented by Koch approximately 125 years 
ago (WHO, 2014). 
TB continues to be, as it has been for centuries, one of the most prevalent infectious 
diseases of humans and is the leading cause of mortality from a single infectious disease 
worldwide. Laboratory methods play a crucial role in establishing the diagnosis, monitoring 
therapy and preventing transmission of TB. In 1895, Roentgen discovered the use of X-rays 
for early diagnosis of pulmonary disease. Various advances have been made ever since in 
the field of laboratory medicine for early and discriminative diagnosis of MTB from clinical 
specimens of TB patients. 
1.8.1 Microscopy      
The most common method for diagnosing TB worldwide remains sputum smear microscopy 
(the cornerstone of TB diagnosis in developing countries) with Ziehl-Neelsen’s staining 
(developed more than 100 years ago), in which bacteria are observed in sputum samples 
examined under a microscope. Figure 1.5 shows acid-fast bacilli (AFB) examination under a 
light microscope; this method only needs a good microscope and a few stains. It is rapid and 
economical, where it can detect bacterial load. It is also a good diagnostic and prognostic 
tool, 0.2 µl of sputum is adequate and prompt diagnosis is achieved after searching as few 
as 100 fields (see Table 1.1). There are two procedures commonly used for acid-fast 
staining:  
• Carbol-fuchsin methods which include the Ziehl-Neelsen and Kinyoun methods (direct 
microscopy); 
• fluorochrome procedure using Auramine-O or Auramine-rhodamine dyes (fluorescent 
microscopy). 
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(a) 
 
 
 (b) 
Figure 1.5 AFB under direct smear microscopy: (a) AFB under fluorescent microscopy 
(Auramine-O or Auramine-rhodamine dyes) and (b) AFB under light microscopy (ZN-stain). 
 
Table 1.1. Quantification scale for ZN TB microscopy (WHO, 2014). 
Number of AFB Number of fields* examined What to report 
 
No AFB in 300 fields 300 fields No AFB seen 
 
1–9 AFB in 100 fields 100 fields Record exact figure 
(1 to 9 AFB per 100 fields) 
10–99 AFB in 100 fields 100 fields 1+ 
 
1–10 AFB in each field 50 fields 2+ 
 
More than 10 AFB in each 
field 
20 fields 3+ 
 
*Oil Immersion fields 
Microscopy does have limitations; the method depends upon the quality and bacterial load 
of bacilli, which must be more than 10,000/ml of the sputum specimen, and the training and 
motivation/dedication of laboratory technicians (microscopists). Although highly specific in 
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most countries, smear microscopy is insensitive – it detects roughly 40% of all the active 
cases of TB, and the sensitivity can be as low as 20% in children and HIV infected people. So, 
it is not dependable for the paediatric group. It does not differentiate other species of 
Mycobacteria from MTB. Smear microscopy also places a burden on the patient as those 
with suspected TB typically have to visit the clinic at least twice before a diagnosis can be 
made and then have to return again for the results. This process can be expensive in terms 
of transportation costs and lost wages from time off work. This can lead to high drop out 
rates by patients to complete the testing process, while some do not return for their results. 
Furthermore, smear microscopy cannot detect drug resistance strains. 
1.8.2 Purified protein derivative (PPD) test  
This is also referred to as the Mantoux test or the Tuberculin Skin Test (TST). It is one of the 
most common tests to determine if someone has been exposed to and become infected 
with TB bacteria. It is a good screening tool for latent TB. A positive skin test is indicated by a 
skin reaction at the point of the injection. However, vaccination with the Bacillus Calmette–
Guérin (BCG) vaccine can also lead to a reaction at the TST site, which can limit the test's 
usefulness in vaccinated children or people repeatedly tested because of high risks of 
exposure (such as healthcare workers); it also lacks specificity. 
1.8.3 Immunodiagnostic tests 
These are serology-based tests using formats well suited for resource-poor countries 
(performed without specialized equipment and with minimal training); they have been 
successfully developed for many infectious diseases (e.g., HIV and malaria) (Steingart et al., 
2007; Stürenburg & Junker, 2009). In these assays, antigens are typically pre-coated in lines 
across a nitrocellulose membrane to which serum or whole-blood samples are applied. 
Antigen antibody reactions may be visualized on the lines using anti-human antibodies 
bound to substances such as colloidal gold. The test takes only minutes to perform. These 
technologies are very attractive as simple, accurate, inexpensive and ideally as a point-of-
care test (POCT) diagnosis of TB. 
Generally, serology tests for TB have a low turn-a-round time, high negative predictive value 
and are useful as screening tests. They have variable or low sensitivity, but could be highly 
dependable for EPTB.  
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(i) Interferon-gamma release assays (IGRAs)  
Interferon-gamma release assays (IGRAs) are whole-blood tests that can aid in the diagnosis 
of a MTB infection. They do not help differentiate between latent TB infection (LTBI) and TB 
disease. This is a screening test of great significance for the detection of TB in patients 
infected with latent TB. One-third of the world’s population is estimated to be living with 
LTBI. This infection will lead to active disease in 10% of these individuals during their 
lifetimes; however, if the infected individuals are immunocompromised (e.g., HIV infected), 
8 to 10% of them will develop TB disease within a year (Dye et al., 1999). Therefore, it is 
imperative to accurately diagnose and treat patients with LTBI and also to predict who 
among the infected will develop the disease. 
IGRAs measure a person’s cellular immune reactivity to proteins that are specific to LTBI 
produced by MTB. White blood cells from most people that have been infected with MTB 
will release interferon-gamma (IFN-) when mixed with antigens (substances that can 
produce an immune response) derived from MTB-specific antigens via an enzyme-linked 
immunosorbent assay (ELISA) or an enzyme-linked immunospot (ELISPOT) assay.  
The results of IGRAs are based on the amount of IFN- that is released in response to these 
antigens. The first-generation Quantiferon-TB assay is a whole-blood test that measures 
IFN- release to PPDs with an ELISA; this test was approved by the FDA (Mazurek et al., 2001). 
(a) QuantiFERON®-TB gold in-tube test (QFT-GIT). The Quantiferon-TB Gold test is an 
enhanced form of the assay, which uses the MTB-specific ESAT6 and CFP10 antigens 
instead of PPDs. A newer version of the test, Quantiferon-TB gold in-tube assay, 
entails simpler sample preparation and is further enhanced by the addition of a TB7.7 
(p4) antigen.  
 
(b) T-SPOT®.TB test (T-Spot) assay. This requires the separation of peripheral blood 
mononuclear cells and detects IFN-release after exposure to ESAT6 and CFP10 with 
an ELISPOT assay.  
A major drawback of either method is that incubation with antigens must be initiated within 
8 to 16 h following blood collection. 
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1.8.4 Matrix assisted laser desorption ionization time of flight mass spectrometry  
This is a rapid analytical technique with significant applications in clinical monitoring, quality 
control in food processing, research and clinical microbiology. Matrix-assisted laser 
desorption/ionization time of flight mass spectrometry (MALDI-TOF MS) is a diagnostic tool 
of microbial identification and characterization based on detection of the mass of 
molecules. In recent years, MALDI-TOF-MS has been validated and used for rapid 
identification of microorganisms and for potential discovery of disease-associated 
biomarkers. In the majority of clinical laboratories, this technology is currently being used 
mainly for bacterial diagnosis, but several approaches in the field of virology have been 
investigated. Its turn-a-round time is < 1 h for the identification of microorganisms isolated 
from clinical samples. Advances in instrumentation (separation and mass analysis), 
ionization techniques and bioinformatics have contributed to the successful application of 
mass spectrometry (MS) for rapid and high-throughput pathogen identification and 
characterization (Singhal, et al, 2015). Electrospray ionization mass spectrometry (ESI-MS) 
has been successfully applied to the identification of clinical isolates of the MTBC based on 
their mycolic acid profiles (Song et al., 2009). However, MALDI-TOF requires MTB isolated 
from clinical samples (which requires between 2 to 8 weeks on solid medium) for accurate 
identification. It is not useful in the direct detection of MTB from clinical specimens. This is a 
serious setback in terms of rapid diagnosis of TB. 
1.8.5 Bacteriophage methods for direct detection of Mycobacterium tuberculosis 
Bacteriophages that specifically infect and replicate in mycobacteria have been used for the 
direct testing of processed clinical specimens to indicate the presence of viable bacterial 
cells. A meta-analysis of 13 studies of MTB bacteriophage-based tests concluded that the 
performance of these tests was not superior to that of smear microscopy (Kalantri et al., 
2005) The phage-based systems were originally developed to offer a rapid and relatively 
low-cost diagnostic approach; however, the findings of these studies indicated that the 
reported sensitivity and specificity of these tests do not support their routine diagnostic use.  
1.8.6 Lateral flow assays 
Lateral flow immunochromatographic assays have been developed for the rapid 
identification of members of the MTBC. There are three products that are currently 
available: the Capilia TB rapid diagnostic test (Tauns Laboratories Inc., South Korea), the SD 
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Bioline TB AG MPT64 rapid test (Standard Diagnostics, Yongin, South Korea) and the BD 
MGIT TBc identification test (BD Diagnostics, Sparks, MD). These assays are based on the 
detection of the presence of a MTBC-specific protein MPT64 in culture isolates. The 
detection limit has been found to be approximately 105 CFU/ml; as a result, bacterial growth 
on a solid or liquid medium is required prior to testing (Park et al., 2009). This is not 
applicable with clinical specimens.  
1.8.7 Culture-based assays 
This is the agreed reference/gold standard for the detection of MTB from clinical samples. 
Positive cultures for MTB confirm the diagnosis of TB disease. There are three types of 
culture media:  
Solid media, which include egg-based media (Lowenstein-Jensen), Ogawa medium and 
agar-based media (Middlebrook 7H10 and 7H11) remain the only reliable means to 
monitor effectiveness of therapy in tuberculosis patients. Solid media, the standard for 
culturing mycobacteria, grow slower than liquid media. Agar-based media (such as 
Middlebrook 7H10 or 7H11) are transparent, and the presence of colonies can be 
detected earlier than with egg-based media. Antimicrobial agents (such as penicillin, 
nalidixic acid, lincomycin and cycloheximide) are often added to solid media to help 
prevent contamination by other flora. Pathological specimens (both PTB and EPTB) are 
treated depending on their integrity before culturing on solid or liquid media. Some of 
the treatment methods are centrifugation (not suitable for all specimen types), 
homogenisation (improves the sensitivity of culture but is not required for all sample 
types), decontamination & neutralisation and Concentration by centrifugation (not 
appropriate for all sample types). However, liquid media now are widely used alongside 
solid media to increase sensitivity and decrease recovery time (Morgan et al., 1983; 
Sharp et al., 2000 and PHE, 2016).  
 Liquid media (Middlebrook 7H12 and other broths). The use of liquid medium 
(MGIT960) for tuberculosis (TB) diagnosis was recommended by WHO in 2007. This is 
recommended as a standard practice for mycobacteriology laboratories because it 
increases recovery of mycobacteria and decreased time to detection compared to solid 
media. However, they are more easily contaminated than solid and the addition of 
antimicrobials is required to reduce contamination.   
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 Commercially available automated (Liquid) broth culture systems (e.g., BACTEC,   MGIT, 
Versa TREK, MBBACT, Middlebrook 7H9 broth, Middle brook 7H12) allow detection of 
most mycobacterial growth in 4 to 14 days compared to 2 to 8 weeks for solid media.  
The automated liquid culture systems available are meant to detect a wide range of 
both slow and rapidly growing mycobacteria; however, reliance should not be placed on 
these systems alone for the isolation of all mycobacterial species because rare isolates 
of M. tuberculosis are recovered only on egg-based media, such as a Löwenstein Jensen 
slope, particularly when investigating patients who are immunocompromised (ATS and 
CDC, 2000). Their limitations lie in a single incubation temperature and the difficulty of 
providing the growth additives necessary for certain very fastidious species.  
1.8.8 Histological diagnosis 
The histological diagnosis of MTB remains a diagnostic challenge despite different methods. 
This is useful in the diagnosis of EPTB from tissue biopsies having TB, for example, 
lymphadenitis. Considering the limitations in the sensitivity and specificity of Ziehl-Neelsen 
staining (Trusov et al., 2009), mycobacterial evaluation, mycobacterial culture and molecular 
and serological techniques (Attallah et al., 2003; Dora et al., 2008, Mishra et al., 2005), 
histomorphological analysis appears to be the only feasible technique for field diagnosis of 
TB in some patients. 
In this analysis, formalin-fixed paraffin wax processed tissue sections are used. The sections 
are stained using haematoxylin and eosin (H & E) and other relevant staining to detect giant 
cell, caseation, epithelioid cells granuloma, lymphocytes and histiocytes showing 
histopathological pattern of TB lymphadenitis and other MTB infected tissues or organs.  
1.8.9 Molecular methods 
Molecular method technology is a welcomed development in rapid and sensitive tools for 
clinical laboratory diagnosis of TB. Along with the development of molecular biology for 
rapid diagnosis, several polymerase chain reaction (PCR) tests for the early detection of MTB 
have been developed since 1990 (Bartlett, 2003). The majority of molecular tests have 
focused on the detection of nucleic acids, both DNA and RNA that are specific to MTB, by 
amplification techniques such PCR. Recent developments in direct and rapid detection of 
mycobacteria, with emphasis on MTB species identification by 16S rRNA gene sequence 
analysis, have contributed to these advances. This new development is needed due to the 
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increased incidence of TB epidemics and the length of time required by conventional 
diagnostic tests, especially among human immunodeficiency virus (HIV)-infected patients. In 
this context, the time required for the identification of mycobacteria has been considerably 
shortened (between 2–4 h), in comparison to the time required for microbiological tests. 
These nucleic acid amplification (NAA) assays amplify MTB-specific nucleic acid sequences 
using a nucleic acid probe. NAA assays enable direct detection of MTB in clinical specimens. 
Whereas AFB smears are rapid but lack sensitivity and specificity, and a culture that is the 
gold standard is both sensitive and specific, but may take from 2 to 8 weeks to produce 
results. The sensitivity of the NAA assays currently in commercial use is at least 80% in most 
studies. These assays require as few as 10 bacilli/mL from a given sample under research 
conditions (Parsons et al., 2011). NAA assays are also quite specific for MTB, with 
specificities in the range of 98% to 99%. 
Among the commercial assays offering the capability to detect MTB and its complex (MTBC) 
from clinical specimens are: 
 PCR (Amplicor PCR assay; Roche Molecular Systems)  
 Transcription-mediated amplification (Amplified MTD assay, Gen-Probe Inc.)  
 GenoType Mycobacteria Direct assay (Hain Lifescience) 
 Strand displacement amplification (BD ProbeTec assay, Becton Dickinson)  
 Loop-mediated isothermal amplification (LAMP, Eiken Chemical Co.) 
Other NAA assays that have been tested include: 
 A ligase chain-reaction-based test (LCx test, Abbott Diagnostics Division, Abbott Park, 
IL) 
 The strand displacement amplification (SDA) test known as the BDProbeTec ET 
Mycobacterium TB complex direct detection assay (DTB) (Becton Dickinson 
Biosciences, Sparks, MD). DTB is a 1 h assay that couples SDA to a fluorescent 
energy-transfer detection system. 
 
Some of the advantages of molecular diagnosis include detection and diagnosis of 
uncultivable, or difficult to culture microorganisms. They are rapid: they overcome the 
inadequacy of phenotypic methods (biochemical) and are helpful in the prognosis and 
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management of patients. However, one limitation is the inability to differentiate between 
the nucleic acids of living and dead organisms (so in patients on anti-tuberculosis therapy, 
ATT). Furthermore, they cannot be used as an indicator of infectivity as this assay remains 
positive for a greater time than cultures do and they do not give drug-susceptibility 
information. 
 1.9 Current clinical laboratory algorithms and guidelines for the diagnosis of 
tuberculosis 
There are different guidelines for national TB diagnosis adopted by the healthcare systems 
of different countries. The major challenge in the control of TB is diagnosis of smear-
negative PTB and EPTB infections and this need to be improved. Rates of smear-negative 
pulmonary and extra-pulmonary TB have been rising. The mortality rate among TB patients 
is higher, particularly for those with smear-negative pulmonary and extra-pulmonary TB. 
Delayed diagnosis may be an important cause of excess mortality in patients who have 
smear-negative pulmonary and extra-pulmonary TB. In the absence of rapid, simple and 
accurate diagnostic tools for smear-negative pulmonary and extra-pulmonary TB, diagnostic 
algorithms have been recommended.  
1.9.1 WHO guidelines 
Background 
In 1991, WHO first published guidelines for national TB control programmes that included 
criteria for the diagnosis of smear positive and smear-negative pulmonary and extra-
pulmonary TB. The existing guidelines for the diagnosis of smear-negative pulmonary TB 
were published by WHO in 2003 (WHO, 2013) and codified in 2006 in the international 
standards for TB care (ISTC, 2006), a publication of organizations, including WHO, who are 
members of the Stop TB Partnership. 
Algorithms for the diagnosis of smear-negative tuberculosis 
The algorithms are aimed at adult and adolescent patients with a cough duration of 2–3 
weeks and which differ according to the clinical condition of the patient (ambulatory or 
seriously ill). 
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AFB microscopy. At least two sputum specimens should be taken and examined for AFB. 
One of the specimens should be early-morning sputum produced after an overnight sleep. 
One positive AFB smear will be sufficient to classify a patient as a smear-positive case if the 
patient is HIV-infected or if there is strong clinical suspicion of HIV infection. Two or more 
negative smears are defined as AFB-negative (see Table 1.2). 
Table 1.2. WHO-approved microbiologic tests for the diagnosis of active tuberculosis. 
Test Site  Comments 
Sputum smear microscopy Pulmonary Fluorescence microscopy is more 
sensitive than bright field (light) 
microscopy 
Nucleic acid amplification tests 
(NAATS, other than Xpert 
MTB/RIF) 
Pulmonary TB and 
extrapulmonary TB 
Commercial, standardized NAATS 
have high specificity and positive 
predictive value; however, they 
have relatively lower (and highly 
variable) sensitivity and negative 
predictive values for all forms of 
TB, especially in smear-negative 
and extra-pulmonary disease. 
Xpert MTB/RIF Pulmonary TB and extra- 
pulmonary TB and RIF resistance 
Xpert MTB/RIF used as an initial 
diagnostic test for detection of 
MTB and rifampicin is sensitive 
and specific. Xpert MTB/RIF is 
also valuable as an add-on test 
following microscopy for patients 
who are smear-negative.  
Automated liquid cultures and 
rapid   
 
Pulmonary TB and extra-
pulmonary TB; speciation 
Automated liquid cultures are 
more sensitive than solid 
cultures; time to detection is 
more rapid than solid cultures. 
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MP64-based species 
identification tests 
 MPT64-based rapid 
immunochromatographic tests 
(ICT) for species identification has 
high sensitivity and specificity. 
 
 
 
1.9.2 European guidelines 
The European Centre for Disease Prevention and Control (ECDC) and the European 
Respiratory Society (ERS) jointly developed European Union Standards for Tuberculosis Care 
(ESTC) aimed at providing European Union (EU)-tailored standards for the diagnosis, 
treatment and prevention of TB. All persons presenting with signs, symptoms, history or risk 
factors compatible with TB should be evaluated for PTB and/or EPTB. 
All patients (adults, adolescents and children who are capable of producing sputum) 
suspected of having pulmonary TB should have at least two sputum specimens submitted 
for microscopic examination, culture and drug susceptibility testing (DST) in a quality-
assured laboratory. When possible, at least one early morning specimen should be 
obtained. Samples sent for bacteriological examinations (sputum smear, culture, DST and 
new molecular methods) should be addressed to a mycobacteriology laboratory which 
implements optimal laboratory practices and quality-assured procedures according to 
European and international recommendations.  
Quality bacteriological diagnosis includes the WHO recommended rapid molecular assays, 
which should be performed as early as possible (ideally on the same day as diagnosis) within 
evidence-based diagnostic algorithms and guidelines. Culture, DST and rapid molecular 
testing should be performed on each sample from both pulmonary and extra-pulmonary TB, 
including samples obtained through surgery or other invasive procedures which usually 
undergo histological examinations (Milgiori et al., 2012). 
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1.9.3 NICE/PHE guidelines 
Public Health England (PHE) working in partnership with the NHS and Public Health Wales 
have developed UK standards for microbiology investigations (SMIs), which are intended as 
a general resource for practising professionals operating in the field of laboratory medicine 
and infection specialties in the UK. These comprise a collection of recommended algorithms 
and procedures (fashioned after the WHO/ESTC guidelines) covering all stages of the 
investigative process in microbiology, from the pre-analytical (clinical syndrome) stage to 
the analytical (laboratory testing) and post analytical (result interpretation and reporting) 
stages. SMIs are National Institute for Health and Clinical Excellence (NICE) accredited and 
represent neither the minimum standards of practice nor the highest level of complex 
laboratory investigation possible.  
The guidelines cover the use of automated liquid culture systems, plus solid media, for 
greater recovery of mycobacteria and the combined application of both phenotypic and 
molecular technologies that gives the most efficient approach to laboratory diagnosis of TB 
from different types of clinical specimens such as sputum, gastric washing, sterile site body 
fluids (CSF, pleural fluids), urine, skin or tissue biopsies, bone marrow, bronchoalveolar 
washings, blood, post-mortem specimens and bone (PHE, 2014) (see Table 1.3). 
Table 1.3. PHE-approved microbiologic tests for diagnosis of active tuberculosis. 
Test Site Comments 
Direct smear microscopy Pulmonary   Ziehl-Neelsen staining 
 Auramine-phenol 
staining (more sensitive 
than Ziehl-Neelsen 
staining) 
Culture-based assay Pulmonary TB and extra-
pulmonary TB 
 Automated (liquid) 
culture systems are faster 
and easier for detection 
of growth of MTB (1–2 
weeks) 
 Löwenstein Jensen (LJ) 
(solid culture) slope is 
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very slow (8–12 weeks) 
Nucleic acid  
amplification tests  
(NAATs) 
 
Pulmonary TB and extra-
pulmonary TB 
For the detection of MTB, when 
applied direct to a primary 
specimen; may be useful in certain 
situations, for example to rapidly 
confirm a diagnosis of tuberculous 
meningitis. 
The WHO has made 
recommendations regarding the 
application of this method – 
notably, for it to be used as the 
initial diagnostic test for TB on at 
least one sputum sample for 
individuals who are suspected of 
having HIV associated TB or MDR-
TB 
Matrix-assisted laser  
desorption ionization– 
time of flight (MALDI- 
TOF) 
Isolates from pulmonary TB and 
extra-pulmonary TB 
Mass spectroscopy analyses  
ribosomal proteins (e.g.16S, 23S) 
Commercial blood based assays 
for the diagnosis of latent TB e.g. 
tuberculin skin test (TST, i.e. the 
Mantoux), QuantiFERON
®
-TB 
gold in-tube and the T-SPOT
®
 TB 
assays 
 
For the detection of latent TB 
which is essential for contact 
tracing and outbreak control 
 
 
1.9.4 United Kingdom national external quality assessment service guidelines for the 
detection of Mycobacterium tuberculosis  
Since 1969, the United Kingdom national external quality assessment service (UK NEQAS) 
has provided a comprehensive worldwide service that enables laboratories to fulfil quality 
goals and facilitate optimal patient care. UK NEQAS now comprises a network of 390 
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schemes operating from 26 centres based at major hospitals, research institutions and 
universities throughout the UK. The services cover qualitative and interpretative 
investigations in reproductive science, cellular pathology, clinical chemistry, genetics, 
haematology, immunology and microbiology. 
Specimens are distributed at a regular frequency and aim to cover the range likely to be 
encountered in clinical practice. This process requires a combination of internal quality 
control (IQC) of the everyday analytical process and participation in external quality 
assessment (EQA) programmes, where the overall accuracy and comparability of results 
between centres may be determined (UK NEQAS, 2016).  
UK NEQAS for microbiology, operated by PHE, is a United Kingdom Accreditation Service 
(UKAS) accredited proficiency testing provider (no. 4715). The scheme is available to 
laboratories in the categories of UK clinical, UK non-clinical and non-UK, which involves 
about seventy countries (Europe and non-Europe) across the world. The aspects covered 
under microbiology are: 
 General bacteriology including MTB 
 Mycology 
 Virology 
 Serological testing: bacteriology and virology 
 Blood donor testing: blood borne viruses and syphilis 
 Parasitology 
Various methods including culture, microscopic identification, serology, point-of-care test 
(POCT) and molecular testing are catered for. Specimens are designed to simulate clinical 
samples and allow participants to use their routine assays. 
 
AAFB microscopy. Examination for the presence of acid and alcohol fast bacilli by 
microscopy. Materials distributed are slides of homogenized positive and negative sputum 
for staining and microscopy. Three distributions are made per annum with four samples per 
distribution across all the participating laboratories in the UK and non-UK. The scheme 
started in 1981. 
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Mycobacterium culture. On isolation of bacteria from simulated sputum, these materials 
are distributed as freeze-dried mixtures of mycobacteria and normal bacterial flora 
presented as a simulated sputum specimen. Three distributions are made per annum with 
two samples per distribution across all the participating laboratories in the UK and non-UK 
countries and this scheme started in 1993. 
 
Molecular detection of Mycobacteria. Detection and characterization (including typing and 
rifampicin resistance testing) of mycobacteria using molecular techniques. Materials 
distributed are freeze-dried mixtures of mycobacteria and normal bacterial flora presented 
as a simulated sputum specimen. Three distributions are made per annum with two samples 
per distribution across all the participating laboratories in the UK and non-UK countries. This 
scheme started in 2007, despite the fact that the RT-PCR assay was invented in the 1990s, 
results are available in a short time and the tests have relatively high sensitivity and 
specificity, compared to conventional AFB smear or AFB culture.   
 
1.9.5 Real–time polymerase chain reaction assay: A replacement for older methods? 
New diagnostic tests are continuously developed, driven by demands for improvements in 
speed, cost, ease of performance, patient safety and accuracy (Campbell et al., 2015). 
Consequently, there are often several tests available for the diagnosis of a particular 
condition. PCR was introduced in the mid-1990s and has had an unforgettable revolutionary 
impact on modern-day laboratories for the diagnosis of infectious diseases. Nucleic acid 
ampliﬁcation assays (NAAAs) are commonly used routinely in laboratories from 
industrialized countries for quick and speciﬁc detection of MTBC in clinical specimens. Over 
the years, signiﬁcant improvement of PCR technologies has been achieved with the 
development of RT-PCR assay testing platforms. The RT-PCR assay is commonly used to 
determine whether a deoxyribonucleic acid (DNA) molecule or sequence of the causative 
agent (MTB) is present in a sample and detects amplified DNA as the reaction progresses in 
real time.  
 
It monitors the amplification of a targeted DNA molecule during the PCR, i.e. in real-time 
and not at its end, as in conventional PCR. A RT-PCR assay detects targeted DNA sequences 
specific to a MTB genome and provides results from clinical samples in less than 2 h (short 
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turn-a-round time). It is sensitive, specific and reproducible, and automation of the 
procedure reduces hands-on time and decreases the risk of cross-contamination (Espy, 
2006).  
 
Figure 1.6 Relative fluorescence versus cycle number 
 
Amplification plots are created when the fluorescent signal from each sample is plotted 
against the cycle number; therefore, amplification plots represent an accumulation of the 
product over the duration of the RT-PCR assay experiment. The samples used to create the 
plots are a dilution series of the target DNA sequence. 
 
1.9.6 Principle of real-time polymerase chain reaction assays 
The PCR is based on amplification of a specific region of DNA/RNA using complementary 
primers to the target sequence. RT-PCR assays use marked probes with fluorophores that 
emit fluorescence in the case of amplification. The cycle of the PCR protocol in which 
significant fluorescence appears, proportional to the DNA/RNA quantity present in the 
sample. This value is called the cycle threshold (Ct) or cycle quantification (Cq) (see Figure 
1.6). 
 
RT-PCR assay steps 
There are three major steps that make up each cycle in a RT-PCR assay reaction. Reactions 
are generally run for 40 cycles. 
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1. Denaturation. High temperature incubation is used to ‘melt’ double-stranded DNA 
into single strands and loosen the secondary structure in single-stranded DNA. The 
highest temperature that the DNA polymerase can withstand is typically used 
(usually 95 °C). The denaturation time can be increased if the template guanine-
cytosine (GC) content is high.  
2. Annealing. During annealing (binding of the primers with the DNA template), 
complementary sequences have an opportunity to hybridize, so an appropriate 
temperature is used that is based on the calculated melting temperature (Tm) of the 
primers (5 °C below the Tm of the primer). 
3. Extension. At 70–72 °C, the activity of the DNA polymerase is optimal and primer 
extension (polymerization) occurs at rates of up to 100 bases/s. When an amplicon 
in A RT-PCR assay is small, this step is often combined with the annealing step using 
60 °C as the temperature. 
 
Figure 1.7 RT-PCR steps. Credit: Applied Biosystems - Essentials of a RT-PCR assay. 
 
1.9.7 Applicability in diagnostic medical laboratory  
Since the introduction of RT-PCR assay technology in the field of diagnostic medical 
microbiology, a lot of tremendous improvements have been recorded, particularly in the 
detection of slow growing or difficult to grow infectious agents and improvements in patient 
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management and care. The first description of application of PCR in medical microbiology 
was for the detection of HIV from infected cell lines and in cells cultured from infected 
individuals (Kwok et al., 1987). 
RT-PCR assay is a closed-tube system which reduces the risk of amplicon carryover. It allows 
for the monitoring of the reaction in real time which provides results immediately after 
cycling and facilitates quantification of the original target sequence. RT-PCR assays measure 
fluorescence over a wider range of wavelengths with a multitude of fluorescent dyes. 
It is useful in the quantitative detection of a wide range of causative agents of viral 
infections such as adenovirus, hepatitis viruses, Epstein-Barr virus (EBV), cytomegalovirus 
(CMV), enteroviruses, herpes viruses and respiratory viruses (avian influenza viruses: H5N1, 
H7N7 and H7N3). 
Its applicability has expanded to the detection of numerous bacterial pathogens e.g. 
Neisseria meningitides, Neisseria gonorrhoeae, Streptococcus pneumonia, Heamophilus 
influenzae, Legionella pneumophila, Chlamydial trachomatis, Bordetella pertussis, 
Clostridium difficile, Mycoplasma pneumonia, Helicobacter pylori, Staphylococcus aureus, 
Methicillin-resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis (MTB). 
The assay is equally used in the detection of antibiotic resistance, antiviral susceptibility and 
toxin genes (Valones et al., 2009). 
1.9.8 Commercial types of real-time polymerase chain reaction assay for Mycobacterium 
tuberculosis detection 
Table 1.4. RT-PCR Primers and probes of oligonucleotide sequence for MTB detection. 
Primers References 
In-house mpt64 RT-PCR:   mpt64 (forward) –    5’CCTCGGCCACATACCAGTCC3’  
  
                                             mpt64 (reverse) –     5’TGTCCGGTCTGCTTGCTCAG3’  
 
(Seith, et al., 2012)     
Real time IS6110-PCR: 
                                  (forward)              59-GTAGGCGTCGGTGCAAAAG-39 
                       
                                   (reverse)             59-GGCTGTGGGATGCACACCT-39 
 
IS6110_FAM probe 6FAM-ACGTAGGCGAACCCTGCC     
(Albuquerque et al., 
2014)         
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IS6110 (multicopy):  
                                  (forward)                 AACAGTGTGTTGGTGGCCAA 
                                                                    GAACGGCTGATGACCAAACT  
                                 (reverse)                   ATCAGCGATCGTGGTCCTG 
                                                                    AGCGGGAAATCGTGCGTG  
(Luo et al., 2010) 
devR quantitative RT-PCR assay (qRT-PCR): 
                             (forward)                          (59-ATCTGTTGTCCCGCATGCC-39) 
 
                              (reverse)                          (59-GTCCAGCGCCCACATCTTT-39)  
  
 
(Barletta et al.,  2014) 
TaqMan-specific probe (and ROX as a passive reference) 
                                                                         (5′-AGGCGAACCCTGCCCAG-3′)                          
 TAQM3 oligonucleotide and TAQM4                            
                                                                         (5′-GATCGCTGATCCGGCCA-3′)  
(Choe et al., 2011) 
(Malhotra et al., 2012) 
 
16S rRNA gene: 
Cobas Amplicor pan-Mycobacterium primers:                            
                                         KY18 (5’ CAC ATGCAA GTC GAA CGG AAA GG-3’)  
                                          
                                         KY75 (5’ GCC CGT ATC GCCCGC ACG CTC ACA-3’) 
 
 Mbakt-14:                       (5’ GRG RTA CTCGAG TGG CGA AC-3’ )  
(Bloemberg et al., 2013) 
(Malhotra et al., 2012) 
INS-1/INS2 primers:     INS-1        ( 5’- CGTGAGGGCATCGAGGTGGC-3’) 
                                        INS-2          (5’- GCGTAGGCGTCGGTGACAAA-3’)  
 
(Hillemann et al., 2011 
and Rosso et al., 2011) 
 
IS6110:      Primers IS6110 D-1       (5’- ACCTGAAAGACGTTATCCACCAT-3’)  
 
                                   IS6110 D-2      (5’-CGGCTAGTGCATTGTCATAGGA- 3’) 
 
                    Probe: (5’-[6 FAM]TCCGACCGCGCTCCGACCGACG[TAMRA-Q]3’)  
(El Khe´chine et al., 2009) 
 
RT-PCR assay targeted senX3-regX3 intergenic region: 
 
                                The primer sets:     TAQ-T1, (5’-GTAGCGATGAGGAGGAGTGG-3’) 
                                                                  TAQ-T2, (5’ACTCGGCGAGAGCTGCC-3’) 
 The probe sequence: 
                                      TAQ-Tp, (5’ FAMACGAGGAGTCGCTGGCCGATCC- TAMRA-3’)  
 
(Antonenka et al., 2013) 
(Choe et al., 2011) 
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1.9.9 Protocol of real-time polymerase chain reaction assay for Mycobacterium 
 tuberculosis detection 
Principle of the procedure 
RT-PCR assay is based on two major processes: 
1. manual specimen preparation to obtain MTB DNA; 
2. simultaneous PCR amplification of target DNA using complementary primers and 
detection of target DNA through cleavage of dual fluorescent dye-labelled 
oligonucleotide probes. 
These processes permit the detection of a MTB target amplified product (amplicon) and 
mycobacterial internal control DNA, which is amplified and detected simultaneously with 
the specimen. 
Clinical specimens are prepared according the manufacturer's specifications and biosafety 
regulations. 
Target selection. The Mycobacterium genome contains a highly conserved region of 
nucleotides encoding the gene under consideration (e.g. 16S rRNA, IS6110, senX3-regX3 
intergenic, Mbakt-14, mpt64 etc.) RT-PCR assay for MTB uses Mycobacterium specific genus 
primers to define a sequence within the region. 
Target amplification. PCR amplification occurs in tubes in which processed specimens are 
added to the amplification mixture. The reaction mixture is heated to denature the double 
stranded DNA and expose the primer target sequences. 
As the mixture cools, the primers anneal to their target sequences. DNA polymerase in the 
presence of Mg2+ and excess deoxynucleotide triphosphates (dNTPs) extend the annealed 
primers along the target templates to produce a double stranded DNA molecule termed an 
amplicon.  
The RT-PCR assay automatically repeats this process for a designated number of cycles, 
where it is intended that each cycle doubles the amount of amplicon DNA. The required 
number of cycles is pre-programmed into the assay. However, amplification occurs only in 
32 
 
the region of the MTB genome between the primers; the entire MTB genome is not 
amplified. 
Internal amplification control. The use of mycobacterium internal control (MIC) is 
encouraged. This permits the identification of processed clinical specimens containing 
substances that may interfere with PCR amplification. MIC is a non-infectious, recombinant 
linearized plasmid DNA with primer binding regions identical to those of the MTB target 
sequence, a randomized internal sequence of similar length and base composition as the 
MTB target sequence and a unique probe binding region that differentiates its amplicon 
from the target MTB amplicon. The MIC is introduced into each amplification reaction to be 
co-amplified with MTB DNA from the clinical specimens that contain inhibitors (reduce the 
efficiency of the assay) that would interfere with the amplification and detection of the MTB 
target sequence. 
Detection of Mycobacterium tuberculosis 
RT-PCR assay technology uses dual-labelled fluorescent probes that provide real-time 
detection of PCR product accumulation by monitoring the emission intensity of fluorescent 
reporter dyes released during the amplification process. 
The probes consist of MTB- and MIC-specific oligonucleotides labelled with a reporter dye 
and a quencher dye. These probes are labelled with different fluorescent reporter dyes. 
During the reaction, the probe hybridizes to a target sequence and is cleaved by the 5' to 3' 
exonuclease activity of the thermostable DNA polymerase. After the reporter and quencher 
dyes are released and separated, quenching no longer occurs and fluorescent activity of the 
reporter dye is increased. The amplification of MTB DNA and MIC DNA are measured 
independently at different wavelengths. This process is repeated for a designated number 
of cycles, each cycle effectively increasing the emission intensity of the individual reporter 
dyes, permitting independent identification of MTB DNA and MIC DNA (Huh et al., 2015). 
1.9.10 Aims and objectives of research project  
The aims of this research project, through systematic review and meta-analysis, are to 
provide summary estimates of the effectiveness of a RT-PCR assay for the diagnosis of MTB 
from pathological (pulmonary and extra-pulmonary) samples; appraise and summarise 
evidence-based information that using this assay increases test accuracy, rapid diagnosis 
33 
 
and a reduced turn-a-round time; critically evaluate the quality of primary studies, checking 
for heterogeneity in results across studies and determining sources of heterogeneity, where 
necessary. Consequently, the findings may aid healthcare practitioners and policymakers in 
adopting the use of this assay on a daily routine basis, most importantly as a point of care 
test (POCT), which will be a good tool for global control of MTB, particularly in developing 
countries that account for about 80% of the global burden of MTB and to shape national TB 
control programme or policy. This will also help funding bodies to appropriately allocate 
resources for diagnostic strategies. 
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Chapter 2: Design of systematic review and meta-analysis 
 
2.1 Introduction 
This chapter discusses systematic review and meta-analysis of research design with a high 
hierarchy of evidence-based medicine. It highlights the organizations that may be involved 
in systematic review. It also explains the stages involved in conducting systematic review 
and meta-analysis and the adoption of a Cochrane Review style for the research. 
What is a systematic review? The Cochrane Handbook defines it as an attempt to identify, 
appraise and synthesize all the empirical evidence that meets pre-specified eligibility criteria 
to answer a given research question. Researchers conducting systematic reviews use explicit 
methods aimed at minimizing bias in order to produce more reliable findings that can be 
used to inform decision making (The Cochrane Collaboration, 2014). 
Therefore, the goal of systematic review is to provide evidence-based healthcare 
information by integrating individual clinical expertise with the best available external 
clinical evidence from systematic research. Systematic reviews may help practitioners solve 
specific clinical problems. It may improve understanding of inconsistency among diverse 
research evidence. By integrating the information of several studies, meta-analyses can 
create more precise, powerful and convincing conclusions (Cook, Mulrow & Haynes, 1997). 
Systematic reviews also help health practitioners keep abreast of the medical literature by 
summarizing large bodies of evidence and helping to explain differences amongst studies 
with the same question. A systematic review involves the application of scientific strategies, 
in ways that limit bias to the assembly, critical appraisal and synthesis of all relevant studies 
that address a specific clinical question. It is used to inform medical decision making, plan 
future research agendas and establish clinical policy; systematic reviews may strengthen the 
link between best research evidence and optimal health care (Dowie, 1996). Evidence can 
lead to bad practice if it is applied in an uncritical or unfeeling way. Understanding the 
complex structure of medical decision-making requires an appreciation of the ways in which 
knowledge, skills, values and research evidence are integrated in each patient-clinician 
encounter (Nancy, 1995). 
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Figure 2.1 Hierarchy of scientific evidence: Reproduced from 
https://thelogicofscience.com/2016/01/12/the-hierarchy-of-evidence-is-the-studys-design-
robust/  
  
2.2 Systematic reviews and meta-analyses  
Systematic reviews and meta-analyses are a position of strength at the very top of the 
evidence pyramid (see Figure 2.1). These are not primary research experiments, but rather 
reviews and analyses of previous experiments. Systematic reviews carefully comb or filter 
through the literature for information on a given topic, condense the results of numerous 
trials into a single paper that discusses everything known about that topic. Meta-analyses 
take a step further by (i) actually combining data sets from multiple papers and (ii) running 
statistical analyses across them all. Consequently, very powerful results are produced that 
avoid the shortfall of relying on any one study which may have the incorrect conclusions.  
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2.2.1 Cohort studies 
 This is classified as moderate to strong in strength. These can either be prospective or 
retrospective. 
Prospective (concurrent or longitudinal) studies: A researcher identifies 
the study population at the beginning of the study and accompanies the subjects through 
time. The characteristics of the group of people researcher wishes to study are first 
identified and then determines the present case status of individuals. Exposure status is 
determined at the beginning of the study. 
2.2.2 Retrospective studies  
These can also be carried out if there is access to detailed medical records. In this case, a 
starting population is selected in the same way, but instead of following the population, 
medical records are considered for the preceding several years (this, of course, relies on 
having access to reliable records for a large cohort). 
 
This type of study is often very expensive and time consuming, but has a considerable 
advantage over other methods in that it can detect causal relationships. As it is possible to 
follow the progression of the outcome, one can see if the potential cause precedes the 
outcome. Additionally, cohort studies generally allow calculation of the risk associated with 
a particular treatment/activity. With retrospective studies, confounding and bias are the 
principle cause of error (Stats Direct, 2000–2014), whereas loss of follow-up is the main 
cause of error for prospective studies (Euser, Zoccali, Jager, & Dekker, 2009). 
2.2.3 Observational 
This study type involves no experimental diagnostic tests or medicines. Clinical care is 
implemented according to existing national guidelines. 
2.2.4 Diagnostic case-control 
Diagnostic case-control design also referred to as the ‘two gate design’. In this study design 
a cohort with the condition (cases) come from one population (i.e. a health care centre for 
patients known to possess the condition), while those without the condition originate from 
another source. 
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2.2.5 Cross-sectional study 
Also often known as a transversal study, these studies are observational and involve all 
patients suspected of having the condition of interest undergoing an index test and a 
reference test. Those who test positive for the condition by a reference test may be 
considered to be cases, whereas those who test negative become controls. In the absence 
of experimental evidence, the best information on which to base practice is that of expert 
opinion. However, individuals, or even groups of like-minded individuals, are subject to a 
number of biases (Tidy, 2010). 
 
2.2.6 Clinical evaluation study 
In the present era of evidence-based medicine (EBM), medical tests cannot escape close 
scrutiny. Before tests are put into practice, claims about their information value and 
usefulness should be thoroughly questioned and critically tested. One needs high-quality 
studies to provide evidence of a test’s practical use (Bossuyt, 2006). In studies of diagnostic 
accuracy, the results of one or more tests are compared with a gold standard. All patients 
receive the index test and all receive the gold standard. The dominant paradigm in the 
clinical evaluation of tests is determination of a test’s diagnostic accuracy (Bossuyt et al., 
2006).  
2.3 Systematic review groups 
Although all systematic reviews use formal, explicit methods to describe and synthesise 
evidence, they may vary considerably in the types of questions they aim to answer. As a 
result, different types of evidence will be required. A major use of systematic research 
synthesis is to inform policy and practice about the effectiveness of health care 
interventions and medicines. 
Some organizations including the Cochrane Collaboration are interested in combining 
numerical data from experimental studies in the form of meta-analyses to answer questions 
about ‘what works’. Others are the Campbell Collaboration and EPPI-CENTRE. 
2.3.1 Cochrane collaboration 
There are six types of Cochrane review:  
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1. Intervention reviews: these assess the benefits and harms of interventions used in 
healthcare and health policy. 
2. Diagnostic test accuracy reviews: these assess how well a diagnostic test performs in 
diagnosing and detecting a particular disease. 
3. Methodology reviews: they address issues as to how systematic reviews and clinical 
trials may be conducted and reported. 
4. Qualitative reviews: these synthesize qualitative and quantitative evidence to 
address questions on aspects other than effectiveness (Bearman & Dawson, 2013). 
5. Prognosis reviews: they address the probable course or future outcome(s) of people 
with a health problem. 
6. Overviews of systematic reviews: these are a new type of study that compile 
multiple evidence from systematic reviews into a single document accessible and 
useful to serving as a friendly front end for the Cochrane Collaboration with regard 
to healthcare decision-making. 
 
2.3.2 Campbell Collaboration 
The Campbell Collaboration (named after Donald Campbell, an American psychologist and 
thinker), a sibling organization to Cochrane, prepares, maintains and promotes the 
accessibility of systematic reviews in areas such as education, criminal justice, social policy 
and social care. 
 
The Campbell Collaboration (C2) is a non-profit organization that aims to help people make 
well-informed decisions about the effects of interventions in the social, behavioural and 
educational arenas. Using systematic reviews of studies of interventions (programmes, 
practices and policies), C2 helps policymakers, practitioners, researchers and the public 
identify what works.  
 
2.3.3 EPPI-CENTRE 
The evidence for policy and practice information and co-ordinating centre EPPI-Centre is 
part of the Social Science Research Unit, Institute of Education, University of London. 
    
39 
 
2.3.4 Joanna Briggs Institute (JBI)  
This is an international, not-for-profit, research and development centre within the Faculty 
of Health Sciences and Medical at the University of Adelaide, South Australia. The Institute 
collaborates internationally with over 70 entities across the world. The Institute and its 
collaborating entities promote and support the synthesis, transfer and utilization of 
evidence through identifying feasible, appropriate, meaningful and effective healthcare 
practices to assist in the improvement of healthcare outcomes globally. In the list of the 
Institute is the systematic review of studies of diagnostic test accuracy. 
2.4 Registration with PROSPERO 
This is an international prospective register of systematic reviews that was launched in 2011 
and is funded by the National Institute for Health Research (NIHR) in the UK. The aim of the 
register is to help prevent unintended duplication of systematic reviews by allowing those 
commissioning or planning reviews to identify whether there are any relevant reviews 
already underway. It simplifies the process of registration in comparison to Cochrane (Booth 
et al., 2013). The objectives were to reduce unplanned duplication of reviews and provide 
transparency in the review process and help identify potential biases by enabling 
comparison of reported review findings with what was planned in the protocol with the aim 
of minimizing reporting bias (Booth et al., 2011). PROSPERO do not take a role in the 
production of reviews in the same sense as Cochrane. Cochrane does not register non-
Cochrane protocols therefore, not all the reviews registered in PROSPERO appear in the 
Cochrane Database of Systematic Reviews. 
2.5 Stages in a systematic review 
A systematic review must have:  
 A Clear inclusion/exclusion criterion 
 An explicit search strategy 
 Systematic coding and analysis of included studies 
 And may or may not include a meta-analysis (where appropriate) 
These essential stages in conducting a systematic review are highlighted below. 
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2.5.1 Formulation of a clear and focused review question 
The development of a clear, well-defined question is essential to maintain transparency of 
the review process, the quality and relevance of the findings. Some aspects of the question 
require particular consideration when planning a review of diagnostic test accuracy. These 
stages/components are as follows: 
The focused review question should contain the components (population, 
intervention/index test, comparator/reference standard and outcome measures: PICO 
framework).  
 Population. This is the population of interest which is the type of participants and 
this should be appropriate for the review question, e.g. patients with symptoms of 
TB.  
 Index text. This is the test whose performance is being evaluated. It can be viewed 
as the intervention. 
 Comparator/reference standard. This is usually the best test ‘gold standard’ 
currently available against which an index test is compared; the comparator is an 
alternative test, usually that which is used in current practice, against which an index 
test must be evaluated in order to assess its potential role. Ideally, this should be 
achieved by comparing an index test and comparator/reference standard in the 
same population.  
 Outcome measures. These describe the relationship between the results of an index 
test and a reference standard at a given diagnostic threshold (point at which results 
are classified as positive or negative) (Deeks, 2001). The terms most frequently used 
are accuracy, sensitivity and specificity. The contingency table includes the number 
of true positives (TP: those that have the disease and test positive), false positives 
(FP: those that do not have the disease and test positive), false negatives (FN: those 
that do have the disease and test negative) and true negatives (TN: those that do not 
have the disease and test negative) (see Table 2.1). 
Table 2.1 A 2×2 contingency table. 
 
 
       Reference standard 
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Index Test 
Positive Negative 
 
Positive TP FP 
 
Negative FN 
 
TN 
2.5.2 Comprehensive literature search  
A search strategy is used to generate a comprehensive and exhaustive list of primary studies 
and to identify research evidence suitable for answering a research question posed. This is 
usually carried out using a wide range of electronic bibliographic databases such as, 
MEDLINE/PubMed, EMBASE, BIOSIS, LILACS, Cochrane Infectious Diseases Group Specialised 
Register (CIDG SR) and CINAHL (Whiting et al., 2008).  
 
To avoid missing relevant studies to be included, searching other sources by looking through 
reference lists of relevant reviews and studies, searching websites of a relevant 
organization, performing forward citation searching of relevant articles using the PubMed 
related articles feature, Google Scholar, Cochrane Library, turning research into practice 
(TRIP), dissertations and theses databases, grey literature, personal communication 
(contacting authors and experts to locate on-going and unpublished studies), hand 
searching journals, conference proceedings and contacting relevant experts for additional 
studies to reduce publication bias are carried out. This process is important to assist in 
achieving more reliable estimates of diagnostic accuracy, and therefore ensuring that the 
studies are identified and are as thorough and unbiased as possible (Dickersin, 2005; 
Easterbrook, 1991). 
2.5.3 Critical appraisal of included studies for quality and data extraction (QUADAS-2) 
A structured appraisal of methodological quality is key to assessing the reliability of test 
accuracy studies to be included in a systematic review (Oosterhuis, Niessen and Bossuyt, 
2000). The quality assessment of diagnostic accuracy studies (QUADAS-2) tool is used to 
assess the quality of included studies (Whiting et al., 2011). QUADAS-2 is a generic tool that 
may be adapted to optimise its usefulness for specific topic areas. This is necessary to 
identify potential sources of bias and to limit the effects of these biases in the estimates and 
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the conclusion of the review. However, publication bias can also be assessed using funnel 
plots. It is acknowledged that asymmetry, of which publication bias is one cause, is difficult 
to detect with a small number of studies (i.e. less than 10) which is often encountered in 
systematic review. It excludes low-quality studies from the review at this stage. Data 
extraction is undertaken in parallel with quality assessment; extracted data are used to fill 
four cell values of a diagnostic 2×2 table (True positive (TP), False positive (FP), True 
negative (TN) and False negative (FN)).  
Missing data: During this assessment, missing data can be encountered often, several of 
these features may not be reported in primary studies or may be unclear in the published 
report, therefore, there may be a need to contact authors of the studies to seek additional 
information.  
2.5.4 Data synthesis and summary of study results 
2.4.4.1 Binary classification of index test  
This test and a reference standard otherwise called test accuracy requires a 2×2 contingency 
table (sensitivity TP/ (TP+FN) and specificity TN/ (TN+FP).           
 
Index Test Outcome 
Disease 
(Reference test) 
Total 
 
Present (positive) Absent (negative) 
Index 
Test 
+ 
TP FP 
Test positives 
(TP+FP) 
- 
FN TN 
Test Negatives 
(FN+TN) 
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Total 
TP+FN FP+TN 
TP+FP+ 
FN+TN 
 
Figure 2.2 Classification of patient test results by condition status. TP: true positive; FN: false 
negative; FP: false positive; TN: true negative. 
                  
The positive predictive value  is the proportion of individuals with positive test 
results who were correctly diagnosed, while the negative predictive value is 
the proportion of individuals with negative test results that were correctly diagnosed.  
2.5.4.1 Graphic representation 
Results of systematic reviews can be graphically presented particularly in diagnostic test 
accuracy. This is presented as forest plots of sensitivity and specificity or creating summary 
ROC (SROC) curves (see Figures 2.3 & 2.4) 
2.5.4.2 Likelihood ratios  
Likelihood ratios assess the probability or likelihood that the test result obtained would be 
expected in a person with a specific condition, compared to the probability or likelihood 
that the same result would be seen in a person without the condition (Deeks, 2001). 
2.5.4.3 ROC analyses  
Receiver operating characteristic (ROC) curve analysis is useful in evaluating the 
performance of diagnostic tests that classify individuals into categories of those with and 
without a condition (Metz, 1978; Zou et al., 2007). 
 
The choice of a decision threshold will have a large effect on the sensitivity and specificity of 
a test. While setting a low threshold will result in a large proportion of true positives being 
correctly identified as positive, it will also decrease the rate of true negatives. In other 
words, a lower threshold increases sensitivity but decreases specificity. The inverse is also 
true for high thresholds. 
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The area under curve (AUC) for a perfect test is 1.0 and a test with no differentiation 
between disorder and no disorder has an AUC of 0.5 (Lalkhen & McCluskey, 2008) (see 
Figures 2.3 & 2.4). 
 
2.5.4.4 Models for meta-analyses 
There are three main models: 
Firstly, a fixed effect model with the other two being random effect models based on a 
hierarchical model and considering the variability present within studies and between 
studies. 
1. The Moses-Littenberg model. This is a fixed effect model extensively used for meta-
analyses of diagnostic test accuracy (DTA); whereas, for many such analyses, a 
random effect model may be required. However, it does not take into account and 
consider the variability between studies but it allows for the performance of SROC 
curves in an exploratory approach (Eusebi et al., 2014; Moses et al., 1993) Therefore, 
Cochrane Collaboration recommends careful use of this model in a heterogeneity 
study, but it should be limited only to preliminary analyses.      
 
2. The Bivariate model. These analyses summarize parameters such as sensitivity and 
specificity jointly across primary studies; therefore, this retains the paired nature of 
the original data and is a method choice (Leeflang, 2014). According to Chu and Cole 
(2006), the within study variability is modelled through binomial distributions, one 
for sensitivity and the other for specificity. The distributions are treated jointly since 
estimates of sensitivity and specificity, within each study, are non-independent. 
 
3. The hierarchal SROC (HSROC). In dealing with variability in positivity cut-point 
values, the HSROC model was developed by Rutter and Gatsonis in 2001 (Macaskill, 
2010). This produces a SROC in which each study provides only one pair of values for 
sensitivity and specificity.  
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Figure 2.3 Forest plot estimates of pooled SROC showing the AUC for PTB 
 
 
 
 
 
Figure 2.4 Forest plot estimates of pooled SROC showing the AUC for EPTB 
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2.5.5 Heterogeneity  
A common place in systematic reviews of DTA is to frequently encounter heterogeneity 
between studies (Macaskill, 2010). This may be a result of differences in study populations, 
procedures adopted for carrying out either the reference or index test and the conditions or 
context of testing. Differences in how studies have been conducted, how the data has been 
analysed and which have biased the results may contribute to heterogeneity. For example, 
one study could have included all test results in the final analysis, whereas another may 
exclude inconclusive or indeterminate outcomes, thereby, making the test appears more 
accurate than it actually is. 
Consequently, it is important to carefully investigate the presence of heterogeneity 
between studies. This may be achieved either by displaying data graphically through paired 
forest plots or SROC curves. It is worth noting that where there are differences in the 
diagnostic threshold between studies, paired forest plots should not be used to estimate 
heterogeneity as variability should exist due to the interdependence of sensitivity and 
specificity. In such cases heterogeneity can be estimated by judging how well studies fit with 
the SROC curve and not by how scattered they are. 
The Chi-square test or Fisher’s exact test can also be used for more objective assessments of 
heterogeneity; however, their power has been noted to be low (Dinnes et al., 2005). Where 
heterogeneity is found, its cause should be carefully investigated by comparing 
characteristics of the differing studies; effort should therefore be made to identify potential 
subgroup analyses and the intention to carry them out declared a priori in the protocol. 
Unfortunately, subgroup analyses that are homogeneous analyses with respect to important 
potential confounders, such as patient spectrum, test methods and study design, carry their 
own difficulties, as when subgroups contain a low number of studies, they are prone to 
heterogeneity (White & Enumameh, 2011).  
The use of random effect models of meta-analysis (discussed above) can help to identify 
heterogeneity by adding a covariate into the model. The covariate, either categorical or 
continuous, is accordingly assumed to be the heterogeneity source. However, these values 
are not easily interpreted, as they show variation in parameters expressed on log odds 
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scales (Leeflang, 2014). When the extent of heterogeneity cannot be explained, reviewers 
should refrain from meta-analysis and instead conduct a narrative synthesis. 
 
2.6 Interpretation of results 
A major focus of systematic reviews of diagnostic test accuracies is to obtain summary 
estimates of test accuracy which should help readers understand the implications for clinical 
diagnostic practice and the need for further research on the research question. This 
interpretation should consider whether evidence derived from the review suitably 
addresses the objectives of the review, whether the included studies indeed investigate the 
intended future role of the test under evaluation, whether the results are unlikely to be 
biased and whether the study sample was representative. Additional information, such as 
costs or important trade-offs between harms and benefits may be included. 
However, knowing that a test has high sensitivity does not inform us as to whether the test 
will have much impact on the patient, nor does it tell us that using this test in practice will 
be beneficial for the patient or cost-effective. In a few cases, improved accuracy is not even 
necessary for patient benefit to occur because new tests may improve outcomes if they can 
be used on a wider patient group, are less invasive, or allow time-critical effective therapy to 
be given earlier (Ferrante di-Ruffano et al., 2012). Although a grading of recommendations 
assessment, development and evaluation (GRADE) approach for diagnostic tests has now 
been developed, providing guidance on how to translate accuracy data into a 
recommendation involving outcomes important to patients requires much more 
consideration (Schünemann et al., 2008).  
2.7 Meta-analysis 
Meta-analysis is a set of statistical techniques for combining results of two or more studies. 
 It provides summaries of the results of relevant studies: providing estimate of the 
average diagnostic accuracy of a test(s), the uncertainty of this average, and the 
variability of study findings around the estimates. It also helps to make sense of 
apparently conflicting study results, as it identifies which differences are likely to be 
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real, which are explicable by chance and which can be explained by known 
differences in study characteristics (Macaskill, 2010).  
Review Manager software (RevMan 5.3) can be used to facilitate the meta-analysis. 
Some of the elements in meta-analysis include: sensitivity and specificity for uncertainty, 
predictive values, likelihood ratios, diagnostic odds ratios, receiver operating characteristic 
curve, summary of receiver operating characteristic plots and forest plots for presenting the 
primary results extracted from the study results with their confidence intervals. 
Heterogeneity is to be expected in meta-analyses of diagnostic test accuracy. The 
consequence of this is that meta-analyses of test accuracy studies tend to focus on 
computing average rather than common effects. To investigate heterogeneity (degree of 
variability), it is better to use graphical visualization and a Chi- square test. 
Publication bias (funnel plot) is designed to check the existence of publication bias in 
systematic reviews and meta-analyses. It assumes that the largest studies are near the 
average and small studies are spread on both sides of the average. Variation from this 
assumption can indicate publication bias. 
2.8 Adoption of Cochrane review method 
The style of Cochrane review adopted in this research work is described as follows. 
The methodological approach for evidence searching and synthesis described in this 
protocol conformed to the Cochrane collaboration methods for assessing diagnostic test 
accuracy (Irwig et al., 1994). Recommendations of the preferred reporting items for 
systematic review and meta-analysis protocols (PRISMA-P) were followed. A systematic 
review is required to answer the specific research question in this study: ‘is RT-PCR assay 
when used alone sufficiently sensitive and specific for the diagnosis of MTB from 
pathological samples?’ 
 
Currently, to the best of the reviewer’s knowledge, there are no Cochrane systematic 
reviews and meta-analysis of effectiveness of RT-PCR assays for the detection of MTB from 
pathological samples. The Cochrane library was searched and the Cochrane collaboration 
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was approached with the possibility of hosting the review and promised to host such review 
in the near future. However, it was obvious to the reviewer no such review was ongoing. 
In order to conduct a systematic review it is necessary to write a protocol (see Appendix 2) 
for decision on protocol manuscript submitted for publication in the systematic review 
Journal of BioMed Central November 2015; unfortunately in February 2016 when the final 
manuscript reached the Editorial Board it could not be published because the review had 
reached the final data extraction stage, as they only publish protocol that has not reached 
such an advanced stage as ours; however, the board advised for the publication of full 
review article (on completion). The protocol served the same role as a research proposal to 
guide in the systematic review process. The systematic review can then be conducted with 
the same rigour expected of all research. The protocol states the review question or 
questions, how studies will be located, appraised, selected and then synthesized.  
According to Mackenzie et al. (2012), publishing a protocol is a good practice in systematic 
review as it enhances the transparency of the process and avoids duplication. It includes 
objectives, background of the target condition being reviewed/diagnosed, index test, 
reference/alternative tests, rationale or justifications for the review and methods for 
conducting the review.  
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Chapter 3: A systematic review and meta-analysis of effectiveness 
of real-time polymerase chain reaction assay for the detection of 
Mycobacterium tuberculosis in pathological samples  
3.1 Abstract 
3.1.1 Background 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) and 
is a major health problem with an annual global mortality ~1.8 million people. With a third 
of the world’s population infected by MTB complex, accurate and timely diagnosis of TB is 
critical for management of this global epidemic and controls of its transmission. However, 
established diagnostic methods suffer from low sensitivity or delays in getting timely results, 
and hence are inadequate for rapid detection of MTB in pulmonary and extra-pulmonary 
pathological samples. This study examined whether a RT-PCR assay would prove effective 
for the detection of MTB in clinical microbiology laboratories. 
3.1.2 Objectives 
To identify, critically appraise and summarize evidence-based information from primary 
studies that using a RT-PCR assay with a 2 h turn-a-round time would prove effective for 
routine detection of MTB from pathological samples in clinical microbiology laboratories. 
3.1.3 Search methods 
A comprehensive systematic literature search was performed for publications in any 
language between January 1995 (RT-PCR became a tool for detecting and quantifying 
expression profiles of selected genes in the mid-1990s; a search using the key words ‘real-
time’ and ‘PCR’ yielded seven publications in 1995) and November 2016 on the detection of 
MTB in pathological samples by RT-PCR assay. MEDLINE via PubMed, EMBASE, BIOSIS 
Citation Index, Web of Science, SCOPUS, ISI Web of Knowledge, Cochrane Infectious 
Diseases Group Specialised Register, grey literature, World Health Organization and Centres 
for Disease Control and Prevention websites.  
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3.1.4 Selection criteria 
Studies were only included if they met the inclusion criteria set for this study. All types of 
studies such as cross-sectional studies, cohort studies (prospective and retrospective) and 
case-control designs for the detection of MTB in pathological samples by RT-PCR assay were 
included, provided culture-based assay was used as a reference/gold standard. Publications 
on animal studies, not using culture-based assay as a reference standard or combination of 
more than one diagnostic test as a reference, application of RT-PCR assay for determining 
drug resistance, RT-PCR assay used for detecting non-TB mycobacteria and RT-PCR assay 
used for detecting MTB from clinical isolates were excluded. 
3.1.5 Data collection and analysis 
Data was extracted from each selected study using forms with a predetermined list of 
categories/characteristics which included participants/population, index test, reference test, 
disease, country and target sequence for MTB DNA detection. The analyses were both 
descriptive and quantitative. Generated pooled summary estimates (95% Confidence 
Intervals [CIs]) were calculated for sensitivity and specificity. For meta-analysis, the bivariate 
meta-regression model was used because it considers potential threshold effects and the 
correlation between sensitivity and specificity using a random effect approach. It also allows 
addition of covariates for investigation of potential sources of heterogeneity. The study 
employed the software RevMan 5.3 and Meta-Disc for statistical analysis of the data. 
3.1.6 Main Results:  Summary estimates for pulmonary TB (31 studies) were as follows: 
sensitivity 0.82 (95% CI 0.81–0.83), specificity 0.99 (95% CI 0.99–0.99), positive likelihood 
ratio 43.00 (28.23–64.81), negative likelihood ratio 0.16 (0.12–0.20), diagnostic odds ratio 
324.26 (95% CI 189.08–556.09) and area under curve 0.99. Summary estimates for extra-
pulmonary TB (25 studies) were as follows: sensitivity 0.70 (95% CI 0.67–0.72), specificity 
0.99 (95% CI 0.99–0.99), positive likelihood ratio 29.82 (17.86–49.78), negative likelihood 
ratio 0.33 (0.26–0.42), diagnostic odds ratio 125.20 (95% CI 65.75–238.36) and area under 
curve 0.96. 
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3.1.7 Author’s conclusions 
Real-time polymerase chain reaction assays showed a high degree of sensitivity for PTB and 
moderate sensitivity for EPTB. It indicated a high degree of specificity for ruling in TB 
infection from sampling regimes. This was acceptable but may suggest RT-PCR assay as a 
rule out add-on diagnostic test. The high degree of sensitivity for pulmonary samples from 
RT-PCR assays and rapidity of detection of TB is an important factor in achieving effective 
global control and for patient management in terms of initiating early and appropriate anti-
tubercular therapy. 
 
3.2 Plain language summary 
3.2.1 Effectiveness of real-time polymerase chain reaction assay for the detection of  
Mycobacterium tuberculosis in pathological samples  
TB is one of the world’s most important infectious causes of morbidity and mortality among 
adults. In 2015, there were 10.4 million new TB cases worldwide. It is estimated that 9.7 
million children are orphaned as a result of TB. Early detection of TB is important for 
improving health, reducing deaths and controlling its transmission. RT-PCR assay is an 
automated and rapid test which proved from the study to be accurate with a turn-a-round 
time of 2 h. The objectives were to determine the diagnostic accuracy (sensitivity and 
specificity) for TB detection in pulmonary (lung) and extra-pulmonary samples. Sensitivity 
indicates how often the test gives a positive result in people who really have TB. Specificity 
indicates how often the test gives a negative result in people who do not have TB. All 
patients with suspected TB infection (in lungs or other organs in the body), either adults, 
young people or paediatrics, irrespective of sex, were included in the review.  
The sensitivity of RT-PCR assay was compared to that of culture which is the gold standard 
for the diagnosis of TB.  
What the results say: 
Forty-six studies were included in the review involving 35,380 samples: 28,406 from PTB and 
6,974 from EPTB sites from 21 countries of high, moderate and low prevalence of TB 
covering low- or middle-income and developed countries. Studies included patients with TB 
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infections identified in primary, secondary and tertiary healthcare settings. Most of the 
studies were thought to have a low risk of bias. 
The key findings were:  
For MTB detection in pulmonary samples, RT-PCR was accurate (it was highly sensitive, 
82%), detecting almost all cases. It was also specific (99%), that is, not registering positive in 
people who were actually negative. In extra-pulmonary samples, RT-PCR showed a reduced 
sensitivity of 70%, but comparably high sensitivity with paucibacillary (low MTB 
load) specimens.  
In simplified language, applying the findings of the review to an imaginary group of 1,000 
people who go to their doctor with PTB symptoms, but where only 100 of them (10%) 
actually have TB, a RT-PCR assay would diagnose 82 cases and miss 18 cases with a turn-a-
round time of 2 h. Endemic countries continue to rely largely on inaccurate tools such as 
direct smear microscopy (less sensitive and specific, involves tedious reading of slides and 
well-experience personnel for high-quality results) and solid culture (sensitive and specific 
but takes 2–10 weeks to get a result).  
To summarize, the review shows that RT-PCR assay is a very accurate, rapid and 
discriminatory (AUC 0.99 and 0.96 for PTB and EPTB respectively) test for the detection of 
MTB from all pathological samples. Adequate control of TB from early diagnosis and 
reduction in the cost of hospital stay/treatment may result in RT-PCR assay being a useful 
replacement test for urgent specimens in many countries with high prevalence of TB that 
depend on smear microscopy.  
3.3 Background 
TB is spread from person to person predominantly through an airborne route. The disease is 
contagious and spreads in air when people who are infected with PTB expel bacteria, for 
example by coughing or sneezing. It remains a major global health problem as it causes ill-
health among millions of people. After HIV, TB ranks as the second leading cause of death 
from an infectious disease worldwide (Al-Ateah et al., 2012; Wallis et al., 2010). The lack of a 
simple and effective diagnostic test that can be utilized in resource-limited settings, where 
the infection is endemic, has hindered control of the disease (Nikam et al., 2013). 
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According to the WHO in 2015, 3 million cases are either undiagnosed, not treated, or are 
diagnosed and not registered by national TB control programmes (WHO, 2016). Over 95% of 
TB deaths occur in low- and middle-income countries. TB is a leading killer of HIV-positive 
people; in 2015, 35% of HIV deaths were due to TB. It is estimated that 9.7 million children 
are orphaned as a result TB (WHO, 2016). According to PHE, a total of 5758 TB cases were 
notified in England in 2015 (PHE, 2016). National TB control programmes in most TB and 
TB/HIV endemic countries continue to rely largely on century old, antiquated and inaccurate 
tools such as direct smear microscopy (less sensitive and specific), solid culture, chest 
radiography and tuberculin skin testing (PHE, 2016). 
Over 95% of new cases and deaths associated with TB occur in developing countries where 
smear microscopy, which detects only 45% of infections (WHO, 2012), remains the most 
practical laboratory test available, alongside clinical and radiological diagnosis. PTB affects 
the lungs, but the disease can affect other sites.  
In contrast to PTB, the diagnosis of EPTB is still a challenge in western countries, where it 
can remain undetected for a long time in many cases. A hindrance to the diagnosis of EPTB 
is the atypical presentation, often simulating neoplasia and/or inflammatory disorders 
(Tortoli et al., 2012). Therefore, nucleic acid amplification techniques play an important role 
in rapid and accurate diagnosis, since conventional laboratory techniques lack sensitivity 
(Suzana et al., 2016). Furthermore, in non-respiratory specimens, the bacterial load is 
generally low and thereby affects the sensitivity of rapid tests such as acid-fast microscopy. 
The incidence of EPTB is often high. In the USA, it is steadily increasing and according to the 
last available data (from 2005) it accounted for 21% of all TB cases (Dye et al., 2006). In 
2009, in European Union countries, a quarter of TB cases were extra-pulmonary and a 
further 4.9% of patients had both pulmonary and extra-pulmonary disease (ECDPC, 2016). 
There has been an increase in the use of immunomodulatory agents and organ transplants 
resulting in increasing number of TB reactivation disease. Furthermore, the effect of 
population movement across the world due to political and economic uncertainties results 
in shifting epidemiology due to mass migration (ECDPC, 2016).  
The burden of the disease is multi-faceted; it has clinical implications, economic impacts and 
social consequences. Some of the consequences involve high costs of hospital care, high 
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income loss due to morbidity from MTB, dissemination of the disease, multi-drug resistant 
MTB and premature death. The impact of TB is most often measured as the direct costs of 
treatment to the health service, that is, the costs of medicines, personnel and facilities used. 
However, the economic impacts are considerably more far-reaching (Steingart et al., 2006). 
Often patients seek costly treatment from traditional healers or the private sector before an 
accurate diagnosis is made. Only then they may shift to the public sector. Economic costs 
include loss of several disability-adjusted life years to illness and premature mortality; this 
translates to several billions of pounds sterling worldwide due to wage loss (Steingart et al., 
2006). The costs to patients and their families that can be quantified are principally in the 
form of lost earnings from loss of work due to illness or death. Additional costs come from 
food required while in hospital and the costs of travel to hospitals or clinics for care. In 
addition to these direct treatment and non-treatment costs, TB imposes intangible costs in 
the form of pain, suffering, grief and discrimination. Social consequences of TB infection 
occur due to discrimination or outright rejection against those infected with TB and 
members of their households. Family and friends may reject TB patients, they may receive 
less social support during treatment, or they may lose their jobs. The association between 
AIDS and TB increases the likelihood of rejection and social isolation of TB patients 
(Steingart et al., 2006). 
In some developing countries, discrimination against TB sufferers has taken particularly 
damaging forms, such as divorce or lowered prospects of marriage. Such discrimination 
represents significant costs because the economic prospects for divorced or unmarriageable 
women in many societies are bleak. Discrimination against those suffering from TB also has 
epidemiological consequences. Stigmatization is another social factor that MTB patients 
contend with in society (Baral et al., 2007 and Dodor & Kelly, 2009). 
Over the past decade, the TB diagnostics pipeline has expanded, with several technologies 
showing promise (ECDPC, 2011). New diagnostic tests are continuously developed, driven by 
demands for improvements in speed, cost, ease of performance, patient safety and 
accuracy (Moure et al., 2012).  
Consequently, there are often several tests available for the diagnosis of a particular 
condition. Polymerase chain reaction (PCR) technology was introduced in the mid-1990s and 
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has since brought a revolutionary impact in the modern-day laboratory for diagnosis of 
infectious diseases. Nucleic acid ampliﬁcation assays (NAAAs) are commonly used in routine 
laboratories in industrialized countries for quick and speciﬁc detection of complex MTBC in 
clinical specimens. Over time, a signiﬁcant improvement of PCR technologies has been 
achieved with the development of RT-PCR assay testing platforms (White et al., 2011).  
RT-PCR is a commonly used assay to determine whether a DNA molecule or sequence of the 
causative agent (MTB) is present in a sample and detects amplified DNA as the reaction 
progresses in real time. It monitors the amplification of a targeted DNA/RNA molecule 
during PCR amplification by using complementary primers to the target sequence, i.e. in 
real-time, and not at its end, as in conventional PCR. A RT-PCR assay detects targeted DNA 
sequences specific to a MTB genome and provides results from clinical samples in less than 
2 h (short turn-a-round time). It is sensitive, specific and reproducible; automation of the 
procedure reduces hands-on time and a decrease in the risk of cross-contamination (White 
et al., 2011).  
RT-PCR-based methods have been shown to detect MTB with higher sensitivity and 
specificity directly from positive cultures or clinical specimens within 2 h (Espy et al., 2006). 
It requires approximately 5 copies/ml of MTB DNA (Steingart et al, 2014) in comparison to 
smear microscopy that requires 5,000–10,000 bacilli/ml (Mosissa, 2016). For concentrated 
samples, such as sputum, sensitivity of smear microscopy has been reported to increase up 
to 39%. Culture which is the reference standard, requires at least 100 viable bacilli to obtain 
a positive culture with a turn-a-round time of between 2–10 weeks (Rachow et al., 2011). 
Therefore, to adequately treat and effectively control MTB, there is need for effective, 
rapid, and accurate diagnosis. 
3.4 Objectives 
The overall objective of this review, therefore, was to assess all the available relevant 
published primary research studies to provide summary estimates of the effectiveness of 
RT-PCR assay for the detection of MTB from pulmonary and extra-pulmonary pathological 
samples.  
An additional objective of this review was:  
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To summarize the current evidence base to help develop future guidelines and policies on 
the most appropriate routine tool for rapid and accurate detection of MTB in pathological 
samples. 
3.5 Methods 
This review was performed with a standardised written protocol (Systematic review 
registration: PROSPERO CRD42015027534) that followed the PRISMA (preferred reporting 
items for systematic reviews and meta-analyses) statement guidelines (Moher et al., 2010). 
The quality of included studies was assessed by QUADAS-2 (Whiting et al., 2011). 
Institutional ethical review approval was waived for the reviewing nature of the current 
study. 
3.5.1  Criteria for considering studies for this review 
3.5.1.1 Selection criteria 
Study designs such as cross-sectional studies, cohort studies (prospective and retrospective) 
and case-control designs for the detection of MTB from human pathological samples of any 
patient age were eligible for inclusion if the studies (1) described original research, (2) 
compared RT-PCR assay to a reference/gold standard method – culture-based (either liquid 
or solid or both) assay, (3) reported the total number of patients tested and 
positive/negative results that allowed calculation of true positives (TP), true negatives (TN), 
false positives (FP) false negatives (FN) and (4) were published between 1995 and 2016 in 
any language. Studies were excluded if (1) all samples were not tested by reference/gold 
standard test – culture-based (either liquid or solid or both) assay, (2) application of RT-PCR 
assay for determining drug resistance, (3) RT-PCR assay was not used in the study, (4) the 
reference test was a combination of greater than one diagnostic tests, (5) it included animal 
studies, (6) RT-PCR assay was used for detecting non-TB mycobacteria (NTM), (7) RT-PCR 
assay was used for detecting MTB from clinical isolates and not the pathological 
specimens/samples and (8) possible duplicate publication (when an author published more 
than one study). The existence of overlapping study populations was ascertained by 
checking sample recruitment sites and/or periods. The article reporting on the largest 
number of samples was included in our study. 
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3.5.2 Search methods for identification of studies  
Electronic searches: A search strategy was used to generate a list of primary studies in any 
language from January 1995 to November 2016. The search was carried out systematically 
by EB and an independent assessor. Searches using electronic bibliographic databases 
(MEDLINE via PubMed, EMBASE, BIOSIS Citation Index, Web of Science, SCOPUS, ISI Web of 
Knowledge, Cochrane Infectious Diseases Group Specialised Register (CIDG SR), Cochrane 
Registry of Diagnostic Studies, National Institute for Health Research, PROSPERO, Google 
Scholar Turning Research into Practice (TRIP) and International Union Against Tuberculosis 
and Lung Disease (IUALTD) took place in July 2015 and was updated in November 2016. 
The MEDLINE search strategy is outlined as shown (see Appendix 3.1). The MEDLINE search 
was further translated to EMBASE, Cochrane Infectious Diseases Group Specialised Register 
and other databases to identify additional records. This prevents missing studies and allows 
us to achieve more reliable estimates of diagnostic accuracy, which is important to ensure 
that the process of identifying studies is as thorough and unbiased as possible (Deville et al., 
2002; Dickersin, 2005). Titles/abstracts generated from databases hits were screened for 
eligibility. 
Searching other sources: Reference lists of included articles were explored to identify 
relevant review articles. Conference Proceedings Citation Index – Science (CPCI-S) was 
searched. We searched the portal of the WHO International Clinical Trials Registry Platform 
(www.who.int/trialsearch) to identify ongoing trials, as well as StopTB Partnership’s New 
Diagnostics Working Group (www.stoptb.org/wg/new_diagnostics/). Forward citation 
searching was performed of relevant articles using the PubMed related articles and relevant 
guidelines (i.e. NICE in the UK) feature. Grey literature searching, i.e. personal 
communication through contacting authors and experts to locate on-going and unpublished 
studies/theses, hand searching of journals, abstracts of conferences in local and 
international scientific conference proceedings, was carried out. Focus was placed on TB 
meetings for example annual scientific conferences on TB diagnosis and control, such as the 
International Union against Tuberculosis and Lung Disease (IUALTD). Commercial RT-PCR 
test manufacturers for MTB diagnosis were contacted for additional information. Besides 
full articles, abstracts and letters to the editor with sample sizes > 20 were also considered 
for inclusion. There was no language limitation to the search. Abstracts or articles in 
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languages other than English were screened using “Google Translator” for immediate 
sieving (see Appendix 3.1 for search strategy).  
3.5.3 Data collection and analysis 
3.5.3.1 Selection of studies 
Full text articles were then screened independently (by EB and an independent assessor) 
using a PRISMA flow chart approach (Moher et al., 2010) for eligibility for use in the study to 
minimize bias in selection. All duplicate studies were removed. Any disagreements were 
resolved through discussion and, where needed, by a third reviewer. Any rejected studies 
were documented. References of included and excluded studies were documented. 
3.5.4 Data extraction and management 
Data were extracted (independently by EB and an independent assessor) from each selected 
study using a predetermined list of categories/characteristics: participants/population, 
index test, reference test, country, disease and target sequence for MTB DNA detection 
(Table 3.1) (see Appendix 3.2 for the data extraction form). 
3.5.5 Assessment of methodological quality 
The methodological quality for the included studies was appraised with the QUADAS-2 tool 
(Whiting et al., 2011). QUADAS-2 consists of four domains: patient selection, index test, 
reference standard and flow and timing. All the domains were assessed for the potential for 
risk of bias and the first three domains for concerns regarding applicability. Questions, 
called signalling questions were used, for each domain to form judgments about the risk of 
bias. As recommended, guidance was first developed on how to appraise each signalling 
question and interpret this information tailored to this review. Two review authors (EB and 
an independent assessor) independently assessed the methodological quality of the 
included studies with the tool. Results were presented in the text, graphs and a table. A 
summary ‘quality score’ was not generated because of problems associated with such 
numeric scores (Whiting, 2005). The study QUADAS-2 quality criteria are given (see 
Appendix 3.3). 
3.5.6 Statistical analysis and data synthesis 
For each study, standard methods recommended for meta-analysis of diagnostic studies 
were used to compute measures of test accuracy: sensitivity, specificity, positive likelihood 
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ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and 95% conﬁdence 
intervals (Deeks 2001; Irwig et al., 1995; Zamora et al., 2006). TP, FP, TN and FN were 
extracted directly from source papers. Where this information was not available, the values 
were calculated from the data that was provided in the article. To assess the overall 
accuracy, the DOR was calculated using the DerSimonian-Laird random model, which 
accounts for both within-study variability (random error) and between-study variability 
(heterogeneity), along with the area under the summary receiver operating characteristic 
(SROC) curve using the bivariate model (Deeks 2001; Zamora et al., 2006). The bivariate 
model considers potential threshold effects and the correlation between binary tests 
(sensitivity and specificity). These measures were pooled using the random effects model 
(Deeks 2001; Zamora et al., 2006). Each study in the meta-analysis contributed a pair of 
numbers: sensitivity and specificity. Since these measures are correlated, their joint 
distribution was summarized using a SROC curve. The SROC curve presents a global 
summary of test performance and shows the trade-off between sensitivity and specificity. A 
symmetric curve suggests that the variability in accuracy between studies is explained, in 
part, by differences in thresholds used by the studies. The area under the SROC curve is a 
global measure of overall performance of the test. An AUC value of 1.0 indicates perfect 
discriminatory ability of the test, while an AUC value of 0.5 means that the test does not 
have discriminating ability (Deeks 2001; Zamora et al., 2006). 
The data were analysed using the freeware program Meta-DiSC (version 1.4) and pooled 
using the DerSimonian-Laird random effects model and the paired forest plot and random-
effect model meta-analyses were performed using Review Manager (RevMan V5.3, 
Cochrane Collaboration, Oxford, UK) (DerSimonian & Laird, 1986; Zamora et al., 2006). The 
data were displayed graphically on forest plots and SROC plots. The SROC curve was ﬁtted 
using the Littenberg-Moses method (Leeflang et al., 2013) (see Appendix 3.4). 
3.5.7 Investigations of heterogeneity 
Heterogeneity in meta-analysis refers to the degree of variability in study results. An 
exploration of the reasons for heterogeneity rather than computation of a single summary 
measure is an important goal of meta-analysis.  
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Exploring heterogeneity is a critical issue to (1) understand the possible factors that 
inﬂuence accuracy estimates and (2) to evaluate the appropriateness of statistical pooling of 
accuracy estimates using random-effects meta-analysis to generate sensitivity and 
specificity with 95% CIs from various studies (Higgins & Green, 2015). The heterogeneity 
among studies was assessed visually with forest plots and SROC curves with 95% prediction 
regions, and statistically with chi‐squared (χ2) and I‐squared (I²) statistics with the following 
interpretation: I² = 0, no heterogeneity; 0 < I² < 25, mild heterogeneity; 25 ≤ I² < 50, 
moderate heterogeneity; 50 ≤ I² < 75, strong heterogeneity; 75 ≤ I² < 90, considerable 
heterogeneity; 90 ≤ I², extreme heterogeneity (Higgins & Green, 2015). The source of 
heterogeneity was investigated using stratified (subgroup) analyses. The following factors 
were specified a priori as potential sources of heterogeneity:  
RT-PCR assay type included CobasTaqMan as the RT-PCR assay, Roche Light cycler as the RT-
PCR assay, Cepheid & other assays.  
RT-PCR assay target sequence gene included IS6110 as the RT-PCR assay target sequence 
gene, 16S rRNA as the RT-PCR assay target sequence gene and other genes as the RT-PCR 
assay target sequence gene.  
Reference test type included both (solid and liquid), solid and liquid culture (see Tables 3.1, 
3.2, 3.3, 3.4 and 3.5). 
For every review question and subgroup, heterogeneity was assessed visually with forest 
plots and SROC curves with 95% prediction regions, and statistically with chi‐squared (χ2) 
and I‐squared (I²) statistics. 
For primary analysis using the culture-based (either solid or liquid or both) reference 
standard, sensitivity analyses were performed for four QUADAS-2 signalling questions to 
explore whether the results found were robust with respect to the methodological quality 
of the studies. The following questions were used: 
 Was a consecutive or random sample of patients/specimens enrolled? 
 Was a case-control design avoided? 
 Were the reference standard results interpreted without knowledge of the results of 
the index test? 
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 Were the index test results interpreted without knowledge of the results of the 
reference standard? 
No study was excluded based on these answers. 
3.5.8 Assessment of reporting bias 
Formal assessment of publication bias using methods such as funnel plots or regression 
tests was not evaluated as this is not usually recommended in the meta-analysis for 
diagnostic test accuracy (Leeflang et al., 2013). Generally, a diagnostic accuracy study does 
not test a hypothesis; therefore, there is no P value for authors and publishers that may 
influence decisions about publications that are based on the statistical significance of the 
results (Lijmer et al., 2002). However, every effort was made to identify unpublished studies 
through searching conference abstracts, grey literature and reference lists of relevant 
primary articles as described in Section 3.5. 
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3.6 Results 
3.6.1 Result of the search 
  
RISMA 2009 Flow Diagram 
  
Figure1. The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses 
(PRISMA) 
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Records identified through 
database searching  
(n = 1628) 
Additional records identified 
through other sources  
(n = 27) 
  
Records after duplicates removed  
(n = 1488) 
Records screened  
(n = 1488) 
Full-text articles 
assessed for eligibility  
(n = 141) 
Studies included in 
qualitative synthesis  
(n = 46) 
Studies included in 
quantitative synthesis 
(meta-analysis)  
(n = 46) 
Records excluded  
(n = 1347) 
Full-text articles excluded, with 
reasons  
(n = 95) 
Reasons for exclusion: 
Culture-based not included 
as reference or 
combined with another 
assay when included: 
65 
Insufficient data (e.g. not 
reporting 2×2, abstract 
only): 14 
Studies involving clinical 
isolates: 6 
Animal/zoonotic studies: 3 
Conventional PCR not RT-
PCR assay studies: 7 
  
  
Figure 3.1 Flow chart of included studies: The preferred reporting items for systematic 
reviews and meta-analyses (PRISMA). 
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3.6.2 Methodological quality of the included studies 
Figures 3.2 and 3.3 show the quality assessment of the 46 included studies. Figure 3.2 shows 
the overall risk of bias and applicability concerns for the 46 included studies. Figure 3.3 
presents the quality assessment results for the individual study centres. In the patient 
selection domain, 45 study centres (98%) were at low risk of bias because the centre 
enrolled participants consecutively and avoided inappropriate exclusions. The remaining 
study centre was an unclear risk of bias because it was unclear how patients were selected 
(Sethi, 2012). Five studies were at high risk of bias because they were case-control designs 
(Barletta, 2014; Dayal, 2010; El Khechine, 2009; Moure, 2012; Sethi 2012). 
In the index test (RT-PCR) domain, all study centres were at low risk of bias and low concern 
regarding applicability. The use, conduct and interpretation of the index test were 
considered applicable. 
In the reference standard domain, all 46 studies (100%) were judged to be at low risk of bias 
because the use, conduct and interpretation of the reference standard were appropriate 
and the results were interpreted without knowledge of the results of the RT-PCR assay. So, 
applicability was of low concern and considered applicable for all studies in the reference 
standard domain. 
In the flow and timing domain, 46 study centres (100%) were at low risk of bias because all 
patients were accounted for in the analysis and information about uninterpretable results 
was provided. In total, three studies were an unclear risk because it was not clear if there 
was appropriate interval between the index test and reference test; therefore, it was not 
clear if the patient flow could have introduced bias (Cho, 2015; Choi, 2013; In, 2014). There 
was nearly complete information for all study centres. So, this domain was judged to be of 
low concern for risk of bias. 
The methodological quality of studies (assessed by the QUADAS-2 tool) was generally high; 
with 37 of the studies meeting all four domains of the criteria (see Figures 3.2 and 3.3). 
All studies used RT-PCR assay as an index test and culture-based assay as the reference test.  
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Figure 3.2 Risk of bias and applicability concerns graph: review authors’ judgements about 
each domain presented as percentages across included studies. 
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Figure 3.3 Risk of bias and applicability concerns summary: review authors’ judgements 
about each domain for each included study centre. 
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3.6.3 Findings  
3.6.3.1 Study characteristics 
Of the 6,706 references that were initially identiﬁed through electronic databases, 1,628 
potentially relevant citations were selected based on relevance to the study topic. An 
additional 27 studies were identified from grey literature and references of full-text articles. 
After screening all the titles and abstracts, removing duplicates and excluding ineligible 
studies, 46 articles (Albuquerque et al., 2014; Antonenka et al., 2013; Armand et al., 2011; 
Barletta et al., 2014; Bloemberg et al., 2013; Causse et al., 2011; Chaidir et al., 2012; Chang 
et al., 2015; Chandran et al., 2010; Chen et al., 2012; Chitnis et al., 2010; Cho et al., 2015; 
Choe et al., 2011; Choi et al., 2013; Dayal et al., 2010; El Khe´chine et al., 2009; Feizabadi et 
al., 2013; Friedrich et al., 2011; Gous et al., 2012; Hillemann et al., 2011; Hofmann-Thiel et 
al., 2016; Huh et al., 2015; In et al., 2014; Jönsson et al., 2015; Kheawon et al., 2012; Kim et 
al., 2011; Lee et al., 2010, 2011, 2013; Lim et al., 2014; Linasmita et al., 2012; Lira et al., 
2013; Luo et al., 2010; Malhotra et al., 2012; Mangat et al., 2016; Miller et al., 2011; Moure 
et al., 2012; Park et al., 2013; Pinhata et al., 2015; Rachow, et al., 2011; Rosso et al., 2011; 
Seith et al., 2012; Sharma et al., 2015; Tortoli et al., 2012; Wang et al., 2013; Yang  et al., 
2011) were selected for full-text review and meta-analysis (see Figure 3.1).  
Twenty-one (Albuquerque et al., 2014; Antonenka et al., 2013; Barletta et al., 2014; Chaidir 
et al., 2012; Chandran et al., 2010; Chen et al., 2012; Feizabadi et al., 2013; Huh et al., 2015; 
In et al., 2014; Kheawon et al.,2012; Lee et al., 2011, 2013; Lim et al., 2014; Lira et al., 2013; 
Mangat et al., 2016; Park et al., 2013; Pinhata et al., 2015; Rachow et al., 2011; Sharma et 
al., 2015; Wang et al., 2013; Yang et al., 2011) of the 46 primary studies reported detection 
of PTB. 
Fifteen (Causse et al., 2011; Chang et al., 2015; Chitnis et al., 2010; Choe et al., 2011; Dayal 
et al., 2010; El Khe´chine et al., 2009; Friedrich et al., 2011; Gous et al., 2012; Hillemann et 
al., 2011; Lee et al., 2010; Linasmita et al., 2012; Luo et al., 2010; Malhotra et al., 2012; 
Moure et al., 2012; Rosso et al., 2011) reported EPTB.  
Ten (Armand et al., 2011; Bloemberg et al., 2013; Cho et al., 2015; Choi et al., 2013; 
Hofmann-Thiela et al., 2016; Jönsson et al., 2015; Kim et al., 2011; Miller et al., 2011; Seith 
et al., 2012; Tortoli et al., 2012) reported on both types of pathological samples using RT-
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PCR assay. Table 3.1 summarizes the main characteristics of the included studies). In total, 
the review and meta-analysis included 35,380 (28,406 PTB and 6,974 EPTB) pathological 
samples obtained from 21 countries. Details of the RT-PCR assays methodology is 
summarized in Table 3.1 Detailed characteristics of included studies are summarized in 
Appendix 3.6. Characteristics of excluded studies with reasons are summarized in Appendix 
3.7. 
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Table 3.1 Characteristics of the included studies. 
Author Year 
(n) 
Country Total number of 
samples (N) 
 
Reference test: 
Culture-based assays 
Index test: 
RT-PCR 
Target sequence 
gene 
 
PTB 
 
EPTB 
Albuquerque 2014 
 
Brazil 140 
 
- LJ (Solid agar) 
7H9 (Liquid medium) 
COBAS TaqMan MTB 
assay 
IS6110 
Antonenka 2013  
 
Germany 116 
 
   - MGIT (Liquid medium) 
LJ (Solid agar) 
 
COBAS TaqMan MTB 
assay 
 rpoB  
Armand 2011 
 
France 70 
 
47 LJ (Solid agar) 
 
BacT/Alert MP (Liquid 
medium) 
COBAS TaqMan MTB 
assay 
IS6110  
Barletta 2014 
 
Belgium 112 - LJ (Solid agar) 
 
Roche Light cycler 480 
Real-time PCR assay 
IS6110  
Bloemberg 2013 
 
Switzerland 829 280 7H11 (Solid agar) 
 
MGIT (Liquid medium) 
COBAS TaqMan MTB 
assay 
16S rRNA  
Causse 2011 
 
Spain - 340 LJ (Solid agar) 
 
7H9 (Liquid medium) 
COBAS TaqMan MTB 
assay 
16S rRNA 
Chadran 2010 
 
India 72 - LJ (Solid agar) 
 
MGIT 960 (Liquid 
medium) 
COBAS TaqMan MTB 
assay 
IS6110  
 
Chaidir 2012 
 
Indonesia - 207 Ogawa egg medium 
(Solid agar) 
 
MB/BacTalert (Liquid 
medium) 
IS6110-PCR BioRad IS6110 
Chang 2015 
 
South Korea 2859 - MGIT 960 (Liquid 
medium) 
3% Ogawa (Solid agar) 
 
AdvanSure TB/NTM 
Real-time PCR assay 
IS6110 
Chen 2012 
 
China 178 - BACTEC™ MGIT™ 960 
(Liquid medium) 
Real-time PCR assay 
used the ABI Prism SDS 
7000 
IS6110  
70 
 
Chitnis 2010 
 
India - 204 LJ (Solid agar) 
 
MGIT-BACTEC (Liquid 
medium) 
Geno-Sen’s MTB 
complex Real-time PCR 
assay 
16S rRNA 
Cho 2015 
 
South Korea 2384 626 2% Ogawa medium 
(Solid agar) 
 MGIT 960 (Liquid 
medium) 
COBAS TaqMan MTB 
assay 
IS6110 
Choe 2011 
 
South Korea - 129 3% Ogawa (Solid agar) 
 
COBAS TaqMan MTB 
assay  
senX3-regX3 
intergenic region 
Choi 2013 
 
South Korea 360 65 MGIT 960 (Liquid 
medium) 
COBAS TaqMan MTB 
assay 
IS6110  
Dayal 2010 
 
India - 47 BacT/Alert (Liquid 
medium) 
Real-time PCR targeting 
16S rRNA 
using Roche Light cycler 
RNA amplification 
syber green 1 kit (Roche 
Applied Biosciences, 
Germany) 
16S rRNA  
El Khechine 2009 
 
France - 134 BACTEC 9000 MB (Liquid 
medium) 
LJ (Solid agar) 
 
Not specified* IS6110 
Feizabadi 2012 
 
Iran 247 - LJ (Solid agar) 
 
COBAS TaqMan MTB 
assay 
Cytochrome P450 
Cyp 141  
Friedrich 2011 
 
South Africa - 25  
MGIT 960 (Liquid 
medium) 
Cepheid rpoB 
Gous 2012 
 
South Africa - 
 
39 BACTEC 9000 MB (Liquid 
medium) 
LJ (Solid agar) 
 
Roche Light cycler 
mycobacterium 
detection assay (LCTB) 
Not specified† 
Hillemann, 2011 
 
Germany - 521 MGIT 960 (Liquid 
medium) 
LJ (Solid agar) 
 
GenoType MTBC and 
CM/AS assays (Hain 
Lifescience) 
rpoB 
Hofmann-Thiel 2016 
 
Germany 
608 107 MGIT 960 (Liquid 
medium) 
LJ (Solid agar) 
 
Abbott Real-time MTB  IS6110  
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Huh 2015 
 
South Korea 
6852 
 
- MGIT 960 (Liquid 
medium) 
L J (Solid agar) 
 
COBAS TaqMan MTB 
assay 
16S rRNA  
In 2014 
 
South Korea 247 - BACTEC MGIT 960 
(Liquid medium) 
LJ (Solid agar) 
 
Ultrafast NBS LabChip 
G2-3 (NanoBioSys) 
Not specified† 
Jönsson 2015 
 
Sweden 2388 
 
1005 MGIT 960 (Liquid 
medium) 
LJ (Solid agar) 
 
COBAS TaqMan MTB 
assay 
16S rRNA 
Kheawon 2012 
 
Thailand 430 - LJ medium (Solid agar) 
 
Commercial PCR Kits 
Amplicor 
IS6110 and MPB64  
Kim 2011 
 
South Korea 96 
 
 
310 Solid culture (type not 
specified) 
COBAS TaqMan MTB 
assay 
IS6110 
Lee 2011 
 
South Korea 99 - 3% Ogawa (Solid agar) 
 
AdvanSure 
TB/NTM Real-time PCR 
assay 
IS6110 
Lee 2010 
 
South Korea - 143 
 
3% Ogawa (Solid agar) 
 
 
Roche Light Cycler 2.0 senX3-regX3 
intergenic region 
Lee 2013 
 
Taiwan 587 
 
- BACTEC MGIT 960 
(Liquid medium) 
LJ (Solid agar) 
 
COBAS TaqMan MTB 
assay 
IS6110 
Lim 2014 
 
South Korea 1167  Not specified COBAS TaqMan MTB 
assay 
Not specified† 
Linasmita 2012 
 
Thailand - 73 MGIT 960 (Liquid 
medium) 
COBAS TaqMan MTB 
assay 
16S rRNA 
Lira 2013 
 
Brazil 165 - LJ (Solid agar) 
 
ABI Prism 7500 
Sequence Detection 
System (Applied 
Biosystems) using 
TaqMan-specific probe 
IS6110  
Luo 2010 
 
USA - 70 Culture-based assay 
(type not specified) 
Smart Cycler II 
Instrument 
IS6110  
Malhotra 2012 
 
India - 555 7H9 (Solid agar) 
 
COBAS TaqMan MTB 
assay 
IS6110  
72 
 
Mangat 2016 
 
India 74 - MGIT 960 (Liquid 
medium) 
LJ (Solid agar) 
 
Roche Light Cycler 
480 Real-time PCR 
system 
 
IS6110  
Miller 2011  
 
North Carolina, USA 89 23 
 
7H9 (Liquid medium) 
LJ (Solid agar) 
 
Cepheid IS6110  
Moure 2012 
 
Spain - 149 MGIT 960 (Liquid 
medium) 
LJ (Solid agar) 
 
GX assay Not specified† 
Park 2013 
 
South Korea 320 - MGIT 960 (Liquid 
medium) 
3% Ogawa (Solid agar) 
 
COBAS TaqMan MTB 
assay 
IS6110  
Pinhata 2015 
 
Brazil 715 - MGIT 960 (Liquid 
medium) 
Ogawa–Kudoh slant 
(Solid agar) 
 
Roche Light Cycler 480 II 
system 
mpt64  
Rachow 2011 
 
Tanzania 292 - Both liquid & solid (type 
not specified) 
Cepheid  
MTB/RIF assay 
rpoB 
Rosso 2011 
 
Brazil - 158 
 
LJ (Solid agar) 
 
ABI Prism 7500 system 
(Applied Biosystems) 
IS6110  
Sethi 2012 
 
India 50 22 MGIT 960 (Liquid 
medium) 
LJ (Solid agar) 
 
In-house mpt64 Real-
time PCR 
mpt64 
Sharma 2015 
 
India 1480 
 
- MGIT 960 (Liquid 
medium) 
LJ (Solid agar) 
 
ABI prism 3130xl genetic 
analyser (Applied 
Biosystems) 
81-bp rpoB 
Tortoli 2012 
 
Italy 4340 1727 MGIT 960 (Liquid 
medium) 
 
LJ (Solid agar) 
 
 
Cepheid  
 
rpoB 
Wang 2013 
 
China 30 - Bact/Alert 3D (Liquid 
medium) 
Roche Light Cycler
®
 480  Not specified† 
73 
 
Yang 2011 
 
Taiwan 1093 - MGIT 960 (Liquid 
medium) 
LJ & 7H11 (Solid agar) 
 
COBAS TaqMan MTB 
assay 
IS6110  
Key: LJ, Löwenstein-Jensen; Middlebrook 7H9 Broth, Liquid growth medium; Middlebrook 7H11, Solid medium; MGIT, Mycobacterium Growth Indicator Tube; PTB, Pulmonary TB;  
EPTB, Extra-pulmonary TB; *, RT-PCR assay type not specified but added to Cepheid and other assays; †,   RT-PCR target sequence gene not specified but analysed as other genes
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3.6.3.2 Meta-analysis 
AUC was 0.99 and 0.96 for PTB and EPTB samples, respectively. The heterogeneity of PTB 
studies, described using chi-square (X2) for sensitivity, specificity, PLR, NLR, DOR and high I2 
showed that there was considerable heterogeneity in these data (see Table 3.2, Figures 3.4 to 
3.6). 
Sensitivities ranged from 50% to 100%, and specificities ranged from 85% to 100% (Figure 3.4). The 
meta-analytical average sensitivity and specificity for all 31 studies was 82% (95% CI 81% to 83%) 
and 99% (95% CI 99% to 99%) respectively. 
The heterogeneity of EPTB studies, described using chi-square (X2) for sensitivity, specificity, PLR, 
NLR, DOR and high I2 showed that there was considerable heterogeneity in these data (see Table 
3.2, Figures 3.7 to 3.9). 
Sensitivities ranged from 25% to 100%, and specificities ranged from 86% to 100% (Figure 3.7). The 
meta-analytical average sensitivity and specificity for all 25 studies was 70% (95% CI 67% to 72%) 
and 99% (95% CI 99% to 99%) respectively.  
Table 3.2 Summary of statistical results for pulmonary tuberculosis (PTB) and extra-
pulmonary tuberculosis (EPTB) pathological samples. 
Test property                                    Summary measure of test 
accuracy* (95% CI) 
 
 
Test for heterogeneity   
 (X2)  
(d.f.=24) 
 (I2) 
 
 
p value 
      PTB  
 (n = 31; †28,406) 
    AUC = 0.99 
Sensitivity 0.82 (0.81–0.83) 586.21 92.8% 
 
< 0.001 
Specificity 0.99 (0.99–0.99) 361.23 91.7% < 0.001 
Positive likelihood ratio 
(PLR) 
42.77 (28.23–64.81) 285.01 89.5% 
 
< 0.001 
Negative likelihood ratio 
(NLR) 
0.16 (0.12–0.20) 359.13 91.6% 
 
< 0.001 
Diagnostic odds ratio (DOR) 324.26 (189.08–556.09) 242.84 87.6% < 0.001 
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         EPTB  
   (n = 25; †6,974) 
       AUC = 0.96 
    
Sensitivity 0.70 (0.67–0.72) 272.48 91.20% < 0.001 
Specificity 0.99 (0.99–0.99) 105.48 77.20% < 0.001 
Positive likelihood ratio 
(PLR) 
29.82 (17.86–49.78) 75.37 68.20% < 0.001 
Negative likelihood ratio 
(NLR) 
0.33 (0.26–0.42) 186.30 87.10% < 0.001 
Diagnostic odds ratio (DOR) 125.20 (65.76–238.36) 70.73 66.10% < 0.001 
*: Random effects model; (X2): chi-squared; d.f.: degree of freedom; (I2): I-squared; †: 
number of specimens; n: number of studies; CI: confidence interval; AUC: area under 
receiver operating characteristics curve; PTB: pulmonary tuberculosis; EPTB: extra-
pulmonary tuberculosis 
 
 
 
 
 
 
76 
 
 
Figure 3.4 Forest plot of estimates of RT-PCR assay for (PTB). TP = true positive; FP = false 
positive; FN = false negative; TN = true negative. Between brackets are the 95% CI of 
sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the 
study (blue square) and its 95% CI (black horizontal line). 
 
77 
 
 
Figure 3.5 Forest plot estimates of the pooled sensitivity for PTB. 
 
 
 
 
 
Sensitivity
0 0.2 0.4 0.6 0.8 1
Albuquerque 2013 1.00    (0.92 - 1.00)
Antonenka 2013 0.74    (0.61 - 0.84)
Armand 2011 0.84    (0.68 - 0.94)
Barletta 2014 0.96    (0.90 - 0.99)
Bloemberg 2013 0.88    (0.78 - 0.95)
Chandran 2010 1.00    (0.90 - 1.00)
Chang 2015 0.59    (0.54 - 0.64)
Chen 2012 0.92    (0.84 - 0.97)
Cho 2015 0.71    (0.64 - 0.78)
Choi 2013 0.92    (0.85 - 0.96)
Feizabadi 2013 0.97    (0.92 - 0.99)
Huh 2015 0.67    (0.61 - 0.73)
Hofmann-Thiel 2016 1.00    (0.97 - 1.00)
In 2014 0.83    (0.73 - 0.91)
Jonsson 2015 0.68    (0.62 - 0.74)
Kheawon 2012 0.66    (0.52 - 0.77)
Kim 2011 0.79    (0.58 - 0.93)
Lee 2010 0.78    (0.58 - 0.91)
Lee 2013 0.83    (0.77 - 0.88)
Lim 2014 0.92    (0.84 - 0.97)
Lira 2013 0.80    (0.69 - 0.89)
Park 2013 0.71    (0.51 - 0.87)
Mangat 2016 0.95    (0.85 - 0.99)
Miller 2011 0.94    (0.79 - 0.99)
Rachow 2011 0.89    (0.79 - 0.95)
Seith 2012 0.73    (0.56 - 0.86)
Sharma 2015 1.00    (0.99 - 1.00)
Pinhata 2015 0.90    (0.80 - 0.96)
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Figure 3.6 Forest plot estimates of the pooled specificity for PTB. 
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Figure 3.7 Forest plot of estimates of RT-PCR assay for (EPTB). TP = true positive; FP = false 
positive; FN = false negative; TN = true negative. Between brackets are the 95% CI of 
sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the 
study (blue square) and its 95% CI (black horizontal line). 
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Figure 3.8 Forest plot estimates of the pooled sensitivity for EPTB. 
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Figure 3.9 Forest plot estimates of the pooled specificity for EPTB. 
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3.6.3.3 Subgroup analyses by RT-PCR assay type  
Subgroup analyses were performed using the following a priori: 
(I) With CobasTaqMan (Table 3.1) as the RT-PCR assay (17 studies, 19,814 specimens) 
the results were as follows: Sensitivities ranged from 62% to 100%, specificities ranged 
from 92% to 100% and AUC 0.98(see Table 3.3; Appendix 3.5; Figures A3.5.1 to A3.5.6). 
The meta-analytical average sensitivity and specificity for all 17 studies was 78% (95% CI 76% 
to 80%) and 99% (95% CI 99% to 99%) respectively. 
The heterogeneity of CobasTaqMan, described using chi-square (X2) for sensitivity, 
specificity, PLR, NLR, DOR and high I2 showed that there was considerable 
heterogeneity in these data (see Table 3.3; Appendix 3.5; Figures A3.5.1 to A3.5.6). 
A test with perfect discrimination has a ROC curve that passes through the upper-left 
corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper-
left corner, the higher the overall accuracy of the test.  
(II) With Roche Light cycler (Table 3.1) as the RT-PCR assay (7 studies, 1159 specimens) 
the results were as follows: Sensitivities ranged from 50% to 98%, specificities ranged 
from 92% to 100% and AUC 0.97 (see Table 3.3; Appendix 3.5; Figures A3.5.7 to 
A3.5.12). The meta-analytical average sensitivity and specificity for all 7 studies was 85% 
(95% CI 80% to 88%) and 99% (95% CI 97% to 99%) respectively. 
The heterogeneity of Roche Light cycler, described using chi-square (X2) for sensitivity, 
specificity, PLR, NLR, DOR and high I2 showed that there was considerable heterogeneity in 
these data (see Table 3.3; Appendix 3.5; Figures A3.5.7 to A3.5.12). 
A test with perfect discrimination has a ROC curve that passes through the upper-left 
corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper-left 
corner, the higher the overall accuracy of the test.  
(III) With Cepheid & other assays (Table 3.1) as the RT-PCR assay (22 studies, 14,839 
specimens) the results were as follows:  
Sensitivities ranged from 25% to 100%, specificities ranged from 91% to 100% and AUC 0.99 
(see Table 3.3; Appendix 3.5; Figures A3.5.13 to A3.5.18). The meta-analytical average 
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sensitivity and specificity for all 22 studies was 78% (95% CI 77% to 80%) and 99% (95% CI 
99% to 99%) respectively. 
The heterogeneity of Cepheid & other assays, described using chi-square (X2) for 
sensitivity, specificity, PLR, NLR, DOR and high I2 showed that there was considerable 
heterogeneity in these data (see Table 3.3; Appendix 3.5; Figures A3.5.13 to A3.5.18). 
A test with perfect discrimination has a ROC curve that passes through the upper-left 
corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper-
left corner, the higher the overall accuracy of the test.  
 
Table 3.3 Subgroup analyses by RT-PCR assay type. 
RT-PCR assay type Summary measure of test 
accuracy* (95% CI) 
 
 
Test for heterogeneity 
(X2) 
(d.f.=24 
(I2) 
  
 
p value 
    CobasTaqMan 
 (n =17; †19,814) 
    AUC = 0.98 
Sensitivity 0.78 (0.76–0.80) 
 
205.13 92.20% 
 
< 0.001 
Specificity 0.99 (0.99–0.99) 127.21 87.40% < 0.001 
Positive likelihood ratio 
(PLR) 
41.59 (27.80–62.18) 98.14 83.70% 
 
< 0.001 
Negative likelihood ratio 
(NLR) 
0.18 (0.13–0.23) 134.36 88.10% 
 
< 0.001 
Diagnostic odds ratio (DOR) 273.14 (181.45–411.17) 47.6 66.40% < 0.001 
Roche Light cycler       
(n = 7; †1,159) 
        AUC = 0.97 
    
Sensitivity 0.85 (0.80–0.88) 61.71 90.30% < 0.001 
Specificity 0.99 (0.97–0.99) 10.09 40.50%    0.121 
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Positive likelihood ratio 
(PLR) 
21.65 (6.82–68.72) 17.45 65.60%    0.008 
Negative likelihood ratio 
(NLR) 
0.17 (0.08–0.38) 63.77 90.60% < 0.001 
Diagnostic odds ratio (DOR) 150.52 (31.97–708.78) 20.35 70.50% < 0.002 
 
    Cepheid & other assays   
      (n = 22; †14,839) 
        AUC = 0.99 
    
Sensitivity 0.78 (0.77–0.80) 729.43 97.10% < 0.001 
Specificity 0.99 (0.99–0.99) 299.13 93.00% < 0.001 
Positive likelihood ratio 
(PLR) 
38.50 (19.65–75.42) 234.62 91.00% < 0.001 
Negative likelihood ratio 
(NLR) 
0.22 (0.15–0.33) 594.30 96.50% < 0.001 
Diagnostic odds ratio (DOR) 221.44 (94.94–516.51) 208.25 89.90% < 0.001 
*: Random effects model; (X2): chi-squared; d.f.: degree of freedom; (I2): I-squared; †: 
number of specimens; n: number of studies; CI: confidence interval; AUC: area under 
receiver operating characteristics curve 
 
3.6.3.4 Subgroup analyses by RT-PCR assay target sequence gene  
I. With IS6110 as the RT-PCR assay target sequence gene (22 studies, 12,004 
specimens) the results were as follows:  
Sensitivities ranged from 42% to 100%, specificities ranged from 91% to 100% and AUC 0.99 
(see Table 3.4; Appendix 3.5; Figures B3.5.1 to B3.5.6). The meta-analytical average 
sensitivity and specificity for all 22 studies was 79% (95% CI 77% to 81%) and 98% (95% CI 
98% to 98%) respectively. 
The heterogeneity of IS6110 as the RT-PCR assay target sequence gene, described using 
chi-square (X2) for sensitivity, specificity, PLR, NLR, DOR and high I2 showed that there 
was considerable heterogeneity in these data (see Table 3.4; Appendix 3.5; Figures 
B3.5.1 to B3.5.6).  
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A test with perfect discrimination has a ROC curve that passes through the upper-left corner 
(100% sensitivity, 100% specificity). The closer the ROC curve to the upper-left corner, the 
higher the overall accuracy of the test. 
II. With 16SrRNA as the RT-PCR assay target sequence gene (7 studies, 12,074 
specimens), the results were as follows:  
Sensitivities ranged from 62% to 98%, specificities ranged from 98% to 100% and AUC 0.97 
(see (see Table 3.4; Appendix 3.5; Figures B3.5.7 to B3.5.12).  
The meta-analytical average sensitivity and specificity for all 7 studies was 69% (95% CI 66% 
to 71%) and 99% (95% CI 99% to 99%) respectively. 
The heterogeneity of 16SrRNA  as the RT-PCR assay target sequence gene, described 
using chi-square (X2) for sensitivity, specificity, PLR, NLR, DOR and high I2 showed that 
there was considerable heterogeneity in these data (see Table 3.4; Appendix 3.5; Figures 
B3.5.7 to B3.5.12).  
A test with perfect discrimination has a ROC curve that passes through the upper-left 
corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper-
left corner, the higher the overall accuracy of the 
 
III. With other genes (see Table 3.1) as the RT-PCR assay (17 studies, 11,870 specimens) 
the results were as follows:  
Sensitivities ranged from 25% to 100%, specificities ranged from 92% to 100% and AUC 0.98 
(see Table 3.4; Appendix 3.5; Figures B3.5.13 to B3.5.18).  
The meta-analytical average sensitivity and specificity for all 17 studies was 82% (95% CI 80% 
to 84%) and 99% (95% CI 99% to 99%) respectively. 
The heterogeneity of other genes  as the RT-PCR assay target sequence gene, described 
using chi-square (X2) for sensitivity, specificity, PLR, NLR, DOR and high I2 showed that 
there was considerable heterogeneity in these data (see Table 3.4; Appendix 3.5; Figures 
B3.5.13 to B3.5.18).  
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A test with perfect discrimination has a ROC curve that passes through the upper-left 
corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper-
left corner, the higher the overall accuracy of the test. 
Table 3.4 Subgroup analyses by RT-PCR assay target sequence gene. 
RT-PCR assay genes Summary measure of test 
accuracy* (95% CI) 
 
 
Test for heterogeneity   
(X2)  
(d.f.=24) 
(I2) 
 
 
p value 
    IS6110 
 (n = 22; †12,004) 
    AUC = 0.99 
Sensitivity 0.79 (0.77–0.81) 470.30 95.50% 
 
< 0.001 
Specificity 0.98 (0.98–0.98) 150.16 86.00% < 0.001 
Positive likelihood ratio 
(PLR) 
31.76 (20.12–50.13) 134.64 84.40% 
 
< 0.001 
Negative likelihood ratio 
(NLR) 
0.17 (0.12–0.24) 356.22 94.10% 
 
< 0.001 
Diagnostic odds ratio (DOR) 243.69 (127.07–437.37) 141.04 85.10% < 0.001 
       16S rRNA      
      (n = 7; †12,074) 
        AUC = 0.97 
    
Sensitivity 0.69 (0.66–0.72) 45.85 86.90% < 0.001 
Specificity 0.99 (0.99–0.99) 32.10 81.30% < 0.001 
Positive likelihood ratio 
(PLR) 
67.64 (36.40–125.70) 34.60 82.50% < 0.001 
Negative likelihood ratio 
(NLR) 
0.29 (0.24–0.36) 19.87 69.8% 0.003 
Diagnostic odds ratio (DOR) 287.19 (193.85–425.46) 9.12 34.20% 0.167 
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         Other genes  
     (n = 17; †11,870) 
        AUC = 0.98 
    
Sensitivity 0.82 (0.80–0.84) 413.02 96.10% < 0.001 
Specificity 0.99 (0.99–0.99) 173.35 90.80% < 0.001 
Positive likelihood ratio 
(PLR) 
42.48 (20.66–87.36) 123.92 87.10% < 0.001 
Negative likelihood ratio 
(NLR) 
0.22 (0.13–0.37) 498.03 96.80% < 0.001 
Diagnostic odds ratio (DOR) 234.56 (86.01–639.63) 125.08 87.20% < 0.001 
*: Random effects model; (X2): chi-squared; d.f.: degree of freedom; (I2): I-squared; †: 
number of specimen; n: number of studies; CI: confidence interval; AUC: area under receiver 
operating characteristics curve; IS6110: Mycobacterium tuberculosis complex-specific 
insertion sequence; 16S rRNA: 16S ribosomal RNA gene of MTB; Other genes: rpoB as target 
sequence, mpt64 gene, 81-bp rpoB gene, senX3-regX3 intergenic region, 61 genomic DNA 
(gDNA) samples of MTB, cytochrome P450 Cyp 141 gene. 
 
3.6.3.5 Subgroup analyses by reference test    
(I) With solid and liquid media combined as the reference test (25 studies, 26,634 
specimens) the results were as follows:  
Sensitivities ranged from 36% to 100%, specificities ranged from 83% to 100% and 
AUC 0.99 (see Table 3.5; Appendix 3.5; Figures C3.5.1 to C3.5.6).  
The meta-analytical average sensitivity and specificity for all 25 studies was 77% 
(95% CI 76% to 79) and 99% (95% CI 99% to 99%) respectively. 
The heterogeneity of solid and liquid media combined as the reference test, 
described using chi-square (X2) for sensitivity, specificity, PLR, NLR, DOR and high I2 
showed that there was considerable heterogeneity in these data (see Table 3.5; 
Appendix 3.5; Figures C3.5.1 to C3.5.6).  
A test with perfect discrimination has a ROC curve that passes through the upper-left 
corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper-
left corner, the higher the overall accuracy of the test. 
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(II) With solid media alone as the reference test (13 studies, 3014 specimens) the results 
were as follows:  
Sensitivities ranged from 42% to 98%, specificities ranged from 91% to 100% and AUC 0.98 (see 
Table 3.5; Appendix 3.5; Figures C3.5.7 to C3.5.12).  
The meta-analytical average sensitivity and specificity for all 13 studies was 80% (95% CI 77% to 
82) and 96% (95% CI 96% to 97%) respectively. 
The heterogeneity of solid media alone as the reference test as the reference test, 
described using chi-square (X2) for sensitivity, specificity, PLR, NLR, DOR and high I2 showed 
that there was considerable heterogeneity in these data (see Table 3.5; Appendix 3.5; 
Figures C3.5.7 to C3.5.12).  
A test with perfect discrimination has a ROC curve that passes through the upper-left 
corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper-left 
corner, the higher the overall accuracy of the test. 
(III) With liquid media alone as the reference test (6 studies, 1037 specimens) the results 
were as follows:  
Sensitivities ranged from 25% to 98%, specificities ranged from 91% to 100% and AUC 0.94 (see 
Table 3.5; Appendix 3.5; Figures C3.5.13 to C3.5.18).  
The meta-analytical average sensitivity and specificity for all 6 studies was 81% (95% CI 75% to 
86) and 99% (95% CI 99% to 100%) respectively. 
The heterogeneity of liquid media alone as the reference test as the reference test, 
described using chi-square (X2) for sensitivity, specificity, PLR, NLR, DOR and high I2 showed 
that there was considerable heterogeneity in these data (see Table 3.5; Appendix 3.5; 
Figures C3.5.7 to C3.5.12 Appendix 3.5; Figures C3.5.13 to C3.5.18).  
A test with perfect discrimination has a ROC curve that passes through the upper-left 
corner (100% sensitivity, 100% specificity). The closer the ROC curve to the upper-left 
corner, the higher the overall accuracy of the test. 
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Table 3.5 RT-PCR assay by reference test. 
RT-PCR assay by reference 
test   
Summary measure of test 
accuracy* (95% CI) 
 
 
Test for heterogeneity   
 (X2)  
(d.f.=24) 
 (I2) 
 
 
p value 
    Both (Solid & liquid)  
(n=25; † 26,634) 
    AUC=0.99 
Sensitivity 0.77 (0.76–0.79) 
 
706.57 96.60% 
 
< 0.001 
Specificity 0.99 (0.99–0.99) 444.37 94.60% < 0.001 
Positive likelihood ratio 
(PLR) 
43.42 (25.32–74.45) 375.64 93.60% 
 
< 0.001 
Negative likelihood ratio 
(NLR) 
0.21 (0.16–0.28) 432.87 94.50% 
 
< 0.001 
Diagnostic odds ratio (DOR) 263.85 (145.31–479.09) 226.19 89.40% < 0.001 
       Solid      
      (n=13; †3,014) 
        AUC=0.98 
    
Sensitivity 0.80 (0.77–0.82) 
 
174.61 93.10% < 0.001 
Specificity 0.96 (0.96–0.97) 
 
89.81 86.60% < 0.001 
Positive likelihood ratio 
(PLR) 
21.73 (11.99–39.38) 60.94 80.30% < 0.001 
Negative likelihood ratio 
(NLR) 
0.17 (0.10–0.31) 229.57 94.80% < 0.001 
Diagnostic odds ratio (DOR) 156.43 (62.61–390.83) 65.90 81.80% < 0.001 
         Liquid  
     (n=6; †1,037) 
        AUC=0.94 
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Sensitivity 0.81 (0.75–0.86) 
 
56.38 91.10% < 0.001 
Specificity 0.99 (0.99–1.00) 23.51 78.70% 0.003 
Positive likelihood ratio 
(PLR) 
24.00 (3.60–159.74) 21.75 77.00% 0.006 
Negative likelihood ratio 
(NLR) 
0.22 (0.08–0.61) 81.21 93.80% < 0.001 
Diagnostic odds ratio (DOR) 127.86 (15.64–1045.40) 19.08 73.80% 0.019 
*: Random effects model; (X2): Chi-squared; d.f.: degree of freedom; (I2): I-square; †: no of 
specimen; n: no of studies; CI: confidence interval; AUC: area under receiver operating 
characteristics curve. 
 
 
3.7 Discussion  
3.7.1 Summary of main results 
TB is a global health problem. To my knowledge, this is the first systematic review and meta-
analysis for ascertaining the effectiveness of RT-PCR assays for the detection of MTB from 
both pulmonary and extra-pulmonary pathological samples. This review provides evidence 
on the effectiveness of RT-PCR assay for the rapid and accurate detection of MTB from 
pathological samples. Early and accurate diagnosis of TB is crucial for preventing morbidity 
and mortality. Some of the recent and  related previous systematic reviews such as Steingart 
et al, 2014, reported using Xpert MTB/RIF only on pulmonary TB and rifampicin resistance 
and the study was limited to adults whereas Maynard-Smith et al, 2014 equally used Xpert 
assay only and there was no meta-analysis performed. 
RT-PCR assay is a novel and robust assay primarily used to quantify nucleic acid molecules in 
all TB specimens (Abbara & Davidson, 2011; Baba et al., 2008; Rosso et al., 2011). The main 
advantages of RT-PCR are shortened turn-a-round time, quantification of bacterial load and 
automation of a procedure that reduces hands-on time and decreases risk of cross-
contamination (Chitnis et al., 2011; Rosso et al., 2011). A special mention should be made of 
the novel role of RT-PCR assay that supersedes gold standard (culture) in detection of 
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genital TB which offers a great potential to improve clinician’s ability to initiate treatment 
that could cure infertility leading to successful pregnancies (Malhotra et al., 2012). RT-PCR 
techniques for the detection of MTB afford greater sensitivity and specificity and a much-
reduced response time, as well as enabling visualization of amplification curves. 
Various methods are employed for the diagnosis of TB such as smear microscopy, culture 
identification, histopathology, tuberculin skin test (TST), serological assays, interferon-
gamma release assays (IGRAs) and nucleic acid amplification (NAA) tests (Katoch 2004; Lang 
2010). Smear microscopy is widely used in the diagnosis of TB, but has drawbacks owing to 
low and variable sensitivity values (0–40%) and cannot readily differentiate between MTB 
and non-tuberculous mycobacteria (NTM) (Derese et al., 2012, Haldar et al., 2011; Liu et al., 
2007). Culture identification for MTB also has variable sensitivities (0–80%) in different TB 
specimens (Takahashi et al., 2008; Padmavathy et al., 2003; Sharma et al., 2004) with a turn-
a-round time of 2–10 weeks and it requires the use of skilful technicians (Mehta et al., 
2012). Diagnosis of TB from tissue samples is usually made by histopathological examination 
that depends on the presence of granulomatous inflammation and caseous necrosis (Almadi 
et al., 2009; Liu et al., 2007). However, histology does not distinguish between EPTB and 
infections from other granulomatous diseases such as NTM, sarcoidosis, leprosy and 
systemic lupus erythematosus (except for the presence of acid-fast bacilli, AFB) (Bravo & 
Gotuzzo, 2007; Chawla et al., 2009). 
In this study, the results indicated that RT-PCR assay produces consistent results with high 
specificity of 0.99 (95% CI, 0.99–0.99), PLR of 43.0 (28.23–64.81) and NLR of 0.16 (0.12–
0.20) for PTB, whereas specificity, PLR and NLR were 0.99 (95% CI, 0.99–0.99), 29.82 (17.86-
49.78) and 0.33 (0.26–0.42), respectively, for EPTB. The high specificity found in this study 
for RT-PCR assay agrees with the literature where most studies find the specificity to be 
above 95% (Kibiki et al., 2007; Kim et al., 2011; Yang et al., 2011). A PLR of 43 suggests that 
patients with a pulmonary MTB infection have a 43-fold higher chance of being RT-PCR test 
positive compared with patients without the infection. This ratio suggests a potential role 
for RT-PCR assay in confirming (ruling in) a MTB infection. The summary estimates of 
sensitivity, however, were 0.82 (95% CI, 0.81–0.83) and 0.70 (95% CI, 0.67–0.72) for 
pulmonary and extra-pulmonary samples, respectively; higher values in pulmonary than 
extra-pulmonary TB are possibly due to paucity of tubercle bacilli in extra-pulmonary 
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samples. Sensitivity estimates were more variable than specificity. According to the AUC and 
the DOR (see Table 3.2), diagnostic accuracy of the RT-PCR assay was excellent for 
pulmonary specimens over extra-pulmonary and these results are acceptable for clinical 
practice (see Table 3.2). 
The positive and negative likelihood ratios demonstrate that RT-PCR assay may serve as a 
suitable method for either conﬁrming or excluding TB. Some degree of heterogeneity of 
diagnostic measures across studies was anticipated and observed due to differences in 
sample size, type of index test (RT-PCR assay), or target sequence gene of MTB, reference 
test type used (either liquid or solid or both), clinical settings of the participants and TB 
prevalence. Subgroup analyses were therefore performed pre-specified to investigate 
potential sources of the observed between-study heterogeneity. High heterogeneity was 
found among studies (as defined by the X2 and I2 statistics) for all measures.  
In the current study, a number of subgroup analyses were conducted by comparing Cobas 
TaqMan, Roche Light cycler, Cepheid and others as RT-PCR assay types; IS6110, 16SRNA and 
other genes as RT-PCR assay target sequence gene. Both solid and liquid combined, solid 
and liquid cultures were the Reference test type (see Tables 3.1 to 3.5). However, 
signiﬁcant heterogeneity of diagnostic accuracy measures was expected and was, indeed, 
found among studies and the random effects model partially accounted for the between-
study heterogeneity. Thus, it is possible that when evaluating RT-PCR assays using a more 
sensitive index test could lead to overestimation of the assay’s sensitivity. No signiﬁcant 
differences were observed in specificities of the different types of index tests. 
3.7.2 Strengths and weaknesses of the review 
The study has several important and novel findings: to the best of my knowledge, this is the 
largest and up-to-date systematic review and meta-analysis of the effectiveness of RT-PCR 
assay for the detection of MTB on a high number of pathological samples from adult and 
paediatric patients with TB infection from endemic and non-endemic countries across major 
continents of the world (America, Africa, Asia including Middle-East, Europe). 
An important strength of the study was its comprehensive search strategy using several 
search engines to identify any unpublished studies in the form of conference abstracts or 
proceedings. Screening, study selection, quality assessment and data extraction were 
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undertaken by me and reproducibly by independent assessor. As such mistakes, due to 
human error should be limited. The problem of missing data was reduced by contacting 
authors. Heterogeneity and potential publication bias in accordance with published 
guidelines were explored (Deville et al., 2002; Petitti, 2001). The evaluation level of 
publication bias was not formally carried out in the study; however, the risk of this bias was 
reduced by not restricting the search to any language. Also, experts were contacted for 
additional studies. The additional strength of this review is that RT-PCR assay has 
comparably high sensitivity with paucibacillary specimens and high-throughput capacities.  
This review does, however, have some limitations in assessing issues such as cost-
effectiveness, the net effect of RT-PCR assay on clinical care and patient outcomes. Also, 
because of poor reporting, an analysis of the effect of factors, such as laboratory 
infrastructure, was not possible. Secondly, empirical evidence suggests that studies with 
significant or favourable results are more likely to be published than those with non-
significant or unfavourable results (Song et al., 2000). In addition, literature search 
strategies are inherently imperfect and studies can be missed, it is therefore possible that a 
proportion of such studies with non-significant or unfavourable results might have been 
missed. Other limitations are the conflict of interest of studies from authors, particularly 
from industry supported studies, and keeping up to date with the primary studies in this 
rapidly evolving field. Most of the primary studies could not repeat the test or report if the 
tests were run in duplicates or do anything to clear discrepant results that exist because of 
the retrospective nature of some of these studies. 
Other limitations of this review include the retrospective design by some of the primary 
studies included. While cultures were performed in real time, the molecular analysis (RT-
PCR in this case) was done much later. As a result, specimens were stored for an extensive 
time prior to testing. The length of storage may impact the sensitivity of some of the target 
sequence genes due to degradation of DNA as a result of specimens being frozen. Given that 
RT-PCR assays in this review cover a wide range of different target genes and procedures, it 
is not possible to recommend any one approach over another owing to a lack of direct test 
comparisons. 
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The findings should be interpreted in the context of the poor quality of studies (Barletta, 
2014; Dayal, 2010; El Khechine, 2009; Moure, 2012; Sethi 2012), and reporting, and 
variability in study quality (Cho, 2015; Choi, 2013; In, 2014). 
 Diagnostic studies in general (Reid et al., 1995) and TB diagnostic studies in particular (Small 
& Perkins, 2000) seem to be beset by these problems.  
3.7.3 Applicability of findings to the review question 
The review question was to find out if RT-PCR assay is sensitive enough to be used for the 
detection of MTB from pathological samples. The findings confirm the applicability of the 
assay due to its high sensitivity and specificity.  
In most low- and middle-income countries with poor resources, smear is the most used 
technique for the diagnosis of PTB, if not the only diagnostic method in place, because it is 
faster, simpler and inexpensive; this is despite the fact it has a limited sensitivity and 
specificity with increased frequency of nontuberculous mycobacteria. On the other hand, 
culture-based assay, despite being considered as a gold standard for the diagnosis of TB, is 
not widely used in the process of clinical decision to start treatment due to the delay (2–10 
weeks) in obtaining the results. However, from the review the RT-PCR technique has 
demonstrated a substantial capacity for the diagnosis of TB. Even though its sensitivity for 
EPTB decreases notably when compared to PTB, the technique still offers a higher sensitivity 
for direct detection of MTB than most conventional techniques. Therefore, RT-PCR may be a 
potentially useful additional tool in cases of EPTB not detected by microscopy, when clinical 
suspicion is high. 
3.8       Author’s conclusions 
3.8.1        Implications for practice 
RT-PCR assay has a high sensitivity for PTB and specificity to confirm TB from any 
pathological samples. Overall, RT-PCR assay accuracy was superior for pulmonary samples 
(sensitivity 0.82 (95% CI, 0.81–0.83); specificity 0.99; 95% CI, 0.99–0.99) as opposed to extra-
pulmonary samples (sensitivity 0.70, 95% CI, 0.67–0.72; specificity 0.99, 95% CI, 0.99–0.99) 
possibly due to paucibacillary. An AUC value of 1.0 indicates perfect discriminatory ability of 
95 
 
a test. RT-PCR assay’s AUC values for PTB and EPTB are 0.97 and 0.95 respectively.  The 
specificity was high for both pulmonary and extra-pulmonary samples, indicating that the 
test should be adopted as a first-line test for ruling in TB infection, but there may need to be 
an add-on test to rule out disease. It offers an alternative and robust approach to detect 
MTB in paucibacillary EPTB samples that shows rapid results with good diagnostic accuracy. 
The results of this assay should be interpreted in parallel with clinical findings and the 
results of conventional tests, but the assay contributes significantly to an early diagnosis and 
exerts an acceptable impact on the clinical management and control of TB. The findings do 
not support the use of this assay for excluding a diagnosis of TB on its own as a standalone 
test. It is believed that the information obtained from this study will aid physicians’ decision 
making. 
Conventional laboratory techniques, like direct microscopy for the diagnosis of TB, are far 
from being sensitive and prone to false-negative results as it can only detect mycobacterial 
concentrations at about 10,000 AFB/ml of specimen. Moreover, cultures (gold standard) are 
time-consuming, require biosafety measures and need trained laboratory personnel. 
Current evidence suggests a potential role for RT-PCR assay in confirming a diagnosis of TB. 
Its use has been extensively evaluated for the diagnosis of MTB infections (Espy et al., 2006), 
but its uptake as an assay on a routine basis in clinical laboratories remains a challenge. For 
EPTB, clinical judgement has both poor sensitivity and specificity. 
The NICE guidelines recommend the use of culture, histology and/or chest X-ray for patients 
with non-respiratory TB (NICE, 2016). Consequently, outcomes of a negative smear for acid-
fast bacilli, lack of granulomas on histopathology and failure to culture MTB do not exclude 
the diagnosis of EPTB; RT-PCR assay has proved to be a novel diagnostic modality in varied 
forms of EPTB (Malhotra, 2012). Therefore, this review proves to be of help as most specific 
test in a rule-in decision. This RT-PCR method may be a useful adjunct for culture- and 
smear-based techniques to allow more rapid TB diagnosis, timelier treatment and could 
lead to the reduction of the infectious pool and improvements in TB control. RT-PCR may be 
useful for the initial diagnosis and prompt initiation of TB therapy, and then culture-based 
approaches may be performed for definitive diagnosis and the evaluation of drug resistance. 
The reliability of RT-PCR to confirm an early diagnosis of TB meningitis and abdominal TB 
has been well established, where smear and culture tests are rarely positive (Galimi, 2011; 
Kulkarni et al., 2011). It has also proved useful for an early diagnosis of osteoarticular TB in 
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tissue samples, which can help to start timely ATT (Pandey et al., 2009) and prevent 
progression to irreversible changes. Due to small sample volumes available and irregular 
dispersion of MTB in specimens both viable and non-viable, RT-PCR has aided in detecting 
MTB compared with conventional tests from an array of different cases of EPTB, such as 
pericardial TB, disseminated/miliary TB, thyroid TB, ocular TB, tuberculous mastitis, skeletal 
TB, genitourinary TB, tuberculous meningitis, pleural TB, tuberculous lymphadenitis and 
others. 
 
Latest technology in the detection of MTB which is rapid and sensitive is based on molecular 
methods such as the loop-mediated isothermal amplification (TB-LAMP) test (Eiken 
Chemical, Tokyo Japan), and line probe assays (LPAs). However, most of the PCR based 
testing requires extraction with problem of contamination and inhibition. RT-PCR assay 
principle, one of the molecular methods on which GeneXpert® System (Xpert MTB/RIF assay) 
is based enables accurate, reliable, sensitive and rapid result with less hand-on and no 
contamination problem with turnaround time of 2h. At present, WHO recommended rapid 
TB diagnostics should be available to all persons with signs or symptoms of TB as a means of 
effective global control of TB. The algorithm recommended and approved by WHO based on 
latest technology and the qualities mentioned above for clinical laboratory diagnosis of TB 
from pathological samples is RT-PCR based assay. The average cost of GeneXpert® cartridge 
is between $25.00 to $35.00 per test. The gold standard test, culture-based assays cost 
between $19.00 to $22.00 per test for the diagnosis of TB. The turnaround time is between 
2-10 weeks.  It is hoped that the faster diagnosis will accelerate the much-needed global TB 
control.  
The World Health Assembly passed a resolution in May 2014 approving with full support the 
new post-2015 End TB Strategy with its ambitious targets to “End the global TB epidemic”. 
WHO opines that “everyone with TB should have access to the innovative tools and services 
they need for rapid diagnosis, treatment and care”. In May 2016, new WHO 
recommendations aim to speed up detection and improve treatment outcomes for 
multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a 
shorter, cheaper treatment regimen were passed. The current WHO recommendations for 
the use of GeneXpert® System (Xpert MTB/RIF assay) will bring progress in controlling TB and 
mitigating its consequences which can be expedited through early diagnosis and treatment. 
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Therefore, WHO is working closely with technical and funding partners to ensure adequate 
resources and support for the uptake of this rapid test (WHO, 2016). 
A high-quality laboratory system that uses modern diagnostics is a prerequisite for the early, 
rapid and accurate detection of TB and drug resistance. WHO has established a structured, 
systematic process to rapidly review the evidence base for new TB diagnostics, ensuring that 
new tools meet the required performance standards. 
From the data of investigations of heterogeneity, factors such as RT-PCR assay types 
(CobasTaqMan, Roche Light cycler, Cepheid & other assays and RT-PCR assay target 
sequence genes (IS6110, 16SRNA and other genes) were considered to have influenced the 
accuracy estimates. 
 
It is anticipated that the findings will aid healthcare practitioners and policymakers in 
adopting the use of this rapid and accurate assay on a daily routine basis, most importantly 
as a point-of-care test (POCT). This will be a good tool for the global control of MTB, 
particularly in developing countries that account for about 80% of the global burden of MTB. 
3.8.2        Implication for research 
Future studies should compare the different types of commercialized RT-PCR assay to 
determine their diagnostic accuracy. The use of guidelines, such as the standards for 
reporting of diagnostic accuracy (STARD), might improve the quality of reporting primary 
studies. Further work is required to devise a simple and cost-effective RT-PCR test for an 
efficient diagnosis of TB that can be used routinely in resource-poor countries. 
Given that RT-PCR assays in this review cover a wide range of different target genes and 
procedures, it is therefore recommended for future research to consider direct comparisons 
of available commercial RT-PCR assays with specific genes and procedures to ascertain the 
best assay for throughput capacities. 
Future studies should consider the next-generation cartridge called Xpert Ultra® based on 
the RT-PCR assay principle that is in development. It is relevant as the initial diagnostic test 
for all adults and children with signs and symptoms of TB and in the testing of selected 
extrapulmonary specimens (CSF, lymph nodes and tissue specimens). This technology could 
potentially replace conventional culture and be used as a POCT for the primary TB 
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diagnostic tool. The Xpert MTB/RIF Ultra assay was redesigned to boost analytical sensitivity 
more than ten-fold and to improve reliability of detecting mutations associated with 
rifampin resistance. Ultra is a second-generation test that was designed to overcome the 
sensitivity limitations of Xpert MTB/RIF and it is under assessment on how it can be most 
effectively leverage the benefits in the global effort to find the missing 4 million TB cases. 
Further studies should consider the biosensing technologies for the detection of MTB and 
management in clinical diagnosis. Biosensor systems are based on the combination of 
nanotechnology and biosensing technology. Biosensing technology have great application in 
the medical diagnostics, clinical medicine, environmental monitoring, food quality control, 
defense, and other industries. The applications of these biosensor systems have been also 
started to flourish in the field of MTB detection. This algorithm is rapid, sensitive and with 
immediate “on-the-spot” interpretation based on different biological elements recognition 
systems and basic signal transducer principles.     
In the same vein, future studies should consider the issues such as cost-effectiveness, 
analysis of laboratory infrastructure, the net effect of RT-PCR assay on clinical care and 
patient outcomes that were not addressed. 
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Chapter 4: Dissemination and Impact of RT-PCR assay for 
Mycobacterium tuberculosis detection  
 
This chapter describes the dissemination strategies aimed at reaching a wide range of 
medical practitioners, clinical scientists and laboratory managers, along with other 
healthcare professionals and policy makers who operate pathology services worldwide on 
the need to adopt RT-PCR assay as the appropriate tool for rapid and accurate detection of 
MTB in pathological samples. 
4.1 Dissemination 
One of the requirements of the doctorate degree research is to ensure dissemination of the 
findings and outcomes of the project; this was achieved through various means both locally, 
nationally and internationally. The major learning outcome from the dissemination of my 
work was the ability to communicate information in a clear and precise manner to the 
audience during presentations, which produced positive feedback.   
  
4.2 Posters and presentations 
 The author, as a volunteer/mentor, presented part of the work at the Technical skills 
lecture series for the clinical laboratory diagnosis of MTB in Agan Khan University Teaching 
Hospital, Nairobi, Kenya in January 2014; Muhimbili Hospital Tanzania in June, 2014; 
Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania in June, 2015 and conference 
sessions in Kampala, Uganda in September, 2016, under the aegis of LabSkills Africa projects 
by Royal College of Pathologists London in collaboration with College of Pathologists of East 
Africa, Central and Southern Africa. The author also presented the findings of the review as 
a presentation at lunchtime meetings to my work colleagues in the Trust on May 4, 2015. 
The protocol for the research work was registered with the international prospective 
register of systematic reviews (PROSPERO) and published online PROSPERO 2015: 
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CRD42015027534 Available from 
http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp? 
ID=CRD42015027534) DOI 10.15124/CRD42015027534 (see Appendix 4.1).  
The author submitted part of the work documented as an abstract presentation at the 
Science Together Post-Graduate Research Conference, University of Portsmouth in June 
2016.  
 The work was sent as an abstract for a poster presentation and has been approved for 
presentation at the September 2017 IBMS Congress in Birmingham, United Kingdom (see 
Appendix 4.2). 
The manuscript from this work titled “Effectiveness of real-time polymerase chain reaction 
assay for the detection of Mycobacterium tuberculosis in pathological samples: a systematic 
review and meta-analysis” was sent on May 4, 2017, for publication in the Systematic 
Reviews journal by BioMed central. The manuscript (SYSR-D-17-00124R1) was assessed by 
journal’s reviewers and based on the reports and Editor’s assessment. It was accepted on 
October 12, 2017, and published on October 25, 2017.        
 (see Table 4.1). 
Table 4.1 Timeline of dissemination 
Date 
 
Title Scope 
 
Location Participants/Audience 
18–22 
January 
2014  
RT-PCR assay 
for detection of 
MTB 
Discussion: 
Diagnosis of 
MTB from 
clinical samples 
Nairobi, Kenya COPECA, MLS Kenya 
16–20 
June 2014 
RT-PCR assay 
for detection of 
MTB 
Discussion: 
Diagnosis of 
MTB from 
clinical samples 
Muhimbili 
Hospital 
Tanzania 
COPECA, MLS, clinical 
scientists, 
medical practitioners 
23–27 
February 
RT-PCR assay 
for detection of 
Discussion: 
Diagnosis of 
KCMC, Moshi, 
Tanzania 
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2015 MTB MTB from 
clinical samples 
21–25 
September 
2015 
RT-PCR assay as 
a tool for rapid 
and accurate 
detection of 
MTB 
Discussion Kampala, 
Uganda 
End of LabSkills Africa 
project conference 
June, 2016 Effectiveness of 
real-time 
polymerase 
chain reaction 
assay for the 
detection of 
Mycobacterium 
tuberculosis in 
pathological 
samples: A 
systematic 
review and 
meta-analysis 
 
Abstract 
presentation 
Science 
Together Post-
Graduate 
Research 
Conference, 
University of 
Portsmouth 
Graduate researchers 
September 
2017 
Effectiveness of 
real-time 
polymerase 
chain reaction 
assay for the 
detection of 
Mycobacterium 
tuberculosis in 
pathological 
samples: A 
Poster 
presentation 
IBMS 
Conference 
Birmingham 
IBMS members, 
researchers, 
policy makers 
102 
 
systematic 
review and 
meta-analysis 
 
Oct, 2017 Effectiveness of 
real-time 
polymerase 
chain reaction 
assay for the 
detection of 
Mycobacterium 
tuberculosis in 
pathological 
samples: A 
systematic 
review and 
meta-analysis 
 
Published paper BioMed 
Journal of 
systematic 
reviews 
Researchers 
Medical and 
Healthcare 
practitioners and 
International 
community. 
 
4.3 Publication in journal article: Why Systematic Reviews? 
The Systematic Reviews journal was considered as the ideal platform to communicate this 
information because of the open-access nature of the journal which will ensure its wide 
dissemination across a wide range of groups internationally and the fact that my research is 
a systematic review related to a very broad definition of health issues with a relevant 
outcome. 
The data gathered during the research will be of practical use to a wide range of medical 
and healthcare professionals in the field of diagnostic laboratory medicine worldwide. 
Because the paper summarizes state-of-the-art evidence that can inform future guidelines 
and healthcare policy when selecting the most appropriate tools (such as RT-PCR assay) for 
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the rapid and accurate detection of MTB in pathological samples of infected patients on a 
routine basis. 
In addition, the journal offers a fast publication schedule that enjoys a rigorous, quality and 
high-standard peer review policy. Articles are published in this journal with their final 
citation after acceptance, in both fully browsable web form and as a formatted PDF. The 
impact and influence of the journal, which cuts across citations to social media, are 
enormous. It equally promotes and provides much visibility and exposure of articles by a 
team of dedicated pressmen who work with the global media, leading to wider coverage in 
the press to highlight research of interest to the public and science media; this thus makes 
the results accessible to other researchers, communities and institutions around the world.  
Personally, I have received articles published in this journal via article alerts on a regular 
basis as email updates. Online publication gives the opportunity to publish large datasets, 
display data in a form that can be read directly by other software packages so that readers 
may manipulate the data to suit themselves and create all relevant links (for example, to 
PubMed).  
Finally, as an author of a published work in this journal, I am able to retain the copyright 
allowing free reproduction and dissemination.  
4.4 Current uptake of MTB RT-PCR assay 
Although RT-PCR has been extensively evaluated for diagnosis of MTB infections (Espy et al., 
2006), its uptake as an assay on a routine basis in clinical laboratories remains a challenge. 
My findings from UKNEQAS made it clear that many clinical microbiology laboratories in the 
UK and by extension globally, have not adopted the RT-PCR assay platform for the routine 
diagnosis of MTB from clinical specimens (see Figure 4.1). 
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Figure 4.1 UKNEQAS MTB RT-PCR assay detection uptakes. 
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Chapter 5: Reflections and personal professional development 
 
‘Focus on the journey, not the destination. Joy is found not in finishing an activity but in 
doing it’ – Greg Anderson. 
I have taken time throughout the previous Chapters to introduce, give the details and 
conclude the uptake of the systematic reviews and meta-analysis as doctorate research 
work. However, this chapter discusses my adventure into the professional doctorate, what I 
gained both on a personal and a professional level. It gives a critical review of previous 
learning prior to starting the Doctorate in Biomedical Science (DBMS), including my formal 
education, training, administrative/managerial, academic/teaching, professional, technical 
skills and development as a biomedical scientist and other activities I was involved in while 
the programme lasted. 
5.1 The journey so far  
5.1.1  Education and training 
‘Whatsoever thy hand findeth to do, do it with thy might’… Ecclesiastes 9:10a (KJV) 
Shortly after completing secondary school, I proceeded to study science for my A level 
course. After two years pursing A levels, I was admitted to study medical laboratory science 
in the School of Medical Laboratory Sciences, Obafemi Awolowo University Teaching 
Hospitals Complex, Ile-Ife, Osun State, Nigeria. I graduated with a specialization in medical 
microbiology and parasitology in 1993.  
 
The medical laboratory science course was a four-year full-time programme comprising pre-
clinical and clinical laboratory courses taught in English language. Clinical courses involved 
18 months rotation through the following specializations; clinical biochemistry (clinical 
biochemists analyse samples of blood, urine, faeces and tissue for diseases such as diabetes 
and renal failure), clinical immunology (clinical immunologists study the body's immune 
system to test for diseases such as allergies and HIV infection), cytogenetic (cytogeneticists 
investigate genetic disease and how chromosomes are affected by disease), haematology 
(haematologists analyse blood samples for diseases such as anaemia and cancer), histology 
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(histologists prepare tissue samples for investigation by a pathologist), medical cytology 
(medical cytologists test cell samples for cancer), medical microbiology and parasitology 
(medical microbiologists detect, cultivate and test bacteria, fungi, virology and parasites) 
and transfusion Science (transfusion scientists prepare blood and blood products for 
transfusion). 
I became state registered in the same year by the Medical Laboratory Science Council of 
Nigeria (MLSCN), formerly the Institute of Medical Laboratory Science of Nigeria, as a 
medical laboratory scientist after passing the prescribed professional qualifying 
examination.  
 
In 1994, I went for the mandatory one-year National Youth Service Corps (NYSC) scheme. 
This is a national graduate working programme established to mobilize under thirty-year-old 
graduates into the work force to allow them to gain exposure after their first degree in 
university/college. I was posted to the Department of Microbiology and Parasitology in 
University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria. This 
afforded me the opportunity to continue my post-university degree placement/training as 
an intern.  
5.1.2 Post-graduate education 
 I enrolled for a Master’s degree in Microbiology (medical option) in the 2001/2002 
academic session at the then University of Ado Ekiti, now Ekiti State University, Ado-Ekiti, 
Nigeria. I did a Postgraduate diploma course in Education (PGDE) at Obafemi Awolowo 
University, Ile-Ife, Nigeria in 2007/2008. 
5.1.3 Stint in academics/adventure into academic world 
 
I have an unrepentant love for teaching. My academic work began on a part-time basis as a 
lecturer in Biology and Integrated science for Sandwich National College of Education 
certificate students (NCE IV class) of the Adeyemi College of Education, Ondo Town, Nigeria, 
where I practiced as a medical laboratory scientist. My love for academics propelled me to 
secure employment on a part-time basis as a facilitator for a postgraduate diploma course in 
HIV/AIDS Education of the National Open University of Nigeria (NOUN) located on Adeyemi 
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College of Education, Ondo campus, Nigeria, until I was employed as a lecturer 
II/coordinator in the medical laboratory science department of Babcock University (BU) 
(academic and administrative) and doubled as a laboratory manager in the Pathology 
department of Babcock University Teaching Hospital (BUTH) (professional and managerial 
role). The two roles were intricately entwined, daunting and challenging. I was deeply 
involved with the establishment of the new department (Medical laboratory science), 
curriculum development, staffing and other logistics, accreditation liaison officer between 
the university and Nigeria University Commission (NUC) on the one hand and Medical 
Laboratory Science Council of Nigeria (MLSCN) on the other hand. This was so that the 
department could stand on a solid ground without failing accreditation by the two bodies 
(academic and professional). This role helped me tremendously to develop/improve my 
administrative, managerial, professional and academic skills. 
5.1.4 PhD in Nigeria 
In 2007, I enrolled on a PhD programme in The Federal University of Technology, Akure, 
Nigeria. The programme produced a publication and progress seminar before I immigrated 
to the UK in 2009. This put an end to the programme. My love for academics, self-
actualization of my life dreams and continuous professional development propelled me to 
start a part-time professional doctorate in biomedical science at the University of 
Portsmouth at the same time as practicing as a biomedical scientist for the NHS, England.  
5.1.5 Practice in the UK  
Immigrating to the UK led to my early retirement in Nigeria. I was assessed by HPC now 
HCPC (Health and Care Professions Council), a UK-wide regulatory body responsible for 
setting and maintaining standards of professional training, performance and conduct of the 
16 healthcare professions which include biomedical science. I became state registered after 
I was deemed fit to practice in the UK. After arriving in the UK, I was employed as a 
specialist biomedical scientist in the microbiology department of NHS England firstly as a 
locum practitioner before a permanent role and recently as a senior biomedical scientist. It 
has been a rewarding experience practicing in the UK with my long years of professional 
background experience from Nigeria. 
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5.2 Reflections of the doctorate of biomedical science (DBMS) 
‘Success is a journey, not a destination’ – Ben Sweetland 
 
This section looks reflectively on the learning undertaken during my studies, taught element 
and research component (part 2) of the degree that have enabled me to execute my 
research plans and report my findings which culminated in the writing of this thesis.  
 
5.2.1 My learning experiences 
‘Learning is the process whereby knowledge is created through the transformation of 
experience’ (Kolb, 1984, p. 38). As a biomedical scientist, reflection has always been part of 
my daily activities of learning from experience. The highpoint of this continuous professional 
programme which I participate in is a critical reflection that is germane for my 
personal development as a professional. Kolb states that learning involves the acquisition of 
abstract concepts that can be applied flexibly in a range of situations.  
Kolb suggested greater structure in reflection: this model suggests that a participant has a 
concrete experience, experiencing which favours experiential learning. This is followed by 
reflective observation, reflecting where extensive consideration is given to the task and 
potential solutions before there is any attempt at action. Then is the formation of abstract 
conceptualizations, thinking in order to achieve preference for conceptual and analytical 
thinking in other to achieve understanding before finally conducting active experimentation, 
involving active trial-and-error learning to test out a newly developed principle (Chenhall et 
al., 2010) (see Figure 5.1). Knowing my own learning style enables learning to be orientated 
according to the preferred method. 
Honey and Mumford (1992) modified Kolb’s (1984) original work on learning styles and 
classified learners into four styles:  
 activist – a person, who learns through constant and enthusiastic activity; 
 pragmatist – a person who likes to try out ideas and turn theories into practice; 
 reflector – a person who stands back, observes and thinks a lot before getting 
actively involved 
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 theorist – a person who likes to rationalize and synthesize information into logical 
patterns.  
My preferred style shifted from reflector (i.e. standing back and watching others first) to 
theorist, pragmatist and activist. 
My critical reflections process is based on Gibb’s reflective cycle (Gibbs, 1988) since I 
registered for this doctoral degree. This model has been incorporated as a reflective skill 
into my daily work particularly in training junior colleagues (trainee BMSs) and students on 
placement. I used the same model during the presentation of my experience as a mentor on 
LabSkills Africa Project to microbiology staff, Sandwell and West Birmingham Hospitals NHS 
Trust. 
 
More so, I critically reflect on my previous learning experience and examine the impact of 
that on my professional development and practice. I evaluate my learning styles, my 
personal learning journey including learning theory and identify my learning needs. This 
helps me describe where I was before my enrolment in terms of my administrative, 
managerial, counselling, academic/teaching, professional and technical skills, and where I 
am now.  
  
Figure 5.1 Kolb’s learning cycle. 
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5.2.2 Why a professional doctorate degree? 
As a professional practitioner with about 24 years of experience who is involved in lifelong 
learning, my learning begins with a concrete experience, followed by reflective observation, 
through the documentation of what happened or the process of doing a thing and making 
sense of them. These four cycles were demonstrated throughout the lifespan of this course. 
My adventure into the study of a doctorate degree in biomedical science was buoyed by my 
unflinching aspiration, self-determination and ambition to attain the highest level of 
qualification possible in my field of professional practice. This decision kick-started a 
concrete experience of my learning cycle. According to Eraut (1994), qualification is a ‘rite of 
passage’ and a ‘landmark in the process of professional socialization’. I started a PhD 
programme with about 80% completion and a publication to its credit in Nigeria before 
immigrating to the UK. This was later abandoned since the degree could not be pursued by 
proxy. My research topic was centred on infectious disease and immunity and was relevant 
to my professional calling just as this is, even though it was a research based degree. 
A colleague and a friend, then an existing professional doctoral student, told me about the 
professional doctorate programme on a part-time basis, which I deemed as not only 
relevant for fulfilling my ambition but equally allowed me to work and at the same time take 
care of my family.  
The course and the taught element were very appealing, relevant to my profession and 
stimulating. The taught element was designed to prepare the student to undertake doctoral 
research. The units included: 
1. Advanced research techniques. This module availed me the much-needed tools that 
later became the solid foundation of my research work. It involved assignments that 
covered analysis of data, critical appraisal of literature for evidence based practice 
and applying theory to practice: a research resource pack for professionals.  
2. Publication and dissemination. Even though I had published before, this unit 
provided me with a vast amount of knowledge regarding publication. I used this a lot 
for the preparation of publication work as a result of this research work outcome. 
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3. Professional review and development. This is what I do from day to day in the 
course of my professional practice, without formally taking note of it to a great 
extent. This module helps me in no small measure because the field of biomedical 
science, like others, depends on the development of an individual’s skills as a 
reflective practitioner. These units laid the solid foundation that kept me going 
throughout my research work, which was part 2 of the programme. They provided 
tremendous help as I navigated through the challenges of doctoral degree research. 
Both components of the DBMS (taught and research) have helped me greatly to be an 
astute professional. The skills I garnered are impacting positively in my career and are being 
employed daily in training my junior colleagues. These skills and knowledge helped me as a 
volunteer/mentor in my engagement with professional colleagues over an array of unique 
challenges in the African continent through the LabSkills Africa Project. It is not an 
overstatement that the skills will remain with me throughout my life.  
My initial research proposal was ‘Diagnostic accuracy of RT-PCR assay for the detection of 
Clostridium difficile from stool samples of patients’. The topic could not be registered 
because a professional doctorate student was already working on Clostridium difficile and 
two students cannot be working on a closely related project within the same department. 
So, I had to look for another title that is relevant to my field of practice. Systematic review 
and meta-analysis was suggested by Dr Sally Kilburn. It was a totally new field to me, but 
with encouragement and support from her and Dr Ann Dewey, I took it as a challenge and 
finally I got the proposal accepted and registered by the Faculty. 
This work was not a primary study but the synthesis of many primary studies on the topic 
from all over the world. Though the primary studies were practically based, this ordinarily 
would have been within my own comfort zone, since I use the assay and methodology 
regularly in my professional practice. The study design: systematic review and meta-analysis 
was not only new but challenging to me. Even though it is the strongest in the hierarchy of 
scientific evidence/research, it has not been generally embraced in the field of diagnostic 
test accuracy (DTA) in biomedical science research. To keep abreast of the design and make 
sense of it I had to regularly immerse myself in self-directed online training by frequently 
visiting the following websites as online learning resource materials: 
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  http://www.joannabriggs.org, 
 http://www.chochrane.org, 
 http://www.cochranelibrary.com/cochrane-database-of-systematic-reviews/ 
 http://www.cochranelibrary.com/ 
 tech.cochrane.org/revman: for Review Manager 5 (RevMan 5) software used  
 meta-disc.software.informer.com 
I attended a three-day course on systematic reviews and meta-analyses of diagnostic test 
accuracy, organised jointly by a faculty from the University of Birmingham and the 
University of Amsterdam. The course was designed for individuals undertaking health 
technology assessment, health service researchers and healthcare professionals interested 
in understanding key issues in the design and conduct of systematic reviews and meta-
analyses of diagnostic test accuracy (DTA) studies. The course was delivered through a 
mixture of interactive presentations, discussions and hands-on computer exercises. At the 
end of the course I was fully fortified with how to appreciate the diversity of test usage and 
study designs, understand potential risk of bias and concerns regarding applicability, 
understand the concept underlying approaches of meta-analysis, explore heterogeneity, 
create different types of analysis (in RevMan and Stata) and summarise results and draw 
appropriate conclusions. This course gave a solid foundation in executing my research work.  
 
5.3 LabSkills Africa Project: Developing leadership & improving pathology 
diagnosis and laboratory medicine in sub-Saharan Africa 
‘The purpose of human life is to serve and to show compassion and the will to help others’ – 
Albert Schweitzer 
As a result of the landmark success of the pilot project, the international collaborator of the 
year award 2016 by Times Higher Education (THE) was given to us in London, now the Royal 
College wants to extend the programme into Western Africa and again, I will be playing a big 
role in that. 
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5.3.1 Mentor/volunteer experience 
Laboratories are not just technology, equipment and buildings; they are people and systems 
that manage the processes and standards required to produce accurate and timely results. 
Successful implementation of new diagnostic tests will still require functional networks of 
laboratories with trained and motivated staff, quality management systems and safe 
working environments (Ridderhof et al., 2008). Experts estimate that each year 
misdiagnoses cost the African government millions of dollars and account for many adult 
and child deaths. 
 
During the course of this doctoral programme, I was chosen to take part as a mentor to 
improve quality standards in the three-year ambitious project to drive-up quality and safety 
standards at hospital laboratories in five African countries. 
 
The initiative, called LabSkills Africa was set up by the Royal College of Pathologists in 
partnership with the College of Pathologists of East, Central and Southern Africa (COPECSA), 
the British Division of the International Academy of Pathology (BDIAP) and the East, Central 
and Southern Africa Health Community (ECSA-HC) to address some of the problems 
confronting clinical laboratory practice in Africa. The initiative has been piloted in 20 public 
sector laboratories in Kenya, Uganda, Tanzania, Zambia and Zimbabwe. In total, these 
laboratories serve a combined population of 110 million and perform more than 1.7 million 
tests annually. Experts estimate that each year misdiagnoses cost the African government 
millions of dollars and account for many adult and child deaths. 
The project was aimed to contribute towards the long-term strengthening of healthcare 
systems, the improvement of clinical decision-making and increased patient safety through 
measures designed to improve the standards and quality of specific laboratory services and 
tests that support the diagnosis and management of health conditions related to WHO 
millennium development goals (MDGs) 4, 5 and 6. 
 
Over a period of 30 months, LabSkills Africa has trained 100 pathologists, biomedical 
scientists and laboratory technologists in the areas of leadership, laboratory skills 
improvement project, laboratory skills improvement network, quality management, 
114 
 
personal development planning and improvement of technical bench skills. Throughout the 
process, the participating laboratories and their staff have been supported and mentored by 
highly skilled and experienced volunteers drawn from the UK, African Diaspora, North 
America and Australasia.  
Work was divided between classroom sessions for staff and the assessment of different 
basic procedures like testing for malaria, haemoglobin, urinalysis, peripheral blood film, HIV 
and TB diagnosis. I was in the TB diagnosis cohort. I trained pathology laboratory staff from 
20 African hospitals in Zimbabwe, Zambia, Tanzania, Kenya and Uganda on assessing 
procedures and trying to find ways to improve safety and quality, while working within the 
limited resources available to each facility. 
The work I participated in involved improving leadership and quality management and 
improving the technical skills of the staff at laboratories. I spent one week each in three 
different laboratories where I held discussions on diagnosis of MTB from clinical samples 
using RT-PCR assay as a tool. I participated in a technical skills training programme in Agan 
Khan University Hospital Nairobi Kenya in January 2014, Muhimbili Regional Hospital in June 
2014 and Dar-es-Salaam and KCMC Moshi in February 2015 over a period of seven days. I 
participated as a resource person in a week-long leadership improvement training 
course/conference in February 2014 at Moshi, Kilimanjaro District, Tanzania.  
The standards of pathology were lower than they are here in the UK due to fewer available 
resources, but with the intervention of the project there were many improvements in 
procedures carried out and the communication between hospital departments. The learning 
skills I gained from my doctoral research programme were useful in the project. The lives of 
millions of Africans at risk from fatal diseases like malaria, TB and AIDS have been made 
safer thanks to the efforts of LabSkills Africa Project. During the project, a blame-free 
culture was introduced to make error-logging more routine. If people are castigated for 
mistakes, it makes it unlikely they are admitted and logged, which prevents improvements 
being made. It makes me so proud, the staff have become quite ingenious in coming up with 
solutions to their problems and they have grown in confidence as their procedures and 
safety standards improve. Also, one of the laboratories I got involved with was fully 
accredited. 
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An international conference held in Kampala, Uganda, marks the conclusion of the LabSkills 
Africa pilot by bringing together the project’s key stakeholders, participants and decision 
makers to:  
1. share experiences, lessons learned and best practices from the pilot;  
2. showcase the work and achievements of participants and laboratories;  
3. explore ways to strengthen and build on the achievements of LabSkills Africa to 
ensure sustainability; 
4. update and develop the knowledge and skills of LabSkills Africa participants and 
conference delegates.  
5.4 Future Goals 
‘We have nothing to fear for the future, except as we shall forget the way the Lord has led us 
and His teaching in our past history’ – Ellen G. White.  
 
One of my future goals is to become an academic in biomedical science, to use my immense 
experience to continue to teach, train, undertake more clinical research and publications 
and perform other roles relevant within the profession of laboratory medicine 
internationally. 
I do hope to partake in the next phase of the LabSkills Africa Project where I will be actively 
involved in protocol development, quality management, technical and leadership skills 
training and contribute to the development of relevant guidelines within the NHS agenda 
for change. 
I aspire to attain consultant grade in biomedical scientist (microbiology) and gain 
membership to the Royal College of Pathology. 
5.5 Summary 
‘Believe you can and you're halfway there’ – Theodore Roosevelt. 
 
‘The best preparation for tomorrow is doing your best today’ – H. Jackson Brown, Jr. 
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As I come towards the end of the journey of my professional doctorate that has been a 
focus on advanced practice of knowledge and skills, professionally oriented degree, which 
also developed my research skills that would be directed in applying gained knowledge to 
solve new and emerging problems in the field of biomedical science, it will give me a sense 
of accomplishment of one of my life ambitions, self-respect, more confidence and a catalyst 
to aspire to more until I reach the top-most level of self-actualization within my capability. 
 
I had a spell as an academic in biomedical science before immigrating to the UK. I love it and 
hope one day to go back in a professional capacity. Having acquired other relevant 
qualifications including a Postgraduate Diploma in Education coupled with almost three 
decades of professional experience, I have therefore positioned myself suitably for both 
academic and professional positions in the evolving field of biomedical science. If I am 
successful in obtaining my doctorate, it would immediately help me with future career 
aspirations which would help me grow my professional network, demonstrate higher-level 
sophisticated skills, impacting positively in my chosen field and consequently could see a 
possible personal economic payoff. 
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Appendix 2 
Decision on Protocol submitted to Systematic Reviews Journal 
Date: 22 Feb 2016  
To: 
"Emmanuel Oladipo Babafemi" 
boladiipo95@yahoo.com,emmanuel.babafemi@myport.ac.uk  
From: "Systematic Reviews Editorial Office" editorial@systematicreviewsjournal.com  
Subject: Decision on your submission to Systematic Reviews - SYSR-D-16-00049  
SYSR-D-16-00049 
Effectiveness of real-time polymerase chain reaction assay for the detection of Mycobacterium 
tuberculosis in pathological samples: A systematic review and meta-analysis 
Emmanuel Oladipo Babafemi, MSc, PGD(Ed),CSci,; Benny P Cherian, FRCPath, Consultant 
Microbiologist; Lee Banting, PhD, MRSC CChem FHEA,; Graham Mills, CertEd, BA(Hons), MA(Ed), 
PhD, CChem, CSci, CEng, 
Systematic Reviews 
 
Dear Mr Babafemi, 
 
Thank you for considering Systematic Reviews for your protocol (above). Unfortunately, 
Systematic Reviews only considers protocol articles for proposed or ongoing research that has not 
yet started the final data extraction stage of the review. As your review has begun the final data 
extraction stage, we are sorry to say that we cannot consider the manuscript for publication and 
are closing your file. 
 
You may be aware that Systematic Reviews considers a broad range of other manuscript types 
and we encourage you to submit your completed systematic review as a research article 
(http://www.systematicreviewsjournal.com/authors/instruction).   
 
Thank you for your interest in Systematic Reviews; we hope you will consider the journal for your 
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work in the future. 
 
Best wishes, 
 
Rebecca Kirk 
Systematic Reviews 
http://www.systematicreviewsjournal.com/ 
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Appendix 3  
3.1 Search strategy 
 
MEDLINE/PUBMED Search Strategy: 
Nov 2016: 
Search terms included ("tuberculosis"[MeSH Terms] OR "tuberculosis"[All Fields]) OR 
(extrapulmonary[All Fields] AND ("tuberculosis"[MeSH Terms] OR "tuberculosis"[All 
Fields]))) AND "Real-time polymerase chain reaction"[All Fields]) OR "rt-pcr"[All Fields]) OR 
"Nucleic Acid Amplification Test"[All Fields]) OR "NAAT"[All Fields]) AND "culture-based 
media"[All Fields]) OR "liquid media"[All Fields]) AND "solid media"[All Fields] 
 
Search History:    
July 2015 
1. Medline; TB.ti,ab; 31,471 results.  
2. Medline; tuberculosis.ti,ab; 151,442 results.  
3. Medline; exp TUBERCULOSIS/; 162,848 results.  
4. Medline; exp MYCOBACTERIUM TUBERCULOSIS/; 38,636 results.  
5. Medline; 1 OR 2 OR 3 OR 4; 221,803 results.  
6. Medline; (real-time AND PCR).ti,ab; 76,991 results.  
7. Medline; (Real-time AND polymer*).ti,ab; 31,904 results.  
8. Medline; exp REAL-TIME POLYMERASE CHAIN REACTION/; 27,814 results.  
9. Medline; (Culture-based AND assay*).ti,ab; 664 results.  
10. Medline; 6 OR 7 OR 8 OR 9; 111,331 results.  
11. Medline; 5 AND 10; 826 results 
Search History:  
July 2015 
1. EMBASE; TB.ti,ab; 39,743 results.  
2. EMBASE; tuberculosis.ti,ab; 161,051 results.  
3. EMBASE; exp TUBERCULOSIS/; 193,977 results.  
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4. EMBASE; exp MYCOBACTERIUM TUBERCULOSIS/; 52,324 results.  
5. EMBASE; 12 OR 13 OR 14 OR 15; 247,183 results.  
6. EMBASE; (real-time AND PCR).ti,ab; 114,589 results.  
7. EMBASE; (Real-time AND polymer*).ti,ab; 37,196 results.  
8. EMBASE; exp REAL-TIME POLYMERASE CHAIN REACTION/; 118,341 results.  
9. EMBASE; (Culture-based AND assay*).ti,ab; 884 results.  
10. EMBASE; 17 OR 18 OR 19 OR 20; 169,510 results.  
11. EMBASE; 16 AND 21; 1,313 results. 
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3. 2 Data extraction form 
Study ID (first author and year of publication) 
  
Title:  
Notes: 
A) General Information 
Date form completed 
(dd/mm/yyyy) 
 
Name/ID of person 
extracting data 
 
Reference citation  
Study author contact 
details 
 
Was author contacted?  
Publication type 
(e.g. full report, abstract, 
letter) 
 
Notes: 
 
B) Study eligibility 
Study characteristics Include Exclude 
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Study design  
- Other, specify: 
 - Unknown/not reported If 
other, specify: 
Cohort 
 
Prospective 
Retrospective 
Others 
Specify:  
 
Design-free 
 
Unknown/not reported 
Participants Active tuberculosis 
Latent tuberculosis 
Others 
Other mycobacterium infection 
 
Index test Real-time polymerisation chain 
reaction 
Microscopy 
Other test(s)  
Reference test  
 
Culture-based assay 
Solid:                           
Liquid:  
Both solid and liquid culture:    
 
No reference test   
Outcomes Sensitivity                  
Specificity  
Rapid 
Others  
 
 
No outcomes 
 
Data  
 
Sufficient for 2X2  contigency 
table 
 
 
Insufficient data  
Other reason for 
exclusion 
 
 
 
DO NOT PROCEED IF STUDY IS EXCLUDED FROM REVIEW 
Notes: 
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C) Characteristics of included studies 
Aim/Objectives of the 
study 
Descriptions as stated in paper Location in text or 
source (pg, 
fig/table/other 
   
Country (where the study 
was conducted) 
  
Study design (e.g.  
Prospective, Retrospective,  
Cohort 
 Cross-sectional,  
Diagnostic case-control 
studies 
Unknown/not reported 
Cross-sectional, primary observational 
studies and Randomised controlled trials 
(RCTs) - blind or unblended- with a high 
degree of heterogeneity are the only 
eligible studies. Cohort studies or 
diagnostic case-control studies 
 
 
Ethical approval 
needed/obtained for study 
      Yes               No               Unclear  
   
Notes: 
 
D) Participant’s characteristics 
 Description Comments 
Population    
Age   
Sex   
Race/Ethnicity   
Disease characteristics   
Specimen types Pulmonary                         
Extra-pulmonary  
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Number of included specimens Pulmonary                
Extra-pulmonary 
 
Notes: 
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3.3 Quality assessment of diagnostic accuracy studies-2 tool   
QUADAS-2 tool: Risk of bias and applicability judgments 
Domain 1: Patient selection 
A. Risk of bias  
Describe methods of patient selection: 
 Was a consecutive or random sample of patients 
enrolled? 
Yes/No/Unclear 
 Was a case-control design avoided? Yes/No/Unclear 
 Did the study avoid inappropriate exclusions? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability  
Describe included patients (prior testing, presentation, intended use of index test and 
setting): 
Is there concern that the included patients do not match the 
review question? 
 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 2: Index test(s) (if more than 1 index test was used, please complete for each test) 
A. Risk of bias  
Describe the index test and how it was conducted and interpreted: 
 Were the index test results interpreted without 
knowledge of the results of the reference standard? 
Yes/No/Unclear 
 If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability  
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Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 3: Reference standard 
A. Risk of bias  
Describe the reference standard and how it was conducted and interpreted: 
 Is the reference standard likely to correctly classify the 
target condition? 
Yes/No/Unclear 
 Were the reference standard results interpreted 
without knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its interpretation 
have introduced bias? 
RISK: LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability  
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
CONCERN: 
LOW/HIGH/UNCLEAR 
Domain 4: Flow and timing 
A. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram): 
Describe the time interval and any interventions between index test(s) and reference 
standard: 
 Was there an appropriate interval between index 
test(s) and reference standard? 
Yes/No/Unclear 
 Did all patients receive a reference standard? Yes/No/Unclear 
 Did patients receive the same reference standard? Yes/No/Unclear 
 Were all patients included in the analysis? Yes/No/Unclear 
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Could the patient flow have introduced bias? RISK: LOW/HIGH/UNCLEAR 
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3.4 Moses-Littenberg statistical modelling of SROC curves and definition of statistical 
parameters 
 
Moses-Littenberg statistical modelling of SROC curves 
 
 
 
AUC: The area under the (regression) curve also measures the overall accuracy of diagnostic 
tests. If the AUC is 100%, then the test differentiates perfectly between diseased and non-
diseased individuals. An AUC of 50% indicates a poor diagnostic accuracy.  
DOR: This was calculated by positive likelihood ratio/negative likelihood ratio or [sensitivity/ 
(1-specificity)]/ [(1-sensitivity)/ specificity]. DOR is a measure of the overall diagnostic power 
of a test. A high DOR implies that the test shows good diagnostic accuracy in all patients; 
whereas a DOR of 1 would indicate that the test cannot discriminate between people with 
and without disease.  
X2: Chi-squared describing degree of freedom (d.f.); p-value with the degree of freedom 
equal to the number of studies minus 1. 
 
165 
 
I2: A statistic describing the proportion of total variation in study estimates that is due to 
heterogeneity. Values greater than 50% suggest greater heterogeneity between the studies. 
If the I2 statistic suggests significant heterogeneity between the studies then the reasons for 
such differences can be examined by relating study level co-variates i.e. type of reference 
test, prevalence, type of PCR or other methodological features. 
Negative likelihood ratio: ratio of the proportion that test negative amongst those that 
have the target condition compared to the proportion that test negative amongst those 
who do not have the target condition.  
Positive likelihood ratio: ratio of the proportion that test positive amongst those that have 
the target condition compared to the proportion that test positive amongst those who do 
not have the target condition. 
Q: Is the intercept of the SROC and the anti-diagonal line through the unit square i.e. the 
point of the curve in which sensitivity equals specificity. Q estimates the overall accuracy by 
finding where sensitivity and specificity are the same. If the curve is closer to the top left 
corner, the better the accuracy. The higher the Q, the more accurate is the test. However, a 
high Q is desirable in tests where high sensitivity and high specificity are equally important. 
If, however, when either the sensitivity or the specificity is more important than one of 
them, then Q does not address the clinical usefulness of the test. 
Receiver characteristic operating curve (ROC): the sensitivity and specificity of a test vary 
depending on the threshold value chosen. The ROC curve describes the trade-off between 
sensitivity and specificity as the threshold changes. 
Sensitivity: proportion that test positive amongst those having the target condition.  
Specificity: proportion that test negative amongst those without the target condition. 
Summary receiver characteristic operating curve (SROC): This displays each study's 
sensitivity and specificity estimates within the ROC space. A regression curve is fitted 
through the distribution of pairs of sensitivity and specificity. A shoulder-like curve indicates 
that the variability between studies may be due to the threshold effect (i.e. variation in cut-
off values used across studies) and that an underlying common DOR exists that does not 
change with the threshold. A non-shoulder-like curve shows that sensitivity and specificity 
are not correlated. 
Threshold: A value above or below which a test result is considered positive. 
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3.5 Subgroup analyses  
 A3.5.1 Subgroup analysis:  Forest plot estimates of the pooled sensitivity for RT-PCR assay 
(Cobas TaqMan) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitiv ity
0 0.2 0.4 0.6 0.8 1
Albuquerque 2014 0.98    (0.88 - 1.00)
Armand 2011 0.81    (0.69 - 0.91)
Bloemberg 2013 0.82    (0.73 - 0.90)
Causse 2011 0.78    (0.62 - 0.89)
Chandran 2010 1.00    (0.90 - 1.00)
Cho 2015 0.67    (0.60 - 0.74)
Choe 2011 0.75    (0.62 - 0.85)
Choi 2013 0.81    (0.68 - 0.90)
Feizabadi 2012 0.97    (0.92 - 0.99)
Huh 2015 0.67    (0.61 - 0.73)
Jonsson 2015 0.62    (0.57 - 0.67)
Lee 2013 0.83    (0.77 - 0.88)
Lim 2014 0.92    (0.84 - 0.97)
Linasmita 2012 0.79    (0.60 - 0.92)
Malhotra 2012 0.94    (0.89 - 0.98)
Park 2013 0.71    (0.51 - 0.87)
Yang 2011 0.91    (0.86 - 0.96)
Sensitiv ity (95% CI)
Pooled Sensitivi ty = 0.78 (0.76 to 0.80)
Chi-square = 205.13; df =  16 (p = 0.0000)
Inconsistency (I-square) = 92.2 %
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A3.5.2 Subgroup analysis:  Forest plot estimates of the pooled specificity for RT-PCR assay 
(Cobas TaqMan) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specificity
0 0.2 0.4 0.6 0.8 1
Albuquerque 2014 0.95    (0.89 - 0.98)
Armand 2011 1.00    (0.94 - 1.00)
Bloemberg 2013 0.98    (0.97 - 0.99)
Causse 2011 0.98    (0.96 - 0.99)
Chandran 2010 0.97    (0.86 - 1.00)
Cho 2015 0.98    (0.98 - 0.99)
Choe 2011 0.98    (0.92 - 1.00)
Choi 2013 1.00    (0.99 - 1.00)
Feizabadi 2012 0.92    (0.87 - 0.96)
Huh 2015 1.00    (0.99 - 1.00)
Jonsson 2015 0.99    (0.99 - 1.00)
Lee 2013 0.96    (0.94 - 0.98)
Lim 2014 0.98    (0.97 - 0.99)
Linasmita 2012 0.91    (0.78 - 0.97)
Malhotra 2012 1.00    (0.93 - 1.00)
Park 2013 0.98    (0.96 - 0.99)
Yang 2011 0.99    (0.98 - 0.99)
Specificity (95% CI)
Pooled Specificity = 0.99 (0.99 to 0.99)
Chi-square = 127.21; df =  16 (p = 0.0000)
Inconsistency (I-square) = 87.4 %
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A3.5.3 Subgroup analysis:  RT-PCR assay type: Cobas TaqMan Forest plot estimates of 
pooled PLR 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positiv e LR
0.01 100.01
Albuquerque 2014 20.12    (8.55 - 47.37)
Armand 2011 103.56    (6.53 - 1,642.77)
Bloemberg 2013 36.48    (24.09 - 55.24)
Causse 2011 46.67    (19.28 - 113.00)
Chandran 2010 24.98    (5.20 - 119.94)
Cho 2015 44.18    (32.32 - 60.40)
Choe 2011 49.24    (7.00 - 346.22)
Choi 2013 1,006.97    (62.87 - 16,128.83)
Feizabadi 2012 12.63    (7.15 - 22.30)
Huh 2015 135.98    (95.28 - 194.07)
Jonsson 2015 89.60    (58.09 - 138.18)
Lee 2013 23.31    (13.62 - 39.89)
Lim 2014 47.29    (30.83 - 72.55)
Linasmita 2012 8.72    (3.36 - 22.62)
Malhotra 2012 97.73    (6.19 - 1,542.24)
Park 2013 34.76    (15.22 - 79.39)
Yang 2011 72.58    (41.27 - 127.64)
Positiv e LR (95% CI)
Random Effects Model
Pooled Positive LR = 41.59 (27.81 to 62.18)
Cochran-Q = 98.14; df =  16 (p = 0.0000)
Inconsistency (I-square) = 83.7 %
Tau-squared = 0.4770
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A3.5.4 Subgroup analysis:   RT-PCR assay type: Cobas TaqMan Forest plot estimates of 
pooled NLR 
 
 
 
 
 
 
 
 
 
 
 
Negative LR
0.01 100.01
Albuquerque 2014 0.02    (0.00 - 0.17)
Armand 2011 0.19    (0.11 - 0.33)
Bloemberg 2013 0.18    (0.12 - 0.28)
Causse 2011 0.22    (0.13 - 0.40)
Chandran 2010 0.01    (0.00 - 0.23)
Cho 2015 0.33    (0.27 - 0.41)
Choe 2011 0.26    (0.17 - 0.39)
Choi 2013 0.20    (0.12 - 0.33)
Feizabadi 2012 0.03    (0.01 - 0.10)
Huh 2015 0.33    (0.28 - 0.39)
Jonsson 2015 0.38    (0.33 - 0.43)
Lee 2013 0.18    (0.13 - 0.24)
Lim 2014 0.08    (0.04 - 0.17)
Linasmita 2012 0.23    (0.11 - 0.47)
Malhotra 2012 0.06    (0.03 - 0.12)
Park 2013 0.29    (0.16 - 0.52)
Yang 2011 0.09    (0.05 - 0.15)
Negative LR (95% CI)
Random Effects Model
Pooled Negative LR = 0.18 (0.13 to 0.23)
Cochran-Q = 134.36; df =  16 (p = 0.0000)
Inconsistency (I-square) = 88.1 %
Tau-squared = 0.2360
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A3.5.5 Subgroup analysis:  RT-PCR assay type: Cobas TaqMan Forest plot estimates of 
pooled DOR
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic Odds Ratio
0.01 100.01
Albuquerque 2014 823.20    (93.31 - 7,262.32)
Armand 2011 538.24    (30.74 - 9,424.84)
Bloemberg 2013 202.79    (102.75 - 400.21)
Causse 2011 209.07    (66.03 - 661.92)
Chandran 2010 1,727.67    (68.08 - 43,840.74)
Cho 2015 133.33    (86.96 - 204.43)
Choe 2011 190.94    (24.46 - 1,490.39)
Choi 2013 5,074.57    (294.40 - 87,470.29)
Feizabadi 2012 404.00    (109.81 - 1,486.31)
Huh 2015 408.98    (265.97 - 628.89)
Jonsson 2015 237.05    (147.17 - 381.82)
Lee 2013 130.77    (67.96 - 251.64)
Lim 2014 582.98    (240.67 - 1,412.19)
Linasmita 2012 38.33    (9.79 - 150.13)
Malhotra 2012 1,605.59    (91.01 - 28,325.62)
Park 2013 119.17    (37.68 - 376.91)
Yang 2011 842.08    (370.49 - 1,913.95)
Diagnostic OR (95% CI)
Random Effects Model
Pooled Diagnostic Odds Ratio = 273.14 (181.45 to 411.17)
Cochran-Q = 47.64; df =  16 (p = 0.0001)
Inconsistency (I-square) = 66.4 %
Tau-squared = 0.3668
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A3.5.6 Subgroup analysis:  RT-PCR assay type: Cobas TaqMan Forest plot estimates of 
pooled SROC  
 
 
 
 
 
 
 
 
Sensitivity SROC Curve
1-specificity
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Symmetric SROC
AUC = 0.9837
SE(AUC) = 0.0053
Q* = 0.9444
SE(Q*) = 0.0107
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A3.5.7 Subgroup analysis:   Forest plot estimates of the pooled sensitivity for RT-PCR assay 
type: Roche Light cycler 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity
0 0.2 0.4 0.6 0.8 1
Barletta 2014 0.94    (0.87 - 0.98)
Day al 2010 0.98    (0.88 - 1.00)
Gous 2012 0.64    (0.43 - 0.82)
Lee 2010a 0.53    (0.36 - 0.68)
Mangat 2016 0.95    (0.85 - 0.99)
Pinhata 2015 0.90    (0.80 - 0.96)
Wang 2013 0.50    (0.23 - 0.77)
Sensitivity (95% CI)
Pooled Sensitiv ity  = 0.85 (0.80 to 0.88)
Chi-square = 61.71; df  =  6 (p = 0.0000)
Inconsistency  (I-square) = 90.3 %
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A3.5.8 Subgroup analysis:  Forest plot estimates of the pooled specificity for RT-PCR assay 
type: Roche Light cycler 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specificity
0 0.2 0.4 0.6 0.8 1
Barletta 2014 0.97    (0.85 - 1.00)
Day al 2010 1.00    (0.03 - 1.00)
Gous 2012 0.86    (0.57 - 0.98)
Lee 2010a 1.00    (0.96 - 1.00)
Mangat 2016 1.00    (0.82 - 1.00)
Pinhata 2015 0.99    (0.97 - 0.99)
Wang 2013 1.00    (0.79 - 1.00)
Specificity (95% CI)
Pooled Specif ic ity  = 0.99 (0.97 to 0.99)
Chi-square = 10.09; df  =  6 (p = 0.1209)
Inconsistency  (I-square) = 40.5 %
174 
 
A3.5.9 Subgroup analysis:  RT-PCR assay type: Roche Light cycler Forest plot estimates of 
pooled PLR  
 
 
 
 
 
 
 
 
 
 
 
 
Positive LR
0.01 100.01
Barletta 2014 31.98    (4.63 - 220.67)
Day al 2010 3.87    (0.35 - 42.73)
Gous 2012 4.48    (1.20 - 16.71)
Lee 2010a 101.73    (6.31 - 1,639.80)
Mangat 2016 37.50    (2.43 - 579.48)
Pinhata 2015 65.53    (34.08 - 126.02)
Wang 2013 17.00    (1.06 - 273.27)
Positive LR (95% CI)
Random Ef f ects Model
Pooled Posit iv e LR = 21.65 (6.82 to 68.72)
Cochran-Q = 17.45; df  =  6 (p = 0.0078)
Inconsistency  (I-square) = 65.6 %
Tau-squared = 1.3792
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A3.5.10 Subgroup analysis:  RT-PCR assay type: Roche Light cycler Forest plot estimates of 
pooled NLR 
  
 
 
 
 
 
 
 
 
 
 
 
Negative LR
0.01 100.01
Barletta 2014 0.06    (0.03 - 0.14)
Day al 2010 0.04    (0.01 - 0.25)
Gous 2012 0.42    (0.24 - 0.74)
Lee 2010a 0.48    (0.35 - 0.66)
Mangat 2016 0.06    (0.02 - 0.18)
Pinhata 2015 0.10    (0.05 - 0.21)
Wang 2013 0.52    (0.31 - 0.86)
Negative LR (95% CI)
Random Ef f ects Model
Pooled Negativ e LR = 0.17 (0.08 to 0.38)
Cochran-Q = 63.77; df  =  6 (p = 0.0000)
Inconsistency  (I-square) = 90.6 %
Tau-squared = 0.9954
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A3.5.11 Subgroup analysis:  RT-PCR assay type: Roche Light cycler Forest plot estimates of 
pooled DOR 
  
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic Odds Ratio
0.01 100.01
Barletta 2014 521.40    (58.64 - 4,636.21)
Day al 2010 91.00    (2.51 - 3,297.88)
Gous 2012 10.67    (1.94 - 58.69)
Lee 2010a 212.79    (12.36 - 3,663.25)
Mangat 2016 585.00    (28.88 - 11,849.61)
Pinhata 2015 667.85    (229.43 - 1,944.08)
Wang 2013 33.00    (1.66 - 656.24)
Diagnostic OR (95% CI)
Random Ef f ects Model
Pooled Diagnostic Odds Ratio = 150.52 (31.97 to 708.78)
Cochran-Q = 20.35; df  =  6 (p = 0.0024)
Inconsistency  (I-square) = 70.5 %
Tau-squared = 2.8167
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A3.5.12 Subgroup analysis:   RT-PCR assay type: Roche Light cycler Forest plot estimates of 
pooled SROC  
 
 
 
 
 
 
 
 
 
 
 
Sensitivity SROC Curve
1-specificity
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Symmetric SROC
AUC = 0.9725
SE(AUC) = 0.0213
Q* = 0.9240
SE(Q*) = 0.0356
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A3.5.13 Subgroup analysis:   Forest plot estimates of the pooled sensitivity for RT-PCR 
assay type: Cepheid and others 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitiv ity
0 0.2 0.4 0.6 0.8 1
Antonenka 2013 0.74    (0.61 - 0.84)
Chaidi r 2012 0.94    (0.88 - 0.98)
Chang 2015 0.59    (0.54 - 0.64)
Chen 2012 0.92    (0.84 - 0.97)
Chi tnis 2010 0.65    (0.56 - 0.73)
El  Khechine 2009 1.00    (0.88 - 1.00)
Friedrich 2011 0.25    (0.09 - 0.49)
Hi llemann 2011 0.36    (0.26 - 0.46)
Hofmann-Thiel  2016 1.00    (0.99 - 1.00)
In 2014 0.84    (0.74 - 0.91)
Kheawon 2012 0.66    (0.52 - 0.77)
Kim 2011 0.71    (0.51 - 0.87)
Lee 2010 0.78    (0.58 - 0.91)
Lira 2013 0.80    (0.69 - 0.89)
Luo 2010 0.53    (0.29 - 0.76)
Mi ller 2011 0.92    (0.78 - 0.98)
Moure 2012 0.59    (0.46 - 0.71)
Rachow 2011 0.89    (0.79 - 0.95)
Rosso 2011 0.42    (0.32 - 0.52)
Sei th 2012 0.79    (0.65 - 0.90)
Sharma 2015 1.00    (0.99 - 1.00)
Tortoli  2012 0.77    (0.72 - 0.82)
Sensitiv ity (95% CI)
Pooled Sensitivi ty = 0.78 (0.77 to 0.80)
Chi -square = 729.43; df =  21 (p = 0.0000)
Inconsistency (I-square) = 97.1 %
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A3.5.14 Subgroup analysis:  Forest plot estimates of the pooled specificity for RT-PCR 
assay type: Cepheid and others 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specificity
0 0.2 0.4 0.6 0.8 1
Antonenka 2013 1.00    (0.93 - 1.00)
Chaidi r 2012 1.00    (0.96 - 1.00)
Chang 2015 0.98    (0.97 - 0.99)
Chen 2012 1.00    (0.96 - 1.00)
Chi tnis 2010 0.99    (0.93 - 1.00)
El  Khechine 2009 0.97    (0.92 - 0.99)
Friedrich 2011 1.00    (0.48 - 1.00)
Hi llemann 2011 0.98    (0.96 - 0.99)
Hofmann-Thiel  2016 1.00    (0.99 - 1.00)
In 2014 0.94    (0.90 - 0.97)
Kheawon 2012 0.91    (0.87 - 0.93)
Kim 2011 0.99    (0.98 - 1.00)
Lee 2010 0.93    (0.85 - 0.98)
Lira 2013 0.95    (0.89 - 0.98)
Luo 2010 1.00    (0.93 - 1.00)
Mi ller 2011 0.93    (0.85 - 0.98)
Moure 2012 1.00    (0.96 - 1.00)
Rachow 2011 0.99    (0.97 - 1.00)
Rosso 2011 0.94    (0.84 - 0.99)
Sei th 2012 0.92    (0.73 - 0.99)
Sharma 2015 1.00    (1.00 - 1.00)
Tortoli  2012 1.00    (1.00 - 1.00)
Specificity (95% CI)
Pooled Specificity = 0.99 (0.99 to 0.99)
Chi -square = 299.13; df =  21 (p = 0.0000)
Inconsistency (I-square) = 93.0 %
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A3.5.15 Subgroup analysis:  RT-PCR assay type: Cepheid and others Forest plot estimates 
of pooled PLR 
 
 
 
 
 
 
 
 
 
 
 
Positiv e LR
0.01 100.01
Antonenka 2013 76.42    (4.83 - 1,210.23)
Chaidi r 2012 192.87    (12.14 - 3,064.30)
Chang 2015 29.16    (21.86 - 38.89)
Chen 2012 188.61    (11.87 - 2,997.68)
Chi tnis 2010 46.91    (6.67 - 329.81)
El  Khechine 2009 30.04    (10.71 - 84.28)
Friedrich 2011 3.14    (0.20 - 49.12)
Hi llemann 2011 18.89    (9.38 - 38.02)
Hofmann-Thiel  2016 199.69    (57.99 - 687.64)
In 2014 14.45    (7.85 - 26.58)
Kheawon 2012 6.91    (4.80 - 9.95)
Kim 2011 85.00    (26.89 - 268.69)
Lee 2010 11.20    (4.70 - 26.71)
Lira 2013 15.90    (6.71 - 37.67)
Luo 2010 54.60    (3.35 - 888.75)
Mi ller 2011 13.78    (5.88 - 32.32)
Moure 2012 101.95    (6.38 - 1,629.48)
Rachow 2011 98.31    (24.68 - 391.66)
Rosso 2011 7.28    (2.37 - 22.36)
Sei th 2012 9.50    (2.50 - 36.09)
Sharma 2015 2,029.82    (127.05 - 32,429.96)
Tortoli  2012 1,123.81    (420.96 - 3,000.15)
Positiv e LR (95% CI)
Random Effects Model
Pooled Positive LR = 38.50 (19.65 to 75.42)
Cochran-Q = 234.62; df =  21 (p = 0.0000)
Inconsistency (I-square) = 91.0 %
Tau-squared = 1.9577
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A3.5.16 Subgroup analysis:   RT-PCR assay type: Cepheid and others Forest plot estimates 
of pooled NLR 
 
 
 
 
 
 
 
 
 
 
Negativ e LR
0.01 100.01
Antonenka 2013 0.27    (0.18 - 0.40)
Chaidi r 2012 0.06    (0.03 - 0.13)
Chang 2015 0.42    (0.37 - 0.47)
Chen 2012 0.08    (0.04 - 0.18)
Chi tnis 2010 0.35    (0.28 - 0.45)
El  Khechine 2009 0.02    (0.00 - 0.28)
Friedrich 2011 0.81    (0.57 - 1.14)
Hi llemann 2011 0.66    (0.57 - 0.76)
Hofmann-Thiel  2016 0.00    (0.00 - 0.02)
In 2014 0.17    (0.10 - 0.29)
Kheawon 2012 0.38    (0.27 - 0.54)
Kim 2011 0.29    (0.16 - 0.52)
Lee 2010 0.24    (0.12 - 0.48)
Lira 2013 0.21    (0.13 - 0.34)
Luo 2010 0.48    (0.30 - 0.76)
Mi ller 2011 0.09    (0.03 - 0.26)
Moure 2012 0.42    (0.31 - 0.56)
Rachow 2011 0.12    (0.06 - 0.22)
Rosso 2011 0.62    (0.51 - 0.74)
Sei th 2012 0.23    (0.13 - 0.40)
Sharma 2015 0.00    (0.00 - 0.02)
Tortoli  2012 0.23    (0.18 - 0.29)
Negativ e LR (95% CI)
Random Effects Model
Pooled Negative LR = 0.22 (0.15 to 0.33)
Cochran-Q = 594.30; df =  21 (p = 0.0000)
Inconsistency (I-square) = 96.5 %
Tau-squared = 0.6972
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A3.5.17 Subgroup analysis:   RT-PCR assay type: Cepheid and others Forest plot estimates 
of pooled DOR 
  
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic Odds Ratio
0.01 100.01
Antonenka 2013 285.46    (16.71 - 4,877.80)
Chaidi r 2012 3,011.92    (167.40 - 54,190.39)
Chang 2015 69.49    (49.39 - 97.79)
Chen 2012 2,223.46    (123.28 - 40,103.23)
Chi tnis 2010 132.74    (17.86 - 986.65)
El  Khechine 2009 1,685.57    (84.59 - 33,587.93)
Friedrich 2011 3.90    (0.18 - 82.76)
Hi llemann 2011 28.83    (13.24 - 62.78)
Hofmann-Thiel  2016 128,753.00    (6,161.36 - 2,690,530.12)
In 2014 85.05    (34.99 - 206.74)
Kheawon 2012 18.18    (9.66 - 34.22)
Kim 2011 295.00    (72.65 - 1,197.82)
Lee 2010 46.90    (12.99 - 169.37)
Lira 2013 76.65    (25.90 - 226.82)
Luo 2010 113.84    (6.14 - 2,111.28)
Mi ller 2011 158.67    (35.80 - 703.21)
Moure 2012 244.81    (14.53 - 4,123.48)
Rachow 2011 852.50    (176.49 - 4,117.84)
Rosso 2011 11.83    (3.45 - 40.53)
Sei th 2012 41.80    (8.39 - 208.37)
Sharma 2015 1,890,861.00    (37,461.46 - 95,440,890.62)
Tortoli  2012 4,945.30    (1,776.43 - 13,766.90)
Diagnostic OR (95% CI)
Random Effects Model
Pooled Diagnostic Odds Ratio = 221.44 (94.94 to 516.51)
Cochran-Q = 208.25; df =  21 (p = 0.0000)
Inconsistency (I-square) = 89.9 %
Tau-squared = 3.1054
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A3.5.18 Subgroup analysis:  RT-PCR assay type: Cepheid and others Forest plot estimates 
of pooled SROC  
 
 
 
 
 
 
 
 
 
          
Sensitivity SROC Curve
1-specificity
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Symmetric SROC
AUC = 0.9911
SE(AUC) = 0.0072
Q* = 0.9612
SE(Q*) = 0.0186
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B3.5.1 Subgroup analysis:   Forest plot estimates of the pooled sensitivity for RT-PCR assay 
target sequence: IS6110 gene 
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B3.5.2 Subgroup analysis:   Forest plot estimates of the pooled specificity for RT-PCR assay 
target sequence: IS6110 gene 
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B3.5.3 Subgroup analysis:  RT-PCR assay target sequence: IS6110 gene Forest plot 
estimates of pooled PLR  
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B3.5.4 Subgroup analysis:  RT-PCR assay target sequence: IS6110 gene Forest plot 
estimates of NLR  
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B3.5.5 Subgroup analysis:   RT-PCR assay target sequence: IS6110 gene Forest plot 
estimates of pooled DOR 
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B3.5.6 Subgroup analysis:   RT-PCR assay target sequence: IS6110 gene Forest plot 
estimates of pooled SROC  
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B3.5.7 Subgroup analysis:   Forest plot estimates of the pooled sensitivity for RT-PCR assay 
target sequence: 16S r RNA gene 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity
0 0.2 0.4 0.6 0.8 1
Bloemberg 2013 0.82    (0.73 - 0.90)
Causse 2011 0.78    (0.62 - 0.89)
Chitnis 2010 0.65    (0.56 - 0.73)
Day al 2010 0.98    (0.88 - 1.00)
Huh 2015 0.67    (0.61 - 0.73)
Jonsson 2015 0.62    (0.57 - 0.67)
Linasmita 2012 0.77    (0.58 - 0.90)
Sensitivity (95% CI)
Pooled Sensitiv ity  = 0.69 (0.66 to 0.71)
Chi-square = 45.85; df  =  6 (p = 0.0000)
Inconsistency  (I-square) = 86.9 %
191 
 
B3.5.8 Subgroup analysis:  Forest plot estimates of the pooled specificity for RT-PCR assay 
target sequence: 16S r RNA gene 
  
 
 
 
 
 
 
 
 
 
 
 
 
Specificity
0 0.2 0.4 0.6 0.8 1
Bloemberg 2013 0.98    (0.97 - 0.99)
Causse 2011 0.98    (0.96 - 0.99)
Chitnis 2010 0.99    (0.93 - 1.00)
Day al 2010 1.00    (0.03 - 1.00)
Huh 2015 1.00    (0.99 - 1.00)
Jonsson 2015 0.99    (0.99 - 1.00)
Linasmita 2012 1.00    (0.99 - 1.00)
Specificity (95% CI)
Pooled Specif ic ity  = 0.99 (0.99 to 0.99)
Chi-square = 32.10; df  =  6 (p = 0.0000)
Inconsistency  (I-square) = 81.3 %
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B3.5.9 Subgroup analysis:  RT-PCR assay target sequence: 16S rRNA gene Forest plot 
estimates of pooled PLR  
 
 
 
 
 
 
 
 
 
 
 
 
Positive LR
0.01 100.01
Bloemberg 2013 36.48    (24.09 - 55.24)
Causse 2011 46.67    (19.28 - 113.00)
Chitnis 2010 46.91    (6.67 - 329.81)
Day al 2010 3.87    (0.35 - 42.73)
Huh 2015 135.98    (95.28 - 194.07)
Jonsson 2015 89.60    (58.09 - 138.18)
Linasmita 2012 203.55    (75.04 - 552.12)
Positive LR (95% CI)
Random Ef f ects Model
Pooled Posit iv e LR = 67.64 (36.40 to 125.70)
Cochran-Q = 34.36; df  =  6 (p = 0.0000)
Inconsistency  (I-square) = 82.5 %
Tau-squared = 0.4641
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B3.5.10 Subgroup analysis:  RT-PCR assay target sequence: 16S rRNA gene Forest plot 
estimates of pooled NLR  
 
 
 
 
 
 
 
 
 
 
 
 
Negative LR
0.01 100.01
Bloemberg 2013 0.18    (0.12 - 0.28)
Causse 2011 0.22    (0.13 - 0.40)
Chitnis 2010 0.35    (0.28 - 0.45)
Day al 2010 0.04    (0.01 - 0.25)
Huh 2015 0.33    (0.28 - 0.39)
Jonsson 2015 0.38    (0.33 - 0.43)
Linasmita 2012 0.23    (0.12 - 0.45)
Negative LR (95% CI)
Random Ef f ects Model
Pooled Negativ e LR = 0.29 (0.24 to 0.36)
Cochran-Q = 19.87; df  =  6 (p = 0.0029)
Inconsistency  (I-square) = 69.8 %
Tau-squared = 0.0443
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B3.5.11 Subgroup analysis:   RT-PCR assay target sequence: 16S rRNA gene Forest plot 
estimates of pooled DOR  
 
  
 
 
 
 
 
 
 
 
 
 
 
Diagnostic Odds Ratio
0.01 100.01
Bloemberg 2013 202.79    (102.75 - 400.21)
Causse 2011 209.07    (66.03 - 661.92)
Chitnis 2010 132.74    (17.86 - 986.65)
Day al 2010 91.00    (2.51 - 3,297.88)
Huh 2015 408.98    (265.97 - 628.89)
Jonsson 2015 237.05    (147.17 - 381.82)
Linasmita 2012 869.07    (237.78 - 3,176.38)
Diagnostic OR (95% CI)
Random Ef f ects Model
Pooled Diagnostic Odds Ratio = 287.19 (193.85 to 425.46)
Cochran-Q = 9.12; df  =  6 (p = 0.1670)
Inconsistency  (I-square) = 34.2 %
Tau-squared = 0.0840
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B3.5.12 Subgroup analysis:  RT-PCR assay target sequence: 16S rRNA gene Forest plot 
estimates of pooled SROC  
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity SROC Curve
1-specificity
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Symmetric SROC
AUC = 0.9671
SE(AUC) = 0.0149
Q* = 0.9151
SE(Q*) = 0.0233
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B3.5.13 Subgroup analysis:   Forest plot estimates of the pooled sensitivity for RT-PCR 
target sequences: other genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitiv ity
0 0.2 0.4 0.6 0.8 1
Antonenka 2013 0.74    (0.61 - 0.84)
Choe 2011 0.75    (0.62 - 0.85)
Feizabadi 2012 0.97    (0.92 - 0.99)
Friedrich 2011 0.25    (0.09 - 0.49)
Gous 2012 0.64    (0.43 - 0.82)
Hillemann 2011 0.36    (0.26 - 0.46)
In 2014 0.84    (0.74 - 0.91)
Kim 2011 0.71    (0.51 - 0.87)
Lee 2010a 0.53    (0.36 - 0.68)
Lim 2014 0.92    (0.84 - 0.97)
Moure 2012 0.59    (0.46 - 0.71)
Pinhata 2015 0.90    (0.80 - 0.96)
Rachow 2011 0.89    (0.79 - 0.95)
Seith 2012 0.79    (0.65 - 0.90)
Sharma 2015 1.00    (0.99 - 1.00)
Tortoli  2012 0.77    (0.72 - 0.82)
Wang 2013 0.50    (0.23 - 0.77)
Sensitiv ity (95% CI)
Pooled Sensitivi ty = 0.82 (0.80 to 0.84)
Chi-square = 413.02; df =  16 (p = 0.0000)
Inconsistency (I-square) = 96.1 %
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B3.5.14 Subgroup analysis:   Forest plot estimates of the pooled specificity for RT-PCR 
target sequences: other genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Specificity
0 0.2 0.4 0.6 0.8 1
Antonenka 2013 1.00    (0.93 - 1.00)
Choe 2011 0.98    (0.92 - 1.00)
Feizabadi 2012 0.92    (0.87 - 0.96)
Friedrich 2011 1.00    (0.48 - 1.00)
Gous 2012 0.86    (0.57 - 0.98)
Hillemann 2011 0.98    (0.96 - 0.99)
In 2014 0.94    (0.90 - 0.97)
Kim 2011 0.99    (0.98 - 1.00)
Lee 2010a 1.00    (0.96 - 1.00)
Lim 2014 0.98    (0.97 - 0.99)
Moure 2012 1.00    (0.96 - 1.00)
Pinhata 2015 0.99    (0.97 - 0.99)
Rachow 2011 0.99    (0.97 - 1.00)
Seith 2012 0.92    (0.73 - 0.99)
Sharma 2015 1.00    (1.00 - 1.00)
Tortoli  2012 1.00    (1.00 - 1.00)
Wang 2013 1.00    (0.79 - 1.00)
Specificity (95% CI)
Pooled Specificity = 0.99 (0.99 to 0.99)
Chi-square = 173.35; df =  16 (p = 0.0000)
Inconsistency (I-square) = 90.8 %
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B3.5.15 Subgroup analysis:    RT-PCR target sequences: other genes Forest plot estimates 
of pooled PLR 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positiv e LR
0.01 100.01
Antonenka 2013 76.42    (4.83 - 1,210.23)
Choe 2011 49.24    (7.00 - 346.22)
Feizabadi 2012 12.63    (7.15 - 22.30)
Friedrich 2011 3.14    (0.20 - 49.12)
Gous 2012 4.48    (1.20 - 16.71)
Hillemann 2011 18.89    (9.38 - 38.02)
In 2014 14.45    (7.85 - 26.58)
Kim 2011 85.00    (26.89 - 268.69)
Lee 2010a 101.73    (6.31 - 1,639.80)
Lim 2014 47.29    (30.83 - 72.55)
Moure 2012 101.95    (6.38 - 1,629.48)
Pinhata 2015 65.53    (34.08 - 126.02)
Rachow 2011 98.31    (24.68 - 391.66)
Seith 2012 9.50    (2.50 - 36.09)
Sharma 2015 2,029.82    (127.05 - 32,429.96)
Tortoli  2012 1,123.81    (420.96 - 3,000.15)
Wang 2013 17.00    (1.06 - 273.27)
Positiv e LR (95% CI)
Random Effects Model
Pooled Positive LR = 42.48 (20.66 to 87.36)
Cochran-Q = 123.92; df =  16 (p = 0.0000)
Inconsistency (I-square) = 87.1 %
Tau-squared = 1.6339
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B3.5.16 Subgroup analysis:   RT-PCR target sequences: other genes Forest plot estimates of 
pooled NLR 
 
 
 
 
 
 
 
 
 
 
 
 
Negative LR
0.01 100.01
Antonenka 2013 0.27    (0.18 - 0.40)
Choe 2011 0.26    (0.17 - 0.39)
Feizabadi 2012 0.03    (0.01 - 0.10)
Friedrich 2011 0.81    (0.57 - 1.14)
Gous 2012 0.42    (0.24 - 0.74)
Hillemann 2011 0.66    (0.57 - 0.76)
In 2014 0.17    (0.10 - 0.29)
Kim 2011 0.29    (0.16 - 0.52)
Lee 2010a 0.48    (0.35 - 0.66)
Lim 2014 0.08    (0.04 - 0.17)
Moure 2012 0.42    (0.31 - 0.56)
Pinhata 2015 0.10    (0.05 - 0.21)
Rachow 2011 0.12    (0.06 - 0.22)
Seith 2012 0.23    (0.13 - 0.40)
Sharma 2015 0.00    (0.00 - 0.02)
Tortoli  2012 0.23    (0.18 - 0.29)
Wang 2013 0.52    (0.31 - 0.86)
Negative LR (95% CI)
Random Effects Model
Pooled Negative LR = 0.22 (0.13 to 0.37)
Cochran-Q = 498.03; df =  16 (p = 0.0000)
Inconsistency (I-square) = 96.8 %
Tau-squared = 1.1673
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B3.5.17 Subgroup analysis:   RT-PCR target sequences: other genes Forest plot estimates of 
pooled DOR 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic Odds Ratio
0.01 100.01
Antonenka 2013 285.46    (16.71 - 4,877.80)
Choe 2011 190.94    (24.46 - 1,490.39)
Feizabadi 2012 404.00    (109.81 - 1,486.31)
Friedrich 2011 3.90    (0.18 - 82.76)
Gous 2012 10.67    (1.94 - 58.69)
Hillemann 2011 28.83    (13.24 - 62.78)
In 2014 85.05    (34.99 - 206.74)
Kim 2011 295.00    (72.65 - 1,197.82)
Lee 2010a 212.79    (12.36 - 3,663.25)
Lim 2014 582.98    (240.67 - 1,412.19)
Moure 2012 244.81    (14.53 - 4,123.48)
Pinhata 2015 667.85    (229.43 - 1,944.08)
Rachow 2011 852.50    (176.49 - 4,117.84)
Seith 2012 41.80    (8.39 - 208.37)
Sharma 2015 1,890,861.00    (37,461.46 - 95,440,890.62)
Tortoli  2012 4,945.30    (1,776.43 - 13,766.90)
Wang 2013 33.00    (1.66 - 656.24)
Diagnostic OR (95% CI)
Random Effects Model
Pooled Diagnostic Odds Ratio = 234.56 (86.01 to 639.63)
Cochran-Q = 125.08; df =  16 (p = 0.0000)
Inconsistency (I-square) = 87.2 %
Tau-squared = 3.4670
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B3.5.18 Subgroup analysis:   RT-PCR target sequences: other genes Forest plot estimates of 
pooled SROC  
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity SROC Curve
1-specificity
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Symmetric SROC
AUC = 0.9827
SE(AUC) = 0.0145
Q* = 0.9424
SE(Q*) = 0.0287
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C3.5.1 Subgroup analysis:   Forest plot estimates of the pooled sensitivity for Reference 
test (Both solid and liquid media) 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity
0 0.2 0.4 0.6 0.8 1
Antonenka 2013 0.74    (0.61 - 0.84)
Armand 2011 0.81    (0.69 - 0.91)
Bloemberg 2013 0.82    (0.73 - 0.90)
Chadran 2010 1.00    (0.90 - 1.00)
Chaidir 2012 1.00    (0.90 - 1.00)
Chang 2015 0.59    (0.54 - 0.64)
Chitnis 2010 0.65    (0.56 - 0.73)
Cho 2015 0.67    (0.60 - 0.74)
El Khechine 2009 1.00    (0.88 - 1.00)
Gous 2012 0.64    (0.43 - 0.82)
Hillemann 2011 0.36    (0.26 - 0.46)
Hof mann-Thiel 2016 1.00    (0.98 - 1.00)
Huh 2015 0.67    (0.61 - 0.73)
In 2014 0.84    (0.74 - 0.91)
Jonsson 2015 0.62    (0.57 - 0.67)
Lee 2013 0.83    (0.77 - 0.88)
Mangat 2016 0.95    (0.85 - 0.99)
Moure 2012 0.59    (0.46 - 0.71)
Park 2013 0.71    (0.51 - 0.87)
Pinhata 2015 0.90    (0.80 - 0.96)
Rachow 2011 0.89    (0.79 - 0.95)
Sethi 2012 0.73    (0.56 - 0.86)
Sharma 2015 1.00    (0.99 - 1.00)
Tortoli 2012 0.81    (0.75 - 0.86)
Yang 2011 0.91    (0.86 - 0.96)
Sensitivity (95% CI)
Pooled Sensitiv ity  = 0.77 (0.76 to 0.79)
Chi-square = 706.57; df  =  24 (p = 0.0000)
Inconsistency  (I-square) = 96.6 %
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C3.5.7 Subgroup analysis:   Forest plot estimates of the pooled specificity for Reference 
test (Both solid and liquid media) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specificity
0 0.2 0.4 0.6 0.8 1
Antonenka 2013 1.00    (0.93 - 1.00)
Armand 2011 1.00    (0.94 - 1.00)
Bloemberg 2013 0.98    (0.97 - 0.99)
Chadran 2010 0.97    (0.86 - 1.00)
Chaidir 2012 0.97    (0.86 - 1.00)
Chang 2015 0.98    (0.97 - 0.99)
Chitnis 2010 0.99    (0.93 - 1.00)
Cho 2015 0.98    (0.98 - 0.99)
El Khechine 2009 0.97    (0.92 - 0.99)
Gous 2012 0.86    (0.57 - 0.98)
Hillemann 2011 0.98    (0.96 - 0.99)
Hof mann-Thiel 2016 1.00    (0.99 - 1.00)
Huh 2015 1.00    (0.99 - 1.00)
In 2014 0.94    (0.90 - 0.97)
Jonsson 2015 0.99    (0.99 - 1.00)
Lee 2013 0.96    (0.94 - 0.98)
Mangat 2016 1.00    (0.82 - 1.00)
Moure 2012 1.00    (0.96 - 1.00)
Park 2013 0.83    (0.78 - 0.86)
Pinhata 2015 0.99    (0.97 - 0.99)
Rachow 2011 0.99    (0.97 - 1.00)
Sethi 2012 0.85    (0.55 - 0.98)
Sharma 2015 1.00    (1.00 - 1.00)
Tortoli 2012 1.00    (1.00 - 1.00)
Yang 2011 0.99    (0.98 - 0.99)
Specificity (95% CI)
Pooled Specif icity  = 0.99 (0.99 to 0.99)
Chi-square = 444.37; df  =  24 (p = 0.0000)
Inconsistency  (I-square) = 94.6 %
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C3.5.3 Subgroup analysis:   Reference test: culture based (solid and liquid media) Forest 
plot estimates of pooled PLR 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Positive LR
0.01 100.01
Antonenka 2013 76.42    (4.83 - 1,210.23)
Armand 2011 103.56    (6.53 - 1,642.77)
Bloemberg 2013 36.48    (24.09 - 55.24)
Chadran 2010 24.98    (5.20 - 119.94)
Chaidir 2012 24.98    (5.20 - 119.94)
Chang 2015 29.16    (21.86 - 38.89)
Chitnis 2010 46.91    (6.67 - 329.81)
Cho 2015 44.18    (32.32 - 60.40)
El Khechine 2009 30.04    (10.71 - 84.28)
Gous 2012 4.48    (1.20 - 16.71)
Hillemann 2011 18.89    (9.38 - 38.02)
Hof mann-Thiel 2016 192.79    (55.99 - 663.80)
Huh 2015 135.98    (95.28 - 194.07)
In 2014 14.45    (7.85 - 26.58)
Jonsson 2015 89.60    (58.09 - 138.18)
Lee 2013 23.31    (13.62 - 39.89)
Mangat 2016 37.50    (2.43 - 579.48)
Moure 2012 101.95    (6.38 - 1,629.48)
Park 2013 4.12    (2.97 - 5.72)
Pinhata 2015 65.53    (34.08 - 126.02)
Rachow 2011 98.31    (24.68 - 391.66)
Sethi 2012 4.74    (1.31 - 17.23)
Sharma 2015 2,029.82    (127.05 - 32,429.96)
Tortoli 2012 1,679.26    (419.42 - 6,723.36)
Yang 2011 72.58    (41.27 - 127.64)
Positive LR (95% CI)
Random Ef f ects Model
Pooled Positiv e LR = 43.42 (25.32 to 74.45)
Cochran-Q = 375.64; df  =  24 (p = 0.0000)
Inconsistency  (I-square) = 93.6 %
Tau-squared = 1.4618
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C3.5.4 Subgroup analysis:  Reference test: culture based (solid and liquid media) Forest 
plot estimates of pooled NLR 
 
 
 
 
 
 
 
 
 
 
 
 
Negative LR
0.01 100.01
Antonenka 2013 0.27    (0.18 - 0.40)
Armand 2011 0.19    (0.11 - 0.33)
Bloemberg 2013 0.18    (0.12 - 0.28)
Chadran 2010 0.01    (0.00 - 0.23)
Chaidir 2012 0.01    (0.00 - 0.23)
Chang 2015 0.42    (0.37 - 0.47)
Chitnis 2010 0.35    (0.28 - 0.45)
Cho 2015 0.33    (0.27 - 0.41)
El Khechine 2009 0.02    (0.00 - 0.28)
Gous 2012 0.42    (0.24 - 0.74)
Hillemann 2011 0.66    (0.57 - 0.76)
Hof mann-Thiel 2016 0.00    (0.00 - 0.03)
Huh 2015 0.33    (0.28 - 0.39)
In 2014 0.17    (0.10 - 0.29)
Jonsson 2015 0.38    (0.33 - 0.43)
Lee 2013 0.18    (0.13 - 0.24)
Mangat 2016 0.06    (0.02 - 0.18)
Moure 2012 0.42    (0.31 - 0.56)
Park 2013 0.35    (0.19 - 0.62)
Pinhata 2015 0.10    (0.05 - 0.21)
Rachow 2011 0.12    (0.06 - 0.22)
Sethi 2012 0.32    (0.18 - 0.57)
Sharma 2015 0.00    (0.00 - 0.02)
Tortoli 2012 0.19    (0.14 - 0.25)
Yang 2011 0.09    (0.05 - 0.15)
Negative LR (95% CI)
Random Ef f ects Model
Pooled Negative LR = 0.21 (0.16 to 0.28)
Cochran-Q = 432.87; df  =  24 (p = 0.0000)
Inconsistency  (I-square) = 94.5 %
Tau-squared = 0.3685
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C3.5.5 Subgroup analysis:   Reference test: culture based (solid and liquid media) Forest 
plot estimates of DOR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic Odds Ratio
0.01 100.01
Antonenka 2013 285.46    (16.71 - 4,877.80)
Armand 2011 538.24    (30.74 - 9,424.84)
Bloemberg 2013 202.79    (102.75 - 400.21)
Chadran 2010 1,727.67    (68.08 - 43,840.74)
Chaidir 2012 1,727.67    (68.08 - 43,840.74)
Chang 2015 69.49    (49.39 - 97.79)
Chitnis 2010 132.74    (17.86 - 986.65)
Cho 2015 133.33    (86.96 - 204.43)
El Khechine 2009 1,685.57    (84.59 - 33,587.93)
Gous 2012 10.67    (1.94 - 58.69)
Hillemann 2011 28.83    (13.24 - 62.78)
Hof mann-Thiel 2016 89,757.40    (4,291.84 - 1,877,142.38)
Huh 2015 408.98    (265.97 - 628.89)
In 2014 85.05    (34.99 - 206.74)
Jonsson 2015 237.05    (147.17 - 381.82)
Lee 2013 130.77    (67.96 - 251.64)
Mangat 2016 585.00    (28.88 - 11,849.61)
Moure 2012 244.81    (14.53 - 4,123.48)
Park 2013 11.92    (5.01 - 28.33)
Pinhata 2015 667.85    (229.43 - 1,944.08)
Rachow 2011 852.50    (176.49 - 4,117.84)
Sethi 2012 14.85    (2.79 - 79.06)
Sharma 2015 1,890,861.00    (37,461.46 - 95,440,890.62)
Tortoli 2012 8,845.86    (2,113.27 - 37,027.63)
Yang 2011 842.08    (370.49 - 1,913.95)
Diagnostic OR (95% CI)
Random Ef f ects Model
Pooled Diagnostic Odds Ratio = 263.85 (145.31 to 479.09)
Cochran-Q = 226.19; df  =  24 (p = 0.0000)
Inconsistency  (I-square) = 89.4 %
Tau-squared = 1.5853
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C3.5.6 Subgroup analysis:   Reference test: culture based (solid and liquid media) Forest 
plot estimates of pooled SROC 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity SROC Curve
1-specificity
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Symmetric SROC
AUC = 0.9894
SE(AUC) = 0.0064
Q* = 0.9570
SE(Q*) = 0.0153
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C3.5.7 Subgroup analysis:  Forest plot estimates of the pooled sensitivity for Reference 
test (solid media) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitiv ity
0 0.2 0.4 0.6 0.8 1
Albuquerque 2014 0.98    (0.88 - 1.00)
Barletta 2014 0.94    (0.87 - 0.98)
Causse 2011 0.78    (0.62 - 0.89)
Choe 2011 0.75    (0.62 - 0.85)
Feizabadi 2012 0.97    (0.92 - 0.99)
Kheawon 2012 0.66    (0.52 - 0.77)
Kim 2011 0.71    (0.51 - 0.87)
Lee 2010 0.78    (0.58 - 0.91)
Lee 2010a 0.53    (0.36 - 0.68)
Lira 2013 0.80    (0.69 - 0.89)
Malhotra 2016 0.94    (0.89 - 0.98)
Mi ller 2011 0.92    (0.78 - 0.98)
Rosso 2011 0.42    (0.32 - 0.52)
Sensitiv ity (95% CI)
Pooled Sensi tivity = 0.80 (0.77 to 0.82)
Chi -square = 174.61; df =  12 (p = 0.0000)
Inconsistency (I-square) = 93.1 %
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C3.5.8 Subgroup analysis:   Forest plot estimates of the pooled specificity for Reference 
test (solid media) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specificity
0 0.2 0.4 0.6 0.8 1
Albuquerque 2014 0.95    (0.89 - 0.98)
Barletta 2014 0.97    (0.85 - 1.00)
Causse 2011 0.98    (0.96 - 0.99)
Choe 2011 0.98    (0.92 - 1.00)
Feizabadi 2012 0.92    (0.87 - 0.96)
Kheawon 2012 0.91    (0.87 - 0.93)
Kim 2011 0.99    (0.98 - 1.00)
Lee 2010 0.93    (0.85 - 0.98)
Lee 2010a 1.00    (0.96 - 1.00)
Lira 2013 0.95    (0.89 - 0.98)
Malhotra 2016 1.00    (0.99 - 1.00)
Mi ller 2011 0.93    (0.85 - 0.98)
Rosso 2011 0.94    (0.84 - 0.99)
Specificity (95% CI)
Pooled Specifici ty = 0.96 (0.96 to 0.97)
Chi -square = 89.81; df =  12 (p = 0.0000)
Inconsistency (I-square) = 86.6 %
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C3.5.9 Subgroup analysis:  Reference test: culture based (solid media) Forest plot 
estimates of pooled PLR  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positiv e LR
0.01 100.01
Albuquerque 2014 20.12    (8.55 - 47.37)
Barletta 2014 31.98    (4.63 - 220.67)
Causse 2011 46.67    (19.28 - 113.00)
Choe 2011 49.24    (7.00 - 346.22)
Feizabadi 2012 12.63    (7.15 - 22.30)
Kheawon 2012 6.91    (4.80 - 9.95)
Kim 2011 85.00    (26.89 - 268.69)
Lee 2010 11.20    (4.70 - 26.71)
Lee 2010a 101.73    (6.31 - 1,639.80)
Lira 2013 15.90    (6.71 - 37.67)
Malhotra 2016 781.84    (48.97 - 12,482.97)
Mi ller 2011 13.78    (5.88 - 32.32)
Rosso 2011 7.28    (2.37 - 22.36)
Positiv e LR (95% CI)
Random Effects Model
Pooled Positive LR = 21.73 (11.99 to 39.38)
Cochran-Q = 60.94; df =  12 (p = 0.0000)
Inconsistency (I-square) = 80.3 %
Tau-squared = 0.8082
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C3.5.10 Subgroup analysis:  Reference test: culture based (solid media) Forest plot 
estimates of pooled NLR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Negativ e LR
0.01 100.01
Albuquerque 2014 0.02    (0.00 - 0.17)
Barletta 2014 0.06    (0.03 - 0.14)
Causse 2011 0.22    (0.13 - 0.40)
Choe 2011 0.26    (0.17 - 0.39)
Feizabadi 2012 0.03    (0.01 - 0.10)
Kheawon 2012 0.38    (0.27 - 0.54)
Kim 2011 0.29    (0.16 - 0.52)
Lee 2010 0.24    (0.12 - 0.48)
Lee 2010a 0.48    (0.35 - 0.66)
Lira 2013 0.21    (0.13 - 0.34)
Malhotra 2016 0.06    (0.03 - 0.12)
Mi ller 2011 0.09    (0.03 - 0.26)
Rosso 2011 0.62    (0.51 - 0.74)
Negativ e LR (95% CI)
Random Effects Model
Pooled Negative LR = 0.17 (0.10 to 0.31)
Cochran-Q = 229.57; df =  12 (p = 0.0000)
Inconsistency (I-square) = 94.8 %
Tau-squared = 1.0197
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C3.5.11 Subgroup analysis:   Reference test: culture based (solid media) Forest plot 
estimates of pooled DOR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic Odds Ratio
0.01 100.01
Albuquerque 2014 823.20    (93.31 - 7,262.32)
Barletta 2014 521.40    (58.64 - 4,636.21)
Causse 2011 209.07    (66.03 - 661.92)
Choe 2011 190.94    (24.46 - 1,490.39)
Feizabadi 2012 404.00    (109.81 - 1,486.31)
Kheawon 2012 18.18    (9.66 - 34.22)
Kim 2011 295.00    (72.65 - 1,197.82)
Lee 2010 46.90    (12.99 - 169.37)
Lee 2010a 212.79    (12.36 - 3,663.25)
Lira 2013 76.65    (25.90 - 226.82)
Malhotra 2016 12,953.82    (742.69 - 225,938.24)
Mi ller 2011 158.67    (35.80 - 703.21)
Rosso 2011 11.83    (3.45 - 40.53)
Diagnostic OR (95% CI)
Random Effects Model
Pooled Diagnostic Odds Ratio = 156.43 (62.61 to 390.83)
Cochran-Q = 65.90; df =  12 (p = 0.0000)
Inconsistency (I-square) = 81.8 %
Tau-squared = 2.1170
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C3.5.12 Subgroup analysis:   Reference test: culture based (solid media) Forest plot 
estimates of pooled SROC  
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity SROC Curve
1-specificity
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Symmetric SROC
AUC = 0.9748
SE(AUC) = 0.0135
Q* = 0.9278
SE(Q*) = 0.0233
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C3.5.13 Subgroup analysis:  Forest plot estimates of the pooled sensitivity for Reference 
test (Liquid media) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity
0 0.2 0.4 0.6 0.8 1
Chen 2012 0.92    (0.84 - 0.97)
Choi 2013 0.81    (0.68 - 0.90)
Day al 2010 0.98    (0.88 - 1.00)
Friedrich 2011 0.25    (0.09 - 0.49)
Linasmita 2012 0.79    (0.60 - 0.92)
Wang 2013 0.50    (0.23 - 0.77)
Sensitivity (95% CI)
Pooled Sensitiv ity  = 0.81 (0.75 to 0.86)
Chi-square = 56.38; df  =  5 (p = 0.0000)
Inconsistency  (I-square) = 91.1 %
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C3.5.14 Subgroup analysis:   Forest plot estimates of the pooled specificity for Reference 
test (Liquid media) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specificity
0 0.2 0.4 0.6 0.8 1
Chen 2012 1.00    (0.96 - 1.00)
Choi 2013 1.00    (0.99 - 1.00)
Day al 2010 1.00    (0.03 - 1.00)
Friedrich 2011 1.00    (0.48 - 1.00)
Linasmita 2012 0.91    (0.78 - 0.97)
Wang 2013 1.00    (0.79 - 1.00)
Specificity (95% CI)
Pooled Specif ic ity  = 0.99 (0.99 to 1.00)
Chi-square = 23.51; df  =  5 (p = 0.0003)
Inconsistency  (I-square) = 78.7 %
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C3.5.15 Subgroup analysis:   Reference test: culture based (Liquid media) Forest plot 
estimates of pooled PLR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Positive LR
0.01 100.01
Chen 2012 188.61    (11.87 - 2,997.68)
Choi 2013 1,006.97    (62.87 - 16,128.83)
Day al 2010 3.87    (0.35 - 42.73)
Friedrich 2011 3.14    (0.20 - 49.12)
Linasmita 2012 8.72    (3.36 - 22.62)
Wang 2013 17.00    (1.06 - 273.27)
Positive LR (95% CI)
Random Ef f ects Model
Pooled Posit iv e LR = 24.00 (3.60 to 159.74)
Cochran-Q = 21.75; df  =  5 (p = 0.0006)
Inconsistency  (I-square) = 77.0 %
Tau-squared = 4.0831
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C3.5.16 Subgroup analysis:   Reference test: culture based (Liquid media) Forest plot 
estimates of pooled NLR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Negative LR
0.01 100.01
Chen 2012 0.08    (0.04 - 0.18)
Choi 2013 0.20    (0.12 - 0.33)
Day al 2010 0.04    (0.01 - 0.25)
Friedrich 2011 0.81    (0.57 - 1.14)
Linasmita 2012 0.23    (0.11 - 0.47)
Wang 2013 0.52    (0.31 - 0.86)
Negative LR (95% CI)
Random Ef f ects Model
Pooled Negativ e LR = 0.22 (0.08 to 0.61)
Cochran-Q = 81.21; df  =  5 (p = 0.0000)
Inconsistency  (I-square) = 93.8 %
Tau-squared = 1.3569
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C3.5.17 Subgroup analysis:   Reference test: culture based (Liquid media) Forest plot 
estimates of pooled DOR 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostic Odds Ratio
0.01 100.01
Chen 2012 2,223.46    (123.28 - 40,103.23)
Choi 2013 5,074.57    (294.40 - 87,470.29)
Day al 2010 91.00    (2.51 - 3,297.88)
Friedrich 2011 3.90    (0.18 - 82.76)
Linasmita 2012 38.33    (9.79 - 150.13)
Wang 2013 33.00    (1.66 - 656.24)
Diagnostic OR (95% CI)
Random Ef f ects Model
Pooled Diagnostic Odds Ratio = 127.86 (15.64 to 1045.40)
Cochran-Q = 19.08; df  =  5 (p = 0.0019)
Inconsistency  (I-square) = 73.8 %
Tau-squared = 4.8650
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C3.5.18 Subgroup analysis:  Reference test: culture based (Liquid media) Forest plot 
estimates of pooled SROC 
  
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity SROC Curve
1-specificity
0 0.2 0.4 0.6 0.8 1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Symmetric SROC
AUC = 0.9430
SE(AUC) = 0.0656
Q* = 0.8813
SE(Q*) = 0.0844
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3.6 Characteristics of included studies 
 
3.6.1 Albuquerque 2014  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection to assess the accuracy of a 
diagnostic test, conducted between August 2009 and January 2012. 
Patient 
characteristics and 
setting  
A total of 140 sputum samples from patients were included in the 
study who were aged 18 and over, HIV-infected and with a clinical 
suspicion of PTB, and who were attending two referral hospitals for 
HIV/AIDS in the city of Recife, Pernambuco, Brazil.  
Index tests  RT-PCR assay 
Ct (threshold cycle) was equal to or less than 37 
Target condition and 
reference standard(s)  
Target condition: Pulmonary TB 
 
Reference standard: Löwenstein-Jensen culture and 7H9 broth 
Flow and timing  Uninterpretable results reported: yes 
Notes  All patients' samples were accounted for.  
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
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Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
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Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  All patients' samples were accounted for.  
 
3.6.2 Antonenka 2013 
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection 
Patient 
characteristics and 
setting  
120 respiratory samples from patients, some frozen in sediment 
were used.  
Index tests  RT-PCR assay  (COBAS TaqMan MTB) 
Target condition and 
reference standard(s)  
Target condition: TB  
 
Reference standard: Löwenstein-Jensen culture and MGIT 960 
Flow and timing  All patients were included in the analysis and accounted for  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
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Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do 
not match the review question?  
Low concern  
Index tests RT-PCR assay (Cobas TaqMan) 
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Target condition and reference 
standard(s) 
TB and Culture-based assay. (Both solid and 
liquid) 
 
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced Low 
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bias?  risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Flow and timing All patients were included in the analysis and accounted for  
 
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.3 Armand 2011  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
117 clinical samples from respiratory (sputum, bronchial aspirate) 
and non-respiratory (lymph node tissue,  pleural fluid, bone tissue, 
abscess and  urine) sites of patients were used  
Index tests  RT-PCR ASSAY  
Target condition and 
reference standard(s)  
Target condition: TB 
 
Reference standard: Lowenstein-Jensen slant and BacT/Alert MP 
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culture bottle  
Flow and timing  All samples were accounted for including the invalid/uninterpreted.  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
Index tests RT-PCR ASSAY (TaqMan) 
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ Low 
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from the review question?  concern  
 
Reference Standard  
A. Risk of Bias  
Target condition and reference standard(s):   TB & CULTURE-BASED assay (Both solid and 
liquid medium) 
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Flow and timing   All samples were accounted for including the invalid/uninterpreted. 
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
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 3.6.4 Barletta 2014  
Patient Sampling  Diagnostic-case control  
Patient 
characteristics and 
setting  
Sputum samples from 112 patients  
Index tests  RT-PCR assay  
Target condition and 
reference standard(s)  
Target condition: TB  
Reference standard: Lowenstein-Jensen slant  
Flow and timing  Uninterpretable results reported: yes  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  No  
Did the study avoid inappropriate exclusions?  Unclear 
Could the selection of patients have introduced bias?  High risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Unclear 
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If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
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Notes  
 
3.6.5 Bloemberg 2013  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
1109 samples from both pulmonary (sputum, tracheal brochial 
aspirate, bronchial alveolar lavage [BAL]) and extra-pulmonary 
(biopsy, pleural aspirate, ascites, CSF, ear swab, catheter drainage, 
deep wound swab, gastric fluid, urine) sites included  
Index tests  RT-PCR assay 
Target condition and 
reference standard(s)  
Target condition: TB  
 
Reference standard: 7H11   and MGIT 960 
Flow and timing  Adults and children were included in the sampling. All samples were 
accounted for  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
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Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
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Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.6 Causse 2011  
Patient Sampling  Cross-sectional design with convenience-based consecutive 
enrolment of participants, retrospective data collection (Clinical 
evaluation study carried out in Spain).  
Patient 
characteristics and 
setting  
340 extra-pulmonary samples (tissues, aspirate, urine, biopsy, CSF, 
gastric aspirates, lymph node, purulent exudate and pleural fluid ) 
from patients 
Index tests  RT-PCR assay (Cobas TaqMan MTB) 
Target condition and 
reference standard(s)  
Target condition: TB  
 
Reference standard: Lowenstein-Jensen media  and Middlebrook 
7H9 broth 
Flow and timing  All samples were accounted for in the analysis.  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
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Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
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B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.7 Chadran 2010  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection (Evaluation study) 
Patient 
characteristics and 
setting  
72 sputum samples of patients from pulmonary site were included  
 
Index tests  RT-PCR assay (Cobas TaqMan MTB)  
Target condition and 
reference standard(s)  
Target condition: TB  (PTB) 
 
Reference standard: Lowenstein-Jensen media  and MGIT 960 
Flow and timing  All samples were accounted for.  
Notes  
 
Patient Selection  
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A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standardlikely to correctly classify the target condition?  Yes  
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Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.8 Chaidir 2012  
Patient Sampling  Cross-sectional design with convenience-based consecutive 
enrolment of participants, retrospective data collection (Clinical 
evaluation study) 
Patient 
characteristics and 
setting  
230  CSF samples from consecutive patients presenting with clinical 
meningitis between 2006 and 2008 were included for this study   
Index tests  RT-PCR assay  
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Target condition and 
reference standard(s)  
Target condition: TB  (EPTB) 
Reference standard: Ogawa for solid culture, and MB/BacT system 
for liquid culture  
Flow and timing  All samples were CSF and accounted for in the analysis  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
237 
 
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.9 Chang 2015  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
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participants, retrospective data collection 
Patient 
characteristics and 
setting  
2859 samples from pulmonary sites (sputum and bronchoscopic 
aspirates) were taken from patients suspected of TB.  
Index tests  RT-PCR assay (AdvanSure TB/NTM) 
Target condition and 
reference standard(s)  
Target condition: TB  
Reference standard: Ogawa medium  and MGIT 960 
Flow and timing  All samples were accounted for  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
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Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
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3.6.10 Chen 2012  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection (Evaluation study) 
Patient 
characteristics and 
setting  
178 sputum samples from 164 patients with suspected PTB  
Index tests  RT-PCR assay  (‘Care TB’) 
Target condition and 
reference standard(s)  
Target condition: TB 
 
Reference standard: MGIT 960 
Flow and timing  All sputum samples were accounted for  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
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Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
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Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.11 Chitnis 2010  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection (204 extra-pulmonary TB 
samples (pleural effusion) from India 
Patient 
characteristics and 
setting  
204 extra-pulmonary TB samples (pleural effusion) from India  
Index tests  RT-PCR assay  
Target condition and 
reference standard(s)  
Target condition: TB  
Reference standard: Lowenstein–Jensen and MGIT-BACTEC 
Flow and timing  All samples were accounted for in the analysis  
Notes  Comparative  
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the Low 
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review question?  concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
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A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  Comparative  
 
3.6.12 Cho 2015  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection 
Patient 
characteristics and 
setting  
3010 samples from pulmonary (sputum, BAL) and extra-pulmonary 
sites (pus, pleural, urine, CSF, Tissues) of patients suspected with TB  
Index tests  RT-PCR assay (Cobas TaqMan) 
Target condition and 
reference standard(s)  
Target condition: TB  
Reference standard: Ogawa medium and MGIT 960  
Flow and timing  All samples were accounted for including the invalid ones in the 
result analysis.  
Notes  Comparative  
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
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Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
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B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Unclear  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Unclear risk  
Notes  
Notes  Comparative  
 
3.6.13 Choe 2011  
Patient Sampling  Cross-sectional design with convenience-based consecutive 
enrolment of participants, retrospective data collection 
Patient 
characteristics and 
setting  
129 abscess and biopsy specimens from lesions/organs of patient 
suspected of TB   
Index tests  RT-PCR assay  
Target condition and 
reference standard(s)  
Target condition: TB (EPTB) 
 
Reference standard: Ogawa medium. 
  
Flow and timing  All samples were accounted for  
Notes  
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Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
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Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.14 Choi 2013  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection 
Patient 
characteristics and 
setting  
425 clinical specimens from both pulmonary TB patients [360 
samples] (sputum, BAL, Endotracheal aspirate) and extra-pulmonary 
TB patients [65 samples] (abscess, CSF, joint fluid, pleural fluid, 
peritoneal fluid, tissue, urine) 
Index tests  RT-PCR assay (Cobas TaqMan MTB) 
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Target condition and 
reference standard(s)  
Target condition: TB  
 
Reference standard: MGIT 960  
Flow and timing  All samples were accounted for  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
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Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Unclear  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Unclear risk  
Notes  
Notes  
 
3.6.15 Dayal 2010  
Patient Sampling   Case-control study 
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Patient 
characteristics and 
setting  
47 CSF samples from patient with suspected Neurotuberculosis  
Index tests  RT-PCR assay  
Target condition and 
reference standard(s)  
Target condition: Neurotuberculosis  (EPTB) 
 
Reference standard: BacT/Alert liquid culture.  
Flow and timing  All patients were accounted for in the analysis  
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  No 
Did the study avoid inappropriate exclusions?  Unclear 
Could the selection of patients have introduced bias?  High risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
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Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
 
 
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
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Notes  
Notes  
 
3.6.16 El Khechine 2009  
Patient Sampling  Diagnostic-case control  
Patient 
characteristics and 
setting  
134 sputum samples  
Index tests  RT-PCR assay (IS6110) 
Target condition and 
reference standard(s)  
Target condition: Pulmonary TB  
Reference standard: BACTEC 9000 MB system 
Flow and timing  All samples were accounted for  
Notes  Hypothesis: Can stool samples be used as alternative sample where 
sputum is difficult to expectorate? 
Based on the known survival of MTB organisms in the gastric fluid, 
the author hypothesized that swallowed MTB organisms would be 
detectable in stool samples. So, they compared the presence of MTB 
organisms in respiratory tract specimens and stool specimens 
collected in parallel from the same patients. 
In four patients, a stool specimen initially yielded the correct 
diagnosis of pulmonary tuberculosis before evaluation of the 
respiratory tract specimen confirmed the diagnosis. These data 
indicate that stools could be used in conjunction with sputum testing 
or as an alternative specimen upon which to base the diagnosis of 
pulmonary tuberculosis by molecular identification of acid-fast bacilli 
and culture. This non-invasive alternative procedure is of particular 
interest for patients who cannot expectorate.  
 
REVIEWER’S COMMENT: The results were not affected by parallel 
stool samples analysis as indicated above. 
This is Diagnostic case control study which has been reflected in the 
QUADAS-2 assessment. 
Patient Selection  
A. Risk of Bias  
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Was a consecutive or random sample of patients enrolled?  Yes 
Was a case-control design avoided?  No  
Did the study avoid inappropriate exclusions?  Unclear  
Could the selection of patients have introduced bias?  High risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
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Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  Stool as alternative sample where sputum is difficult to expectorate.  
3.6.17 Feizabadi 2013  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
Sputum samples from 247 Iranian patients suffering from  
pulmonary TB 
Index tests  RT-PCR assay 
Target condition and 
reference standard(s)  
Target condition: Pulmonary TB 
 
Reference standard: Lowenstein-Jensen media  
Flow and timing  All patients were accounted for in the analysis. 
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Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
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Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.18 Friedrich 2011  
Patient Sampling  Cross-sectional design with convenience-based consecutive 
enrolment of participants, prospective data collection 
Patient 
characteristics and 
setting  
25 consecutive patients (pleural fluid specimens) referred to 
Tygerberg Hospital, a tertiary medical institution in Cape Town, 
South Africa, with an undiagnosed pleural effusion and high clinical 
suspicion of pleural TB 
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Index tests  RT-PCR assay (Xpert  MTB/RIF) (rpoB gene) 
Target condition and 
reference standard(s)  
Target condition: Pleural TB (EPTB) 
 
Reference standard: MGIT 960 
Flow and timing  All patients were accounted for in the analysis. 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Unclear  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Unclear  
Could the selection of patients have introduced bias?  High risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
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B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.19 Gous 2012  
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Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection 
Patient 
characteristics and 
setting  
Liver, lymph node, tissue, lung and CSF samples were collected from 
patients (39 cadavers) older than 18 years of age, who died in the 
wards of the Charlotte Maxeke Academic Hospital (Johannesburg, 
South Africa), with known HIV infection, who either were on 
antiretroviral therapy (ART) or would have been eligible for ART if 
they had lived, were enrolled.  
Index tests  RT-PCR assay (Roche Light cycler mycobacterium detection assay 
(LCTB)) 
Target condition and 
reference standard(s)  
Target condition: Extra-pulmonary TB 
 
Reference standard: Lowestein-Jensen medium and BACTEC 9000 
MB   
Flow and timing  All patients were accounted for in the analysis. 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
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All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
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Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.20 Hillemann 2011  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection 
Patient 
characteristics and 
setting  
521 specimens (91 urine, 30 gastric aspirate, 245 tissue, 113 pleural 
fluid, 19 cerebrospinal fluid [CSF], and 23 stool specimens) sent to 
German National Reference Laboratory for Mycobacteria (NRL) from 
May 2009 to August 2010 that originated from patients with 
suspected Mycobacterium tuberculosis infection on the basis of 
clinical criteria or to rule out these infections were included in the 
study. Consecutive specimens were used, and specimens were not 
selected by the use of special criteria. 
Index tests  RT-PCR assay (GeneXpert MTB/RIF) 
Target condition and 
reference standard(s)  
Target condition: Extra-pulmonary TB 
Reference standard:  Lowenstein-Jensen media  and MGIT 960 
Flow and timing   All patients were included in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
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Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced Low 
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bias?  risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes 412 random samples with negative cuThe final set of study samples included  
 
3.6.21 Hofmann-Thiel 2016  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection 
Patient 
characteristics and 
setting  
715 clinical specimens (608 respiratory specimens [273 sputum 
samples, 274 bronchial aspirate samples, 45 bronchoalveolar lavage 
[BAL] samples, and 16 tracheal aspirate samples] and [107 
extrapulmonary specimens (31 tissues/biopsy specimens, 23 
puncture samples, 20 pleural fluid samples, 5 urine samples, 3 
gastric aspirate samples, 1 cerebrospinal fluid [CSF] sample, 14 other 
fluid/puncture samples, and 10 swabs from operative sites and 
wounds]) from both pulmonary and extra-pulmonary sites were 
included in the study between April to November 2015.. 
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Index tests  RT-PCR assay (Abbott RealTime MTB) 
Target condition and 
reference standard(s)  
Target condition: TB 
Reference standard: Lowenstein-Jensen media  and MGIT 960 
Flow and timing  All samples accounted for 
Notes  Residual material of after decontamination was preserved in the -
30°C freezer for later analysis by RT-PCR MTB. To avoid bias, 
specimens were excluded from the study if the patient already 
received anti-TB therapy for more than two weeks before specimen 
collection. Maximally three study specimens per patient were 
included 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the Yes  
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reference standard?  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
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Notes  
Notes  
 
3.6.22 Huh 2015  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, Retrospective data collection 
Patient 
characteristics and 
setting  
A total of 6,852 Cobas MTB test results for respiratory specimens (no 
breakdown given) from April 2013 to June 2014 were retrospectively 
reviewed. 
  
Index tests  RT-PCR assay (Cobas TaqMan) 
Target condition and 
reference standard(s)  
Target condition: Pulmonary TB 
 
Reference standard: Lowestein-Jensen and MGIT 960 
Flow and timing  All patients were included in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
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Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
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Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.23 In 2014  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
247 sputum samples were prospectively collected from patients 
suspected of having pulmonary TB at Korea University Hospital, a 
tertiary-care hospital in Seoul, South Korea, 
between March 2012 and November 2013. 
Index tests  RT-PCR assay (Real-Time PCR Using NBS LabChip) 
Target condition and 
reference standard(s)  
Target condition: Pulmonary TB 
 
Reference standard: Löwenstein- Jensen medium and  
 
BACTEC MGIT 960 
Flow and timing  All samples were accounted for 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
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Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced Low 
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bias?  risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Unclear  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Unclear risk  
Notes  
Notes  
 
3.6.24 Jonsson 2015  
Patient Sampling  Cross-sectional design with convenience-based consecutive 
enrolment of participants, retrospective data collection 
Patient 
characteristics and 
setting  
This study was retrospective and the 3393 (2388 respiratory and 
1005 non-respiratory) human specimens arrived consecutively 
between January 1, 2010 and December 31, 2012.  
 
Index tests  RT-PCR assay (Cobas TaqMan MTB) 
Target condition and 
reference standard(s)  
Target condition: TB  
 
Reference standard: Lowenstein-Jensen medium and in the MGIT ™ 
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960 system 
Flow and timing  All samples accounted for 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
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A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.25 Kheawon 2012  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection. 
Patient 
characteristics and 
430 bronchial washing specimens from patients who had undergone 
bronchoscopic examination due to symptomatic abnormal CXR or 
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setting  Chest-CT with sputum samples negative or no sputum for AFB by the 
authors between December 1, 2008 and September 31, 2011 
Index tests  RT-PCR assay 
Target condition and 
reference standard(s)  
Target condition: Pulmonary TB 
Reference standard: Lowestein-Jensen medium 
Flow and timing  All patients were included in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
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B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.26 Kim 2011  
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Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
A total of 406 clinical specimens (96 respiratory and 310 
nonrespiratory specimens. The respiratory specimens were sputum 
and pleural and bronchoalveolar lavage (BAL) fluids, and the 
nonrespiratory specimens were body fluids, including joint fluids, 
ascites, and drainage and tissue specimens) were prospectively 
collected from 247 patients with suspected tuberculosis infection 
between June and August 2008 at a tertiary care hospital in Seoul, 
South Korea. 
Index tests  RT-PCR assay (Cobas TaqMan MTB) 
Target condition and 
reference standard(s)  
Target condition: TB 
Reference standard: Ogawa medium 
Flow and timing  All samples accounted for 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
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A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
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Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.27 Lee 2010  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection 
Patient 
characteristics and 
setting  
The electronic medical record database at Seoul National University 
Bundang Hospital, a tertiary referral centre, was reviewed for 1307 
TB suspects from January 2006 to April 2008. 143 bronchial washing 
specimens from patients made the study. 
Index tests  RT-PCR assay 
Target condition and 
reference standard(s)  
Target condition: TB 
Reference standard: Ogawa medium. 
Flow and timing  All patients were included in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
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Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
 
 
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference Low 
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standard does not match the question?  concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.28 Lee 2011  
Patient Sampling  Cross-sectional design with convenience-based consecutive 
enrolment of participants, retrospective data collection 
Patient 
characteristics and 
setting  
We retrospectively enrolled 99 (bronchial washing) from patients 
who had lesions on chest CT that suggested pulmonary TB as a 
possible diagnosis and who underwent bronchoscopy because they 
were unable to produce a sputum sample or had smear-negative 
sputum from March 1 to September 30, 2008. 
Index tests  RT-PCR assay 
Target condition and 
reference standard(s)  
Target condition: TB 
Reference standard: Ogawa medium 
Flow and timing  All patients were included in the analysis 
Notes  
 
Patient Selection  
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A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
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Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.29 Lee 2013  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
587 Respiratory specimens (all sputum specimens) were collected 
for preparation of acid-fast smears and mycobacterial culture from 
patients with clinically suspected pulmonary TB where anti-TB 
therapy had not been initiated.  
Index tests  RT-PCR assay (Cobas TaqMan MTB assay). 
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Target condition and 
reference standard(s)  
Target condition: Pulmonary TB 
 
Reference standard: Lowenstein-Jensen media  and MGIT 960 
Flow and timing  All specimens were accounted for in the analysis. 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
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Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.30 Lim 2014  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
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participants, prospective data collection 
Patient 
characteristics and 
setting  
 A total of 1,167 clinical samples from sputum and bronchial alveolar 
lavage (BAL) were collected from patients prospectively after 
approval by the institutional review board (IRB number; 12-003). The 
samples were collected from April to July 2012 from five university 
hospitals in Chungcheong area in South Korea. 
Index tests  RT-PCR assay (Cobas TaqMan MTB) 
Target condition and 
reference standard(s)  
Target condition : TB 
 
Reference standard: Ogawa medium. 
Flow and timing  All patients were included in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
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Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
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Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.31 Linasmita 2012  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
A prospective cross-sectional study was undertaken among 73 ( 
cervical lymph node specimens ) from patients of the Faculty of 
Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, 
Thailand, from April 2009 to March 2010. Adult patients (age, >18 
years) for whom there was clinical suspicion of TBL or who 
presented with a ≥2-week history of cervical lymphadenopathy were 
enrolled. 
Index tests  RT-PCR assay (Cobas TaqMan) 
Target condition and 
reference standard(s)  
Target condition: Tuberculos lymphadenopathy (TBL) 
 
Reference standard: MGIT 960 
Flow and timing  All patients were included in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
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Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
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Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.32 Lira 2013  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
165 sputum samples from respiratory symptomatic 
patients. 
Index tests  RT-PCR assay (IS6110 TaqMan) 
Target condition and 
reference standard(s)  
Target condition:   PTB  
Reference standard: Lowenstein-Jensen (LJ) 
Flow and timing  All patients were included in the analysis 
Notes  
 
Patient Selection  
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A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
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Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.33 Luo 2010  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection 
Patient 
characteristics and 
setting  
A retrospective study was performed on 70 formalin-fixed paraffin-
embedded tissue biopsy specimens collected at a major academic 
hospital over a 10-year period. 
Index tests  RT-PCR assay 
Target condition and Target condition: Extra-pulmonary TB 
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reference standard(s)  Reference standard: Culture assay (type not stated) 
Flow and timing  All patients were included in the analysis and accounted for 
Notes   There was concern around the integrity of the samples being frozen 
for 10 years. That the DNA of the MTB might have been degraded. 
The integrity of the DNA in the formalin-fixed paraffin embedded 
tissues is dependent of the methodology used for extracting DNA. 
Probably the very good result may be as a result of good DNA 
extraction procedure. However, the study met the inclusion criteria. 
I did not want to introduce selection bias by excluding the study 
based on long duration of frozen samples. This concern is addressed 
under the limitation section of the discussion. 
 
 “Specimens, typically formalin-fixed and paraffin embedded (FFPE), 
are stored in hospital archives for years to decades. DNA can be 
efficiently and effectively recovered from paraffin-embedded 
specimens if the appropriate method of extraction is applied”. (Ref: 
Pikor, L. A., Enfield, K. S. S., Cameron, H., & Lam, W. L. (2011). DNA 
Extraction from Paraffin Embedded Material for Genetic and 
Epigenetic Analyses. Journal of Visualized Experiments : JoVE, (49), 
2763. Advance online publication. http://doi.org/10.3791/2763) 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
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Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
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A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
3.6.34 Malhotra 2012  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection (Hospital observational) 
Patient 
characteristics and 
setting  
555 female genital samples (endometrial, fallopian tube biopsies, 
menstrual blood and vaginal discharge) collected from women of 
ages 20 and 40 presenting with infertility. 
Index tests  RT-PCR assay (Cobas TaqMan MTB) 
Target condition and 
reference standard(s)  
Target condition: Genital TB 
Reference standard: Middlebrook 7H9 medium 
Flow and timing  All patients were included in the analysis and accounted for 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
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Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
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Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.35 Mangat 2016  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection. 
Patient 
characteristics and 
setting  
The present study was conducted in the Department of 
Microbiology, Govt. Medical College Amritsar. The study comprised 
of 74 clinical samples which included sputum and Bronchoalveolar 
lavage [BAL] were taken from the patients with suspected 
Tuberculosis, attending Chest & TB Hospital Amritsar. 
Index tests  RT-PCR assay (Roche Light Cycler 480 Real Time PCR system) 
Target condition and 
reference standard(s)  
Target condition: TB 
Reference standard:  Lowestein-Jensen and BACTEC MGIT 320  
Flow and timing  All patients were included in the analysis and accounted for 
Notes  
 
Patient Selection  
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A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
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Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low 
risk  
Notes  
Notes  
 
3.6.36 Miller 2011  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants by convenience, retrospective data collection 
Patient 
characteristics and 
setting  
112 (89 pulmonary specimens: bronchial brush, bronchial wash, 
bronchoalveolar lavage, expectorated &induced sputum, lung biopsy 
specimen, nasopharyngeal aspirate, pleural fluid, sputum, tracheal 
aspirate. 
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23 extrapulmonary specimens: brain biopsy, lymph node biopsy, 
sinus biopsy, Endometrial biopsy, lymph node biopsy, neck abscess 
aspirate, neck mass biopsy, retroperitoneal fluid, and stool) used in 
this study were collected from 90 patients between August 2007 and 
April 2011 and stored at -70°C. 
Index tests  RT-PCR assay (laboratory-developed test (LDT) targeting 
IS6110) 
Target condition and 
reference standard(s)  
Target condition: TB 
Reference standard: Bactec MGIT tube and a Lowenstein-Jensen 
slant  
Flow and timing  All patients were included in the analysis and accounted for 
Notes   
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
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Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
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Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.37 Moure 2012  
Patient Sampling  Case-control study 
Patient 
characteristics and 
setting  
 A total of 149 smear-negative samples (CSF, ascetic fluid, urine, 
pericardial fluid, abscess aspirate, knee aspirate, biopsy, tissue, 
stool)  (one sample per patient) collected from July 1999 to May 
2011 in Costa Ponent (Catalonia, Spain) were included in the study. 
Index tests  RT-PCR assay (Xpert MTB/RIF assay (GX)) 
Target condition and 
reference standard(s)  
Target condition: Extra-pulmonary TB 
Reference standard: Lowestein-Jensen and BACTEC MGIT 960 
Flow and timing  All patients were accounted for in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  No 
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  High risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the Low 
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review question?  concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
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A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.38 Park 2013  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
A total of 320 respiratory specimens, including 254 sputum and 66 
bronchoalveolar lavage (BAL) fluid samples, were prospectively 
collected from 311 adult patients with suspected pulmonary TB 
between 26 May 2011 and 2 December 2011 at a tertiary care 
hospital in Seoul, South Korea. 
Index tests  RT-PCR assay (Cobas TaqMan) 
Target condition and 
reference standard(s)  
Target condition: Pulmonary TB 
 
Reference standard:  Ogawa and MGIT 960 
Flow and timing  All patients were accounted for. 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
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Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced Low 
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bias?  risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
3.6.39 Pinhata 2015  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
715 Sputum samples from suspected TB patients that were routinely 
sent to the IAL unit located in Santo Andre City, Brazil (Santo Andre 
IAL) for smear and culture were included in the study 
Index tests  RT-PCR assay (Roche Light Cycler 480 II system) 
Target condition and 
reference standard(s)  
Target condition: TB 
Reference standard: Ogawa slant and MGIT 960  
Flow and timing  All patients were accounted for in the analysis 
Notes  
 
Patient Selection  
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A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
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Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.40 Rachow 2011  
Patient Sampling  Cross-sectional design with convenience-based consecutive 
enrolment of participants, retrospective data collection 
Patient 
characteristics and 
setting  
Two hundred and ninety-two sputum samples from consecutive 
patients with symptoms suggestive of pulmonary TB who presented 
to the Mbeya Referral Hospital between July 2007 and September 
2007 were included in the study.  
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Index tests  RT-PCR assay ((Cepheid) Xpert MTB/RIF Assay) 
Target condition and 
reference standard(s)  
Target condition: TB 
Reference standard: Lowenstein-Jensen media (LJ) and BACTEC 
MGIT (MGIT) 960 
Flow and timing  All patients were accounted for in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
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risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Unclear 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
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3.6.41 Rosso 2011  
Patient Sampling  Cross-sectional design with convenience-based consecutive 
enrolment of participants, prospective data collection 
Patient 
characteristics and 
setting  
158 pleural fluid samples from patients presenting with pleural 
effusion on chest radiography referred by their clinicians to the 
Pulmonary Service for Diagnostic Methods, Thoracic Diseases 
Institute/Clementino Fraga Filho University Hospital Federal 
University of Rio de Janeiro for diagnostic thoracentesis were eligible 
for the study between January 2003 to July 2005. 
Index tests  RT-PCR assay 
Target condition and 
reference standard(s)  
Target condition: Extra-pulmonary TB 
Reference standard: Lowestein-Jensen medium 
Flow and timing  All samples were accounted for  
Notes  Inclusion criteria were age ≥ 18 years old, absence of known history 
or clinical or radiographic evidence of renal, cardiac or liver failure, 
and no known diagnosis of cancer or TB at the moment of enrolment 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
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All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
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Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.42 Sethi 2012  
Patient Sampling  Diagnostic-case control 
Patient 
characteristics and 
setting  
A total of 102 (72 cases, 30 controls) pulmonary and extra-
pulmonary specimens from admitted patients were evaluated by 
mpt64 real-time PCR from July to December, 2010. 
Index tests  RT-PCR assay (In-house mpt64 RT-PCR) 
Target condition and 
reference standard(s)  
Target condition: Extra-pulmonary TB 
Reference standard: Lowestein-Jensen and MGIT 960 
Flow and timing  All patients were accounted for in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Unclear  
Was a case-control design avoided?  No  
Did the study avoid inappropriate exclusions?  No 
Could the selection of patients have introduced bias?  High risk  
B. Concerns regarding applicability  
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Are there concerns that the included patients and setting do not match the 
review question?  
Unclear 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
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A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Unclear  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.43 Sharma 2015  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
1480 (Respiratory samples included sputum (n = 1141), endotracheal 
tube aspirate (n = 146), broncho-alveolar lavage (BAL) fluid (n = 128), 
induced sputum (n = 73) and bronchial washings (n = 4))adult 
subjects with the clinical suspicion of PTB were included (from 
September 2012 to December 2014) from All India Institute of 
Medical Sciences (AIIMS, New Delhi) 
Index tests  RT-PCR assay 
Target condition and 
reference standard(s)  
Target condition: Pulmonary TB 
 
Reference standard: Lowenstein-Jensen medium AND MGIT 960 
 
Flow and timing  All patients were accounted for in the analysis 
Notes   Six hundred fifty seven patients were on ATT for less than 2 weeks 
before the date of sample collection for diagnostic tests. 
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12 samples from original 1492 were eluded due to insufficient 
sample to run all the analysis  
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
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A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.44 Tortoli 2012  
Patient Sampling  Cross-sectional design with convenience-based consecutive 
enrolment of participants, retrospective data collection 
Patient 
characteristics and 
6067 PTB and EPTB samples (Biopsy, pleural fluid, aspirate, pus, CSF, 
urine, stool, sputum and BAL) were involved in the study, conducted 
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setting  in Italy. 
Index tests  RT-PCR assay (Xpert MTB/RIF) 
Target condition and 
reference standard(s)  
Target condition: TB 
 
Reference standard: Lowenstein-Jensen media  and MGIT 960 
Flow and timing  All samples were accounted for in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Unclear 
risk  
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B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes  
Notes  
 
3.6.45 Wang 2013  
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Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, retrospective data collection 
Patient 
characteristics and 
setting  
30 bronchoalveolar lavage fluid (BALF) from patients aged <15years 
were enrolled in this study between June 2008 and November 2012, 
Index tests  RT-PCR assay (LightCycler®480, Roche) 
Target condition and 
reference standard(s)  
Target condition: TB 
 
Reference standard: Bact/Alert 3D 
Flow and timing  All patients were accounted for in the analysis. 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the Yes  
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reference standard?  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
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Notes  
Notes  
 
3.6.46 Yang 2011  
Patient Sampling  Cross-sectional design with convenience-based enrolment of 
participants, prospective data collection 
Patient 
characteristics and 
setting  
A total of 1,093 respiratory samples (1,036 sputum, 39 bronchial and 
tracheal aspirate, and 18 bronchial alveolar lavage samples) were 
sent to the Division of Clinical Microbiology, Department of 
Laboratory Medicine, Kaohsiung Medical University Hospital 
(KMUH), Taiwan for mycobacterial testing. The specimens were 
collected from 446 patients with clinical signs of pulmonary TB or in 
order to exclude the possibility of TB infection. 
Index tests  RT-PCR assay (Cobas TaqMan MTB test) 
Target condition and 
reference standard(s)  
Target condition: TB 
Reference standard: 7H11 agar, Lowenstein-Jensen medium, and the 
Bactec MGIT 960 
Flow and timing  All patients were accounted for in the analysis 
Notes  
 
Patient Selection  
A. Risk of Bias  
Was a consecutive or random sample of patients enrolled?  Yes  
Was a case-control design avoided?  Yes  
Did the study avoid inappropriate exclusions?  Yes  
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Could the selection of patients have introduced bias?  Low risk  
B. Concerns regarding applicability  
Are there concerns that the included patients and setting do not match the 
review question?  
Low 
concern  
Index Test  
All tests  
A. Risk of Bias  
Were the index test results interpreted without knowledge of the results of the 
reference standard?  
Yes  
If a threshold was used, was it pre-specified?  Yes  
Could the conduct or interpretation of the index test have introduced bias?  Low 
risk  
B. Concerns regarding applicability  
Are there concerns that the index test, its conduct, or interpretation differ 
from the review question?  
Low 
concern  
Reference Standard  
A. Risk of Bias  
Is the reference standard likely to correctly classify the target condition?  Yes  
Were the reference standard results interpreted without knowledge of the results 
of the index tests?  
Yes  
Could the reference standard, its conduct, or its interpretation have introduced 
bias?  
Low 
risk  
B. Concerns regarding applicability  
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Are there concerns that the target condition as defined by the reference 
standard does not match the question?  
Low 
concern  
Flow and Timing  
A. Risk of Bias  
Was there an appropriate interval between index test and reference standard?  Yes  
Did all patients receive the same reference standard?  Yes  
Were all patients included in the analysis?  Yes  
Could the patient flow have introduced bias?  Low risk  
Notes   
3.7 Characteristics of excluded studies 
3.7.1 Amin 2011 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.2 Amita 2013 
Reason(s) for 
exclusion 
 
Insufficient data for 2X2 contingency table 
 
3.7.3 Araújo 2014 
Reason(s) for 
exclusion 
 
Animal study 
 
3.7.4 Baba 2008 
Reason(s) for 
exclusion 
 
Combination of more than one reference standards 
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3.7.5 Barber 2008 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.6 Barrios-Payán 2012 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.7 Bogard 2001 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.8 Broccolo 2003 
Reason(s) for 
exclusion 
 
Culture-based assay not included as reference standard 
 
3.7.9 Carvalho 2015  
Reason(s) for 
exclusion 
 
Animal study 
 
3.7.10 Chang 2008 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study 
 
3.7.11 Ciftçi 2011 
Reason(s) for 
exclusion 
 
Combination of more than one reference standards 
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3.7.12 Cohen 1998 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.13 Choi 2012 
Reason(s) for 
exclusion 
 
Combination of Mtb and Non-Mtb 
 
3.7.14 Choi 2014 
Reason(s) for 
exclusion 
 
Culture-based assay not included as reference standard 
 
3.7.15 Costa 2013 
Reason(s) for 
exclusion 
 
Animal study 
 
3.7.16 Costa 2014 
Reason(s) for 
exclusion 
 
Animal study 
 
3.7.17 Costa 2015 
Reason(s) for 
exclusion 
 
Animal study 
 
3.7.18 Cui 2012 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.19 Duarte 2012 
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Reason(s) for 
exclusion 
 
Combination of more than one reference standards 
 
3.7.20 Darban-Sarokhalil 2013 
Reason(s) for 
exclusion 
 
Combination of more than one reference standards 
 
3.7.21 Dervisoglu 2006 
Reason(s) for 
exclusion 
 
Insufficient data for 2X2 contingency table 
3.7.22 El-Sharif 2012 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study/Drug resistance. 
 
3.7.23 Fang 2010 
Reason(s) for 
exclusion 
 
Combination of more than one reference standards 
 
3.7.24 Flores 2009 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb combined with clinical samples  
 
3.7.25   Gan 2013 
Reason(s) for 
exclusion 
 
Animal study 
 
3.7.26 Gómez-Laguna 2010 
Reason(s) for 
exclusion 
 
Animal study 
 
3.7.27 Gülhan 2014 
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Reason(s) for 
exclusion 
 
Culture-based assay not included as reference standard 
 
3.7.28 Gunisha 2000 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.29 Güzin, 2014 
Reason(s) for 
exclusion 
 
Combination of more than one reference standards 
 
3.7.30 Haldar 2009 
Reason(s) for 
exclusion 
 
More than one index test (Conventional PCR included) 
 
3.7.31 Hanif 2012 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.32 Hasle 2011 
Reason(s) for 
exclusion 
 
MTB and Non-MTB combined 
 
3.7.33 Hillemann 2006 
Reason(s) for 
exclusion 
 
Culture-based assay not included as reference standard. 
 
3.7.34 Hong 2011 
Reason(s) for  
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exclusion Clinical isolates /MTB and Non-MTB combined  
 
3.7.35 Hou 2014 
Reason(s) for 
exclusion 
 
More than one reference standard  (histology included) 
 
3.7.36 Hyeyoung 2014 
Reason(s) for 
exclusion 
 
Combination of Mtb and Non-Mtb 
 
3.7.37 Incandela 2015 
Reason(s) for 
exclusion 
 
Culture-based assay not included as reference standard  
 
3.7.38 Kaur 2003 
Reason(s) for 
exclusion 
 
Culture-based assay not included as reference standard  
 
3.7.39 Kayigire 2014 
Reason(s) for 
exclusion 
 
Drug resistance study 
 
3.7.40 Kibiki 2007 
Reason(s) for 
exclusion 
 
More than one index-test (PCR, RT-PCR, MycoDot® serological test) 
 
3.7.41 Kim 2008 
Reason(s) for 
exclusion 
 
Combination of Mtb and Non-Mtb 
 
3.7.42 Kim 2010 
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Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study 
 
3.7.43 Kim 2013 
Reason(s) for 
exclusion 
 
Combination of more than one reference standards 
 
3.7.44 Kim 2015 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study 
 
3.7.45 Kobayash 2006 
Reason(s) for 
exclusion 
 
Insufficient data for 2X2 contingency table 
 
3.7.46 Kocagoz 2005 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study 
 
3.7.47 Kox 1995 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.48 Lemaître 2004 
Reason(s) for 
exclusion 
 
Culture-based assay not included as reference standard. 
 
3.7.49 Lim 2014 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
330 
 
 
 
3.7.50 Linuma 2003 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.51 Li 2014 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.52 Liu 2013 
Reason(s) for 
exclusion 
 
Drug resistance study 
 
3.7.53 Luo 2011 
Reason(s) for 
exclusion 
 
Drug resistance study 
 
3.7.54 Makeshkumar 2014 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.55 Marín 2004 
Reason(s) for 
exclusion 
 
Drug resistance study 
 
 
3.7.56 Massoud 2009 
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Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.57 Mehta 2012 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.58 Miller 2002 
Reason(s) for 
exclusion 
 
Insufficient data for 2X2 contingency table 
 
3.7.59 Mokrousov 2014 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study 
 
3.7.60 Nagesh 2001 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.61 Nagdev 2015 
Reason(s) for 
exclusion 
 
Culture-based assay not included as reference standard 
 
3.7.62 Narayanan 2001 
Reason(s) for 
exclusion 
Conventional PCR used not RT-PCR assay  
 
 
3.7.63 Nasr 2012 
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Reason(s) for 
exclusion 
 
Combination of Mtb and Non-Mtb. 
 
3.7.64 Nikam 2013 
Reason(s) for 
exclusion 
 
Combination of more than one reference standards 
 
3.7.65 Omar, 2011 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study 
 
3.7.66 Patel 2013 
Reason(s) for 
exclusion 
 
Combination of reference standard and drug resistance studies. 
 
3.7.67 Pholwat 2012 
Reason(s) for 
exclusion 
 
Drug resistance study 
 
 
3.7.68 Portillo-Gómez 2000 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.69 Querol 1995 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.70 Rafi 2007 
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Reason(s) for 
exclusion 
Conventional PCR used not RT-PCR assay  
 
 
3.7.71 Rajalahti 1998 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.72 Rondini 2003 
Reason(s) for 
exclusion 
 
Non-Mtb study 
 
3.7.73 Reddington 2011 
Reason(s) for 
exclusion 
 
Animal study 
 
3.7.74 Reddington 2012 
Reason(s) for 
exclusion 
 
MTB and Non-MTB combined 
 
3.7.75 Roug 2014 
Reason(s) for 
exclusion 
 
Animal study 
 
3.7.76 Rozales 2014 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.77 Sales 2014 
Reason(s) for  
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exclusion Clinical isolates of Mtb used in the study 
 
3.7.78 Sankar 2013 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
3.7.79 Seagar 2012 
Reason(s) for 
exclusion 
 
Drug resistance study 
 
3.7.80 Seo 2014 
Reason(s) for 
exclusion 
 
Combination of Mtb and Non-Mtb and No culture as reference standard 
 
3.7.81 Serrano-Moreno 2008 
Reason(s) for 
exclusion 
 
Animal study and not RT-PCR  
 
3.7.82 Sevilla 2015 
Reason(s) for 
exclusion 
 
Combination of Mtb and Non-Mtb 
 
3.7.83 Shrestha 2003 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study 
 
3.7.84 Singh 2011 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
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3.7.85 Surat 2014 
Reason(s) for 
exclusion 
 
Insufficient data for 2X2 contingency table 
 
3.7.86 Takeda 2008 
Reason(s) for 
exclusion 
Conventional PCR used not RT-PCR assay and more than one index test 
 
 
3.7.87 Torres 2003 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study 
 
3.7.88 Tranc 2014 
Reason(s) for 
exclusion 
 
Non-MTB study (Mycobacterium avium complex (MAC), 
 
3.7.89 Tueller 2005 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
 
 
3.7.90 Van Coppenraet 
Reason(s) for 
exclusion 
 
Combination of Mtb and Non-Mtb 
 
3.7.91 Wang 2015 
Reason(s) for 
exclusion 
 
Clinical isolates of Mtb used in the study 
 
3.7.92 Xu 2008 
Reason(s) for  
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exclusion Clinical isolates of Mtb not from original specimens 
 
3.7.93 Ye 2013 
Reason(s) for 
exclusion 
 
Culture-based assay not included as reference standard 
 
3.7.94 Yonemaru 2009 
Reason(s) for 
exclusion 
 
Combination of Mtb and Non-Mtb 
 
3.7.95 Vuorinen 1995 
Reason(s) for 
exclusion 
 
Conventional PCR used not RT-PCR assay  
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Appendix 4 Dissemination 
4.1 The protocol registered with International prospective register of systematic reviews  
(PROSPERO) and published online PROSPERO 2015: CRD42015027534 
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Citation  
Emmanuel Babafemi, Lee Banting, Graham Mills, Benny 
Cherian. Effectiveness of the Real-Time Polymerase Chain 
Reaction assay for the detection of Mycobacterium 
tuberculosis in pathological samples: a systematic review 
and meta-analysis. PROSPERO 2015:CRD42015027534 
Available from 
http://www.crd.york.ac.uk/PROSPERO/display_record.asp?
ID=CRD42015027534  
Review question(s) 
Is the Real-time Polymerase Chain Reaction assay (RT-PCR), 
when used alone, sufficiently sensitive and specific for the 
diagnosis of Mycobacterium tuberculosis (Mtb) in 
pathological samples? 
Searches 
The following databases will be searched: MEDLINE, 
EMBASE and the Cochrane review registers, in addition to 
grey literature, etc. 
The search will include publications in all languages from 
January 1995 to present. 
Types of study to be included 
Prospective, retrospective, cohort, cross-sectional, 
diagnostic case-control studies, clinical evaluations, and 
(RCT) - blind or unblended - with a high degree of 
heterogeneity are eligible for inclusion in this review. 
Inclusion criteria: 
Revision 
Notes 
Revision 
History 
Oct 26 2015 
11:43AM 
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• Primary studies evaluating and validating real-time PCR 
as a diagnostic test 
for Mycobacterium tuberculosis will be eligible for inclusion 
if the studies;  
• Described original research: prospective, retrospective, 
cohort and cross-sectional studies, clinical evaluations, and 
RCT - blind or unblended - with a high degree of 
heterogeneity, cohort studies or diagnostic case-control 
studies with cases and controls from the same population; 
• Studies which have performed pathological specimen 
analyses from in-patients and outpatients among all age 
groups; 
• Studies comparing RT-PCR to the reference/gold standard 
method - culture assay;  
• Studies which have reported the total number of patients 
tested and the positive/negative results that allow 
calculation of true positives (TP), true negatives (TN), false 
positives (FP) and false negatives (FN), or indicate where 
they can be extracted; 
• Studies which were published between 1995 and 2015 in 
all languages. 
Exclusion criteria:  
Studies will be excluded on the basis that:  
• All samples were not tested by reference/gold standard 
test - culture-based assay; 
• They involved animal studies; 
• The reference test was a combination of greater than one 
diagnostic test; 
• The RT-PCR assay was not used in the study; 
• If non MTB is included. 
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Condition or domain being studied 
Accurate and rapid detection of Mycobacterium 
tuberculosis from patients with tuberculosis infection. 
Participants/ population 
The population involves all patients of different age groups 
(children and adult) with tuberculosis infection. 
Intervention(s), exposure(s) 
RT-PCR assay accuracy for the diagnosis of Mycobacterium 
tuberculosum presence in pathological samples. 
Comparator(s)/ control 
Culture-based assay (reference standard). 
Context 
The clinical setting is all patients diagnosed with clinical 
symptoms of tubeculosis will be included. 
Outcome(s) 
Primary outcomes 
Accurate and rapid diagnosis. 
Early treatment. 
Secondary outcomes 
To reduce the risk of infection to others. 
Data extraction, (selection and coding) 
Manual data extraction will be conducted by two 
independent reviewers using a predesigned data extraction 
form. 
Discrepancies will be resolved by discussion between the 
two independent reviewers, and if agreement cannot be 
341 
 
reached, a third reviewer will be consulted. 
Risk of bias (quality) assessment 
The QUADAS-2 checklist will be used for the (quality) 
assessment of the included studies. 
Strategy for data synthesis 
Statistical software such as RevMan and Stata will be used 
to aggregate data from multiple primary studies in the 
review (data analysis/synthesis will include: Diagnostic 
Odds Ratio - DOR, Chi-square test, Receiver Operating 
Characteristic - ROC, summary ROC-SROC, Forest Plots of 
accuracy measures, AUC, etc.). 
Analysis of subgroups or subsets 
Not yet ascertained. 
Dissemination plans 
Publication in journal(s) - titles yet to be decided. 
Contact details for further information 
Emmanuel Babafemi 
8 Roslin Grove 
Birmingham 
B19 2HT 
boladiipo95@yahoo.com 
Organisational affiliation of the review 
University of Portsmouth 
www.port.ac.uk 
Review team 
Mr Emmanuel Babafemi, Sandwell and West Birmingham 
Hospitals NHS Trust 
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Dr Lee Banting, School of Pharmacy and Biomedical 
Sciences 
Professor Graham Mills, School of Pharmacy and 
Biomedical Sciences 
Dr Benny Cherian, Consultant Microbiologist, Basildon and 
Thurrock University Hospitals NHS Foundation Trust 
Basildon 
Anticipated or actual start date 
01 October 2014 
Anticipated completion date 
31 May 2016 
Funding sources/sponsors 
None (self-sponsored review) 
Conflicts of interest 
None known 
Language 
English 
Country 
England 
Subject index terms status 
Subject indexing assigned by CRD 
Subject index terms 
Clinical Laboratory Techniques; Diagnosis; DNA, Bacterial; 
Humans; Mycobacterium tuberculosis; Polymerase Chain 
Reaction; Real-Time Polymerase Chain Reaction 
Stage of review 
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Ongoing 
Date of registration in PROSPERO 
26 October 2015 
Date of publication of this revision 
23 November 2015 
DOI 
10.15124/CRD42015027534 
Stage of review at time of this submission Started   Completed  
Preliminary searches No   Yes  
Piloting of the study selection process No    Yes  
Formal screening of search results against eligibility criteria No    Yes  
Data extraction Yes    No  
Risk of bias (quality) assessment No    No  
Data analysis No    No  
 
  
PROSPERO 
This information has been provided by the named 
contact for this review. CRD has accepted this 
information in good faith and registered the review in 
PROSPERO. CRD bears no responsibility or liability for 
the content of this registration record, any associated 
files or external websites. 
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4.2 Congress of the Institute of Biomedical Science 24-27 September 2017, 
 ICC Birmingham, Poster Presentations 
 
  
 
 
Dear Emmanuel 
Congress of the Institute of Biomedical Science 
 24-27 September 2017, ICC Birmingham, Poster Presentations. 
Abstract title:     (RT-PCR) for Mycobacterium tuberculosis detection: A systematic review 
and meta-analysis 
Presented by:   Emmanuel Babafemi 
Main author:      Emmanuel Babafemi 
Co-authors:          
Discipline:            Medical Microbiology  
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Date of display: Tuesday 26 September 2017       Poster number: 13 
I am pleased to inform you that your abstract has been accepted for a poster presentation 
at the IBMS Congress 2017.  On arrival at the ICC please report to the registration area 
before proceeding to the poster court in Hall 4, where a steward will be on duty. 
§ You will be allocated one poster board. Your poster must be on A0 size paper/card 
measuring 841mm in width by 1189mm in height.  This cannot be exceeded and the poster 
must be presented in portrait. 
§ The poster board is covered by nylon loop material, to accept Velcro only.  You will be 
required to bring your own Velcro to display your poster. Pins are not permitted. 
§ Your mounted poster should be in position by 10.30am and it would be helpful if your 
photograph could appear at the top right-hand corner of the poster. 
§ You are required to be present at your poster between 12.30pm and 2.00pm to accept 
questions from the judges. (Please note that in the larger disciplines the judges may have 
already made a second shortlist and may not be able to speak to all presenters). 
§ Your poster must be removed between 4.30pm and 6.00pm on the day of the 
presentation. No responsibility can be accepted for posters left in the display after this 
time.           
 We are assuming that you are the presenter of this poster and eligible to receive free 
admittance to the Congress on the day of the presentation.  We hope that you will be able 
to register your attendance for days in addition to your free day. 
 CPD credits are awarded for poster presentation at the Congress.  For further information 
please enquire at the IBMS stand in the registration area. 
 An award of £150.00 will be given for the best poster in each discipline. 
 Tips on how to design a successful poster can be found on our website 
at https://congress.ibms.org/posters/designing-posters/ 
We look forward to seeing you at the Congress and thank you for the contribution you have 
made. 
Yours sincerely 
Marie-Helen Jean 
PA to Sarah May, Deputy Chief Executive 
0207 713 0214 ext. 144 
congress@ibms.org 
346 
 
Appendix Five  
5.1 Research Ethics Review Checklist 
 
 
347 
 
 
